var title_f25_3_25648="Cutaneous ulceration in RV";
var content_f25_3_25648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous ulceration in rheumatoid vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The classic cutaneous finding of rheumatoid vasculitis is a medium-vessel inflammatory process associated with ulcerated lesions of the lower extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25648=[""].join("\n");
var outline_f25_3_25648=null;
var title_f25_3_25649="Critical view of safety in laparoscopic cholecystectomy";
var content_f25_3_25649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Critical view of safety in laparoscopic cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The critical view of safety is a \"window\" crossed by two structures: the cystic duct and artery. This is achieved by exposing the base of the liver bed and dissecting Calot's triangle free of all tissue except for the cystic duct and artery. The two structures emanating from the gallbladder (cystic duct and cystic artery) and the interface with the liver at the base of the gallbladder fossa should be definitively identified. The critical view of safety should be achieved prior to clipping or dividing any tubular structures in a laparoscopic cholecystectomy. Difficulty with identification of the critical view should lead the surgeon to consider performing cholangiography or converting the laparoscopic cholecystectomy into an open procedure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25649=[""].join("\n");
var outline_f25_3_25649=null;
var title_f25_3_25650="Hyperglycemia treatment for hospitalized patients on normal diet";
var content_f25_3_25650=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Hyperglycemia treatment for hospitalized patients eating a normal diet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 671px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Proposed algorithm for management of diabetes and hyperglycemia in the noncritical care setting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Inzucchi SE. Diabetes facts and guidelines. Yale Diabetes Center, 2011. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25650=[""].join("\n");
var outline_f25_3_25650=null;
var title_f25_3_25651="Circinate balanitis 2";
var content_f25_3_25651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circinate balanitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAUkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5t1WzMKCSOJgp65H61knJ612unyjVLZbG/ZIDIep6ke3pWJ4h0O70W4KTRkwn7soHB/wrKEujN5xMyBtgIXBY9/SpHYABB+JqOOFh8xBC0pyG3EfhTdmxxukPxGoB/j/lWhYWsb3Ktt/dAbizdKpW0LTNkjC9zW8siNawxxRssQOM45as5OxvFEk0kt22AdkPRVHGBV+wsF2jggdzUVvEGAAU7u1btnblLZi4w3ZR1FYtmhRS223JATK4xV9tLEjZMeTjkmtHSLER7C5JLnknmt826RjGAT3rJy7GkUcraaWluGZVCHG1cDvUWp6IdTMaEN5UQO33PrXXw2nnMCVxGv6mr8dqiLwtQ5tM0Ubnlr+DlH3d2emKff8AhR7h4ljc+XDGsSHHXHX8zmvT2slbAx8x/QUCzA6gYFHtpD5EeSv4MuBja/8A9arVloOs2bjybhiB/C2SK9SFuoIBA+tWfs6bCQuTj86ft5D5EedXXh99RQ3F+Wimx80u4kt9T1P41lXmh6hcKqQOVtkG1FxjI9T9a9Se1SYDbzDHwv8AtMO/0FQxxQxoI3Rgy8YxR7VoSieT/wDCPatCwaJuR0qK60nU0w8atz95fQ16w0O58RRke5pkun7cOxyenFNVn1KszymUXtloMjOr+bcTBOnREGT+bMPyrOu726iMUQDfu0G7j+I8n+lez3WjRzQW0ZUELHuwR/eOf8KoT+HbeR2YxruJ6kdaqNZdUJp9zx86jc+jA0n9o3Z4+avS73w5EM5iA/Cs5vDseDgdO1aKrHsFpdzk7i9vbuC3lLMXRRA2Sei/dP5cfhUtvBcv8zSH1Fb7aV5O4hCVA5x1pYrQqQcZHUHPBFJ1LiSa0MqSKUSKzkhuCGHB49PerSYdD5uVbrvjA5PqV/qK0ZLQypgKfWqr2Ujgr91l6jP6/Sp5ricSI2ru+5JFkVhu4Yg/keeuaclnIpKtGc+mKmSGSNdj4z2A5+op6ZwcqNvXjtRcmxVe0dGyOP8AeOKW5aO1sv3nmO8h+7H1I9M1e2wyy+VCTJKv3j0QfU/4VDfrOJC+McbRInX8D2/CqRD1MlSI5G851hHWO2Rck+7DoB7nn0FP1Pzpbb7NBKyxsiyzW/TzCRncT/F9Ogphtl3BemDkE9efWr+oW5uraGXPMDNb7hwQB8yH8iR+FVe2xDXc42ZHWXbg5qW9DRxqXBAI/E1evbWSNmZgN/8Aexwff2qrfpJ5duZDnI4NVclkOkj/AEstJjb5b8f8BNRuoCDHQVLbx7VlfqSpUfU1A6lTjr71V7sWxWlPlTA9q17S4NxpLwAZCHIrHulY4z3rV8NZRZTKMQt/Ee59vWqkvduZa81ie3iYRyhEJeTESgdfU1N/ZTf8/Ft/3/FJeTguIrdTGkhJbnlvr6D2pn2cf3V/75rK5TZnWxt45yZpmkJ6ketdbo3i2G0tHsr+2N9YyKVxIMsv0J6iuMTylQ5OQeK09LWG4Xyww46bqtiaNiXRLe5sBdadOrxE4EPdaxJdHcN8v7wg8gdR+FLJFqWlXatAdmRnK9G9q0k1MXpQXts9rN2niHBPvRqtUwRgSeYkvlPGUA/hrfiicWFthQDkk/Sp5baeSNUnjEyk/JPH1/GpXSVZI4sEoo2jngmocjVE2nRMzqCfmzwP61vyHH7iMgy/xv1xWPbCWL7igOeMnsK0LJPLBG4uxOWPWsmzVI1ba6CBkcYIGBWjaMblFHOP4iayxAGAcgnHT61q6S5dtnRl7Vmy0jat0AUAgbRVliipubAA4x3Y+gqqZuiYy3ZR1NTRnZJvlO+XGAq8hfp/jWTRqgAaMM0mPMbqP7o9KO3XNSNGzcsdij8SabI6QxjPy56dy30FKw72EWMAguRnsKSRjcx7Ys+Rnlx/F7D/ABp0djNcgtPmKLtH3b/e/wAK0La1BXggAdvQVTiRzGfsKqAoCgDAX0HpT0ByNy1pS2nXGSag8pkbaQfrU7FppkPloxHHb1qJlQHaw4q35RB6AiomDA7tvHrTBCSRFCN4IZQFP4Diq8i+Yx4wVPatVwouJNvLZyc1WuUXzSY1wpOcZ6U2NGfNbKykN+dZc1kCeG61uy4K9CKzH5lIHTpSQzOmtEBK8ZrMa0FvOEK4gkPyN/cY/wAJ9j2/KunMBLf41HNao6SJIoZGG1lPcU7gY0mmp5Occis2e0VgAfldT8rjqP8A63tXQxkWY8q+k/dniGdv4/8AYb/b/nUV1au2W8sxDtvHzfl2/nVJkM5i4G5fIkAjmJBikXhdw+6Qex9jTIozcATXCrvV8PABhVYHkMO//wBetoxBVZCoZG6qRnNZd9GbHbNDhYGbbNvOVX+6fXrxnJxxxVpkNdyJ4R8+wHB6A9R7cVXMMsf3WYAds8VpKWVsTQuvuvzD8xUqCKQ4EkZPcZ5p3FZGN9k+0KmQA+9Rx7kVevIy97cwxKMTk7U9GQnH/sw/Gr1rAqXUTtjaJUJBPBAYVX1GOSK/vo9wDx3UkiMP4fm5x+hq+hjL4rHPSLuzkA57Yzms25skezdcyL5Z3ADnrXTXdvukMiLhH+fAH3T/ABD88/gRVbyI87nyQRg/SncNzj47dCAFugoH8LKc5pz28IbmcNnuqk1f1K0aOZlAx6YqiIznbgk9OKu5Ay4WIQ74UDsB1k6Z9cVSmae1ukjuCRKQCQTyv4dvpWvZMscyLGf3xOQ/9z6e/vWNrEDLfu/JBb73rVwd9GZzvujU1BlSWF1YHpnHvWlti/vj865xGEijJO0YzV37RD6NU2B7mCx4xVi2+WIE5+Zuo7UxkV2wo71beNlwigfKMc1s5aE8ruaNjetdwm1ukd8/6uUHkVNGkttAVnvgg3cbuazbV7gERxDGB1FRyRzvIfMBY56Vmy0jqdLuLZSrteuuDnCjg/UVvMNNvWXzpSEcf61eNprg7dBGFXgH+L/Ct22MkkKxp1YVlJGiRrRadZR3JFnqkd0P7rcEVqwwSpIM7JI/SM1m6XYRrCsj4L55+tasMZL7gMfSs2zVRZqQ3ELxLGIJlccFnwBUcjmKSOQEDBxuWoZHUrgkjPX3plq1tukjuo2dAMfK2DjsancqzW50EAihG5mLN1JY9amGpQK/yuM4+5GNxP5VmWkFnKQwj2seSCCxx0FblpalUBheBB2yu3+VS4lKegsCXdw2Qq20Z/ik+ZyPZf8AGrtrZxwSmRSZZj/y0kOSf8B9KZBb3JYgLC7f9dMVaUXaYBs1I9PNFITaLTROQPMAxVlooVjGwhpfQVnyT3iIN1mxDcAJMp/nURvjDzPZ30QHBYRCRfr8pJ/SmyTRyc56GlaZZf8AWoATxuFV7a6trpGe2uY5gOWCnkfUHkfjUsZSTK4yD71I7CGzVpARJ8vqKV4wo2LgknBzT0hyR8wAHPpUki7/ALxHHGF4Bpeg031M+Qr9vfK8EZodRu3KMA09VDSy7s8KFyTTRE+DtOfY0uhVyCVNy5AqjJApbJ/OtD53Zk4x71VmJyVKgCmUmRiIj7mC56VQmk3l4bRVmnXh2JxHGfc/0FWpYt7DzdxHbBxx6UFCAqxgKq9FAwPyotYEyi1h5Sl7r/SHcYLMOB/uj+H69feqjXTW4MdzvmtwOJcZdPZvUe/51tSJNIgT09az5rba/wAp+btimgIZI4WgEsZDoRwy85/Gs6eFZQyyLmNxtKkcEdwauixXzS8TtbytyTGOGP8AtKeDSzRTohM0CyAfxW5/mp5/I1SfYhvuc/b77ZxaTEsVH7mQ9XT0/wB4dP1q6FDr86K4/wBpQTSyC1u8QyuUcsNm/KMrdiM8Zp8EyriO4eLf/C6sNr+/sfaqSuJvoQPFEEOIY8A5+6KuapbRte3JhWMAyl12jgZ5xTZBECQ0kYHoXA/rTDfRSFt8imRf3ZEa5zjgdPaqW1iGtblF4dp9mzgHsfQ1QuIlxzkKeuO1a08sgYvHb/Kw2t53AYfTrWdcxCRvmYtkZ2DgKfp3HvTuS0ZN3D5ttuPMkXyMwHBXsawbtSqEKv5dTXX2EyW0zpcxmS1ZSpUdVBHasnXdMmsIlkkUtbyruilHRx25q0ZswNHQvqEHGMk1DfRDz7iJiNrt8ufWrOiSbb2JugEgB9s1Q1iby9Wnjbs5Bq0nczbsytbwNbSyRzJn0Jq7s/2V/KtGKIXVmhYYkUYyw6iq32Z/+ef60pSuxx0Ri2yCVy2OF/nQrFXYFu/c1LHdyRRDAjUsc4CCo1upi/BUH/cFa2BGzpUWIXnMgA9cVDcHyWBXc0p9BVy6f7HpcSiQec5yVAH45qK7kn+z20iSuGb72PpWRaIYrOeQBvLfnk/LxW/pVpcoQTDJjHes7TZp3wHlkOOuWPSuihywHzn86mTNIouWNtMWlxwAQ20n1q7l0VQ4wfasyKLFwCP7vXPvWvDE8mBnjHU1my1oMX5sBR8x45qe3syJlMuDnjANWrW0G9QTz/OtGe3RBEc8h1HFTsPcbGPJjSQDGxtp9lP/ANetS3lQH96T5fcryRUEFm0m9Dn5wR9DU9rZEWyFm5GVYe4ODUlWRrWKQtFufOe+DSXagMpjkYg8delUwjxREIx2Me/b3pIo5A2Nxz70XRPL1uX4g6pw3/AT3q3sjMY2OQ/UqOMVmMzRzjcTg9cVZTzijzqNqqMEkdRRuKw27sYLxwxQCQHKuvysD7Ec0kCTRSiKZ8jGVkxyfY+9LFKRtPy9M4qS5O6MNnoQ3BqSrWLCLck4R4CRzznmql3cXcAPmJa8HtIwP4cGrktxsCLbKC7jOW7VXnSJPufNcS/IGfrk9T+FL0BMg0t7i5geWa38jcxZTv3bh9Ks4fzNzceuK0IoEiAVG3L9wegqsWRCd/ysvc+tAFdY8nPSqd1Ccknp9K0vN3bpBjJ6VVkYlXJ7CqRLvuZe5l+YZI9DSBt5J6c1LtWXPJH0quq+Vuzlhnjiiw1ImllYJggexqk6HJIPzVoFWaNSMGoBHiUNIMIKLDUiruBTBX5vWmu4UAZ49Kncp57BAdueKZKqO2O3cUWBsidFlXG0Nnrms25sYTkPBEw75QVoQpsYj+dSyCMg9fXNUhGB9jWEj7OseP7roCPwPaoI5ZIL25R4yokCyALz22n+Vaki4LYGR61QnbE9vMOCpMbfRv8A64/WqE9SOedHUgnn3FZ8zgrvUgSR/qPStaUhjyAR71m3qgPwo54PFNCZRlZWBfk5GQO4qzpd61zYSaZNAbgDLxQkcsOrKvv/ABD8RUc8DRDcM7SPm/xrC1Waa1aOaB3jljYPG6cFWByCKuO5lJXRT1bTo7G1Nzp0jXFrIwcFRynsayPEMqpq6TxoNs6K4YjvXQazdPNbr4i0yNVtbmTytStE4SG5IzkDssmCynsdw9KztUcXOiRXdkwcwth43UMVB9c1vazOdO6KcNzNlSZGOMg/SnedN6j8qrWuoLN8skEOcY+XK/1pPtUf/PAf9/D/AIVDTLTMoMWb26Vo6OkZuA0g3Edj0rNLbRhfzq9Y4jiLN99ulaz2CGrNDUX+03BZQAF+UVr/AGQHSoSfbtWKhAIHfpXV28Zk0iDAOcisJOxtYy7dNrDjkccVs2ithSeAPaore2/e88VrwRAKAOgqGy07C20ZeUYPIFdHYwYUAjPvVHToV3jcv1NdPZ24+UtwvXPpUMpa7jIrZWZRgfX1q7JZh7d4x988qT6jkfrVmKMEgKMn9asRR75iJMACoLIrYLJFFNGDscZ9x6j8DkfhTVRFvZkTcd2JFz+R/pUkzLYs0hYLaTN8zHpHIe5/2W7+h+tTPH5cXm4PnQSZYeqnqPy/lRYm5Itk1xDvi5YcEdgKla2iijG4FiByw6A+lWAPKyiuVRu46Gobm8CxbWHI+8R3o0JbZRmhEsTOpGABx3FNlFwMfOWTAz7ipPMG/wCTPB9OtSS+Y0K7WXg4Yd6bkCTKTWyhgC3FFw6wwNt53YHJpWaQORkHjHAqjcr5k8SHIUHJ5qC7M2LVxFCpY7nI6VXjnNxdtISpiQ7Iye/qf6VXedncwROFB++4/gX/ABNWE5ZAirsxtG3sBTDlNJCdoVWyc4AomJEiBgGK8nNZ6bll4c/L3qQswzvOS3U0th8pOypL5jKQB2FROoVJGdSRjHpio8eWFbIIHp2qORy65ZicnpTQWIrZxH/Bu+o6VYWAOMspCnqRT7aPzFZGIXAzk1dieKKJVJ59PWqRlLQw5EaKUqOUHemyyR7ggzzWk0TTTu4IIIx9KozWeDkHGDRYaa6lTyzuJxgUrQAYZDznNWWfa+2QZ7A06Rcx5TnFDAovGpHAycflVOSMgE5zitApxk1C6Ak47Ui0Yk0jD5SDz0NUrqIyQOnPzDjHr/8Arremt4zzgA9gapywgqQOgqyWZds6zwJIO459iOv65pXhDg8A56VFbxrb3ksWeJiZUHYN/EB/P86tNxx/k0B0K0URZCrdV4rmPElvtt2WNCMKe/6Y/wA9K60koQyjp1rD8UqRbNJE21l+YEdqqO5DOB8PaymmakyX0JuNLu4/s97ADgyRk9R/tKcMp9RWskC6Fqht3kWa2mQGKfHyzRN9x/x6H0ORXP3my7DXMCKjo2ZI1HCH1Hsf0rX02aPV9M/si4cRzKS9hKeiyH70RP8Adft6N9a63qrHHazcjJu7cR3jmJSpVuUpfNj/ALtSXAd4PtGCl1AfLmRhzxxzVT7Qn90VLTZorFPtk1LE5JGSaifAOPSnJk9q0ewouzNWzKhgT1rtbOcC1hT2rjdKg3uMtjmujWTMwQfdHGa5po6IsuiX/SRz3rftFOwMeRWDCiBww5NdHpI8+QD+CM8k9z6Vky0jYtIsRg5wa2LWRtgD84PeqQIVRwPericKG5PtWdzVI1Y2EW1gcuaejGWUqxxnrVS0yW+fgn9BV1lU/dPJ70xFuJIskXCFoyCMNyGHpjvVSJ20tgPLkurKRPuj5pIAOg9XX9R71ankMkEaIQ2O1T7UMsKp3UgMxxjimZsgikDW6orrLEF/dup4K9jn26VWlbaOXB3qR9KdcwKsJmik2XBO87RkOeh3Dvx39qyWu5lRlki3q3Rkbp+BpWBMuIhSMHcS2OcGlEhDAqTkdfes6S6/ux3HHGFSmJPLtLRQMCO0jAfgcc1NjReZoPJtBbncKpPL5shNscDHMuPlB9vU1A0bysPtcm/J/wBWown+JqxnHyhhxwMj7vtSsWWIvKWMxxjgjcS3Ut6miDKEDJxTAh+yNKZF3jjZ3I9arR3BMZ3BuDz7UXGrNF8ymMNjuetLFcdmOVU54qitwJCPN5HoKdHIgViu049DR5hpsXS6ndzwTxQHyRggEcGs0sGG7zCvoDUxuHZY0yMj+LHP40CaNP7Qd33QQRgkVLK6MyZbDgcZ7j1rNinaMgFQc9TT/OkLb+oHGfSrRDiWYbtoleIYwxyTU0MyyOYJMfNzuqrHKfKZQu5SeciqkrGOYbTnIp7EONy7dwbHR25iBwSKpy/IcxMcHtU080sVrHkhlboOtJazJcfI6BXUc8YqrJmd2tSNZUaMgkZFVxw/y8irl1bqqfuyCx7CqCOQdm3B9alxsXGVxlxypI4NZs7EdyPxrRlJHDdfpWZc4YFR17e1CRVzIvVMhG3/AFsbb0Pow/zipIrkSQrIoxu/h/unuKjlJSXP49KqzyC0mM+ALabAl/6Zt2f6HoaaJehb8wseBx6Vm68P9FcEfIe/pWgxI4wMjjioJ2BhfeNw7rVLcTV0eQGdrTUWePHUgg9GHoa07m1jW0+02wzbv2zyh9D/AEqLxPpxtrpriI77eQ8MO3saZot+YgYmOVYbSp6MPQ11PWKkjkWknFmst0NQBvXG+8hULdqOs0Y4Ev8AvDgN+frUOdM/vD8qruj2E8d9YNgI3GeSh7qw7gjI9wat/wBp6f8A9C5af9/XpOz1Gk4nLBuc1Ijn1qAVJGMtitmjGEnc2NLb5w7E4FbVrKCwPfrisOybdiNBn1x3ratkCSAMRu/u5/nXNI7Y7G1aliQF4J6H0rrdKVYolVcBfT3rmdOQE88H2rpLMkKBkVzyNomszHK46GtSyO8beuB19Kx4MlhngGtK1STzCijg9Kku5qwkbt2eOnArWNqvkhiCXb9KpW1rLCoR9p6F8VeN6YR5OwBM8FqpJLcylJvYRNsSspXZIozmqs0jNwHUk9eeh+tR3Zllfag3Tf3V5zUM1jKUDXzrCTghFOTj6UrNgrdSKe5niUqJxwfmVRnH41nTXHmhtschycgAdPatwQ2nkKkVs7TN1kdu30o8l1IbbjB7dxSY0uph26XLsG8kxY7t6VaWOTflpFUY9K1CUZRtbt3FQzYLkgZ+g6UF2MiaBQnMjls54FMh+d8lmGO3TNa+G7Rkk+1Ojt2kl/1SjjOCcUrMd7FMKiJlGAbp9KjaORiZA+CepxWmbXzCR5agnofSnzaSuwDzGIPTnFFhXRQ055La5D7UJwcEjNTSwxKAwh+Y/e96sx2MMTbvNbH+0auyQ26ouJATtGCM8exoaYXSehhTWcLKCq7T7nimzaZN5aSRuzIDjIXNbKW0MylTKiA5wWPNRvZKIZPKvowV7ByMn2FNIlyfcxmSRkydrMAcYzwabFdCNRHKrAsPvY61bAuI1PlspXkD1qWMI1v5c8eWUcEcg1Vg5mtyrDccAB8o3GfSnF1MLJIeT901LPYWzyxrbTGJmG4qeQDUEVvIFKuofn7w5p8rFzoeiTLbDc24ddpHSqLu0dwskeQOhq08oWYbWJTocUkiqxUAgrSHoy3DPEOS3JHGKZPENhYcgnORWZJL9nkAx+7PGauxOVUb2yp6ClchxK1yp2j+8eazJ48Nk1t3TCVV2jp1xWTek8YGarzEnbQxr3B5FVVcFcMAwI2sCMgj0rQuYgynHeswrtJXpzSLZUSU6ewglJazPEUpOTF/sN7ehqS8l2xkZxxRNghlcBlYYZSMg1g38klnEwQtJbnoCcsn+Iq1qRsczqN95N3KrDfC5wydvr9azTF5MyzQfNFncPalu1lup3MUbSY5O0ZxUELMh2jOO4rqjGy0OaUrzszoIrgXTtJGirIVwyno496j8uH/AJ83/wC+zVCJucxHDA8VN9oufUVk12NDEGD1FSrIoG1V+pNQk5oXrXVY4lK2xqWUrAYUhR7da39NTI5rmLR/3i11tgP3QYHiuaorM7qbujbsCVYc8V0VgrEHPK965axOZFA9c11ummQ4C9PaueRuma1rGXKhATz3robaNolyo3NjkkVUsrfaBKwIVBkk1s2EU1/GzPKlpYRjLzN1PsKUYtkykNGoK0xVI3dsABIxncfem3Bf7QyakTEq8G3iwW9sntU39qDy5NP0KHyraTmW4K/vZPp6VpaNoXmTxpseRifnLH7p9z3NaqPzM72V3oZZEpikNuPssLHK45b/AL6ptskQjUbXeUtnkdR9a7O90m0jm2O3mPjhR0HvxWfLbGzkMwWJUBGBKcfpRKL6jhNPYyPKeQ5C7FBxwc0i2yySAAtIeeM9KddXkDGUR7mfqSOh/wDrVlPeSbH2IQpOC3TJ+tY2NkXmhjhkDRx7ifvIep9x71E88UbO0bgqOCDkEfhVPz5yuN6gDjLc/lT0tjMASjysBwduP1pqI7llJ8jOML3z+lJ5jy52BF4xwMkmi6tLi0h3S7417KQcVWiMrkZZ9gPFWohcnMcrEsN+D1FTbZ9u4jgDqaeLWE8SXQEoHoRj8e9RM0Sq4bcWI4J5zUtWDcfAkSkhplHcVZBtDu3XAbHQHuayfPRckkD6VJHeRb/3hYE9xU3K5GaIe13cMTzjOw4qRotNdAzSSBumFjP481nC4R9qozAZ7jA/Grwlhhyv26MoBwVQtn6+lUiJRIJYrMu22WRlBwG8ojimfZrYLuiv4shsBWUqcevIq1JdRuVK3VvtOBg5Q0WqLcl2N3ZRsMjDy8/yquW/Ql6Faexl2DZ5M3PDRuGzVItJayk5MUg/hZeK1n0eQv8AujZTZ/54XChv1xVSbT9RhcqbW6bPJBQtn8RnNHKTe/UpSz2k4HmQi3lA++nIY/Sq00RSLzBIrEjKlT/OpJ1SQlH/AHEin7kibT+dVZbOWNQ2Mqx4I5BpNAtCEsZkUOuPU1D50lsx8w7os/Kae0hiOJvu+wqF1DRsG5jPI9aTQ0zSilSVcr83HTFU7qNWz/WqtnKI22E9eAe9XZWVAGLDJ55oRLWuhiTblfDf5FZd8MOCO9dBfrvG7v8A1rBvxntg9qRaKMrblJ6VzevzbIdue1bkspUckY6HNcd4jn3SsB0ArSCuyJMxbuWSK6UxMUwo2lCQenqK1LXU7W7Tytdt3lB4W7t8LPH9R0cexwfes7ZHc2CyBz9oiO0rjqvY1DJ8qge9dS7HM1e7Ne80maxg+22skd9ppwPtUAO1T/ddTyh9j+FZnmv7fnUun6hdafOZrOZomYbXA5V1/usDww9jVv8Atof9AvSP/Ac/40mkCbW5zlLSkYpBWxyEtucSCuys3C2ikYBIri4f9YtdVaMfIQelYVjsw70Oh0lDJMu3k5xXb6bGYwN459K53w1a7YldvvdhXc2KxJEGcEzEdK5HqdS1LcMhRRJPnYT8sQP3vrTpJZb1ljRiY88qPur7Cp4YBMxabAUfN/8AWpbSOSeUW1opG4/5Oapdh2W5o6eLa3CxzBvKLfOUGXfHVfaupaWeWOB0AtLBchIhxs9CW4yfWsgXGneH4l2ut1dj5nkb7qN7etZFzqt3rM7SXty6hfugqcn2AFVzW0IcHLXob2p6/aWsHlWsjzXSgYlPQ456VjX3268Cz6lOsZkAZYy2WIPsOlaOm6cbebdJJHZRuM75wDMwx91V7Z98U/Tjo1t5kt9bu20YEQyzs3r2UAfjQ9dwVl8JjSQpMSIAxxgAAnIx7D+tWxYOU827juZGOZNrFYkI/vZzk/gBU2bmXMiB7eyPyFyAmVHQYXGTTIGiidliEzI33zxkj6n+XSpv3Ls+hXa7VGCWsVum3kCNSzH8aUwXl0i+Rv5OfLL4wO+e4rYbCrF5ERhMnBLckelWoUVFVHmQyjjaBjGaTY9jMv7KW4hjS5kEIRdqiPc/y+mST3rOW2NsrLFK77gRudcY9a6Z78Q7l3KXBwAQM5pswluYklLKh54AxmnzXJV1uYdrDI7gtbs6AALg+lXHtQnyiKBVPPzNmpoklkYIryOQcE/dA9hUhE8YKKqpt6kYOaHIq12ZkNlCcu0a9eSkYGKsBbVFJQEMP75qwkD3PyPNuHVgtRmGFMsrRiNRu+ZwCfQCoKaM17ZXcsrF8/3Riq81r8pUFlAGR3OfStCby0kb50POc7uPwzUEu1lUGNBwMFIzuI9c9/rQiilBAUV2MBdcclhwKsQ2hnK5hTGM4VAP1rRi053BYWd1sZdxdyEDD8asLpZeICC0usA5/dkN/Kq5WQ5xRjTaNGPnwynnH9eKkSyaJsW4ulkUgB4ZTt/Cuht9JmjQFluPMzghgVwPcH8s1A2oywyGSxukhYfwgA5GfcVXLbchz5tEZF1dXSQtCL+aUHgwXcAfH4mqUGnm5MrfZRIgGStm5BX3AOa0ZNSkvLuU3jRbWTAEQB/edjzjaCetT3dpbG0gltRcR3igb+RgnuVYc/gad0xWscncwOoKywts9W4P41lzxYLbSfof8a7m3vL1z9n2rcs3SO5XLfTd1/nWW6adI04u7eSGRj8pjPAPpg0rJ6ofqcNO5DZB5U1NFcG4XOQMcZrq9S8P6NdW/m6dqIMoGWim+Rs/7Oetcy+kywE/Z5VYHqpqGrAncVnUqAG57isrUE2jkc1ZTdFLtlBXnvTdRIkG5eTioKaOT1RggJ6cVwWqTNJK+Tnmu212YRxvkjnpmuBvWzKea6aK1MKrshtnP5FwHwGHQqe9OuwM5X7h6VXjPzCpJWORXQ1rcwT90cPu03H0/KpI+BnFN3f5xUlFToKSgmkrY5GPjbDg11emusixAEAnFckK6zwVB9tvUjI+VeTWNZaXOjDvXlPUfDtsqWySzAgdAK3rJd8rMBx2rOtVACwqcKOPpXTaFZx/Z5WnIHGFOcYriWrPRa5VYls7aa7BCK+xSd5xjge9WNR1O1tbA2mmRnefvS/xN7Vn6hq1wSLW3+VFPAX+tXdOslsf3txb/aLyVdyGZTtX1wn8X1PFUnfRC5basbpmgXl4be5mdTGxz+8UiJSO3q5HoK22FxobhwIraeTiMyoHu5M/xCPkR+2ea0dMi1Vz502oHT4vKCyXFw2+Tb/sDomenH61PpvkwxXMuhpHFErFX1a8PzdOqg8k9TWqgktDGc23rqc88TRAtfXDxzSNloiS9w568/8A160vltodzQxWKAZja5xJcPnpheij3NSPsBX+yY3iRh+8umzJPKO7ZPCg/hWFPcCC9EwAmIbOHO4t9TWcnbY1jHm3On0p4rhvtc9mn2aFSXuruTduIH8K9PyrO1PV9NuIoVtY3jkRcF+FRvcDrmoryXUNbhabUphleIbcYSOIfTvxVYafbw2zFF8wnbzs4JGec0OTtZDjBXu9y/ZX8fkRwxq0qEdSMfifanqluyy52uc4OGJ5rKmFyQ2H+UIAxz2zxTVimYKDJhVGVx2/Gs7mnL1Lf2VmLMrhCB953Cj6DPerEN/5cCRtLuU5xzuOcVnmOJJSA/mgjliD39jT/LQAHcoY9P8ACldobinubc9vexpDJdIVEgyoHJIPQjFULnzfLkLyRLg7Shb5if6+9QRXr26ERXMkeV2NtbjB6iqkMqmcFwHA6oSQCPrRdMIxa3J5rppreMHcSowADtVR6ADr9TUkcR2jA568AKT7DNRCdH4ZFDAghiePxqSbWLfKxyy7RH80LAbgGHr7U0lfUHfZIhkvbe1hhSLDXYz5zSR8A5+7g9x61Yl8S6vIURb0RIq7QI1AO361h6prljc7QllHDLu8x23cs349vaqlx4hSSZ9nlxoW3CJBkKabk1sw9nf4onSR3E07q95NLIg9SCfqKRpJo8iJ3Qg5G1iD+VYlt4m3OGMkBYdAVAq5H4iErsZPKctnqBxzyaOa/UlwfYuPqeoCF7dr27ML8NG7nBPcEHP+FQIqnksV9l6VdtZdOvEVp7ea1Tbgy5Eg3Z9M5A+nSi8soElCW1ysq9SVGAn1PSm0+9yE0na1iSNkldXmgedywDsVGCntjoRWvp1zpEkjfb7GRFOQu0HjjuP61DpdoSok02a3Uqf311cKML7ID146+vaqjaQy4W21CGdicApICAc+nUfStUpLUzk4y0egh05L0SLaThZkbmKVuMZOCp6gAdaS3+xeXs17T5GAIQXMQyJB2Unpn3qtcaTqMbF4lW4ZW27oGyfrjriq0V3PbJIsk3lHblrd1JST8D0NK/L0Hy8y0Yy3/cXzTadBG6LkeXOm9WU/wn1+oqa4/sPUAuVbSZVGGUgvGCffripdKngHlNKJLeFl2NIq7wD6kelSz2dvcbpLSe3uSASdh2Nj6N1/ChPQmS1OP1fTrcSNEJUdsnDocqfcGuWnVo5GjkPIH513GradIivsiKMBym3afyrlNVtma0EqD54+DjrionZ7FR0R5f4zuPLmEWa4uRyWJPeuk8Z73vAxHHSuaKk110UlG5x1227CxHnNSD5myelRdBinKcCtGjOLtoW8gqAKZtPoaIX4GO1TeZWT0N1Z6mXRRRW5xCivRfhha4hnuD94ttWvOh1FezeArAx6faxEYJG9u1YV37tjrwkffcux19na/KGY9eWrYtYHu5JsSKltCu5nzwT2AqrPtSDYp+bPAqTTreQssQPznnB6L7tXGtz0dWtDb8M2jyXoaG2Sa6x8iSDKKTwC3qeeldxZHT9NY7RLqGtv8pwu87sfcHZQP0Fcvp3myxPp2iRsxJ3T3OcZH+92HXmrrvFpVuLe7u0cMmDBY/M757NKeg9gK2hLlVznqR5nYLqT7VOsd/593c7jjTbQHapzwHf0/wA8VFcLLdSRf2pKiSr8ttZWqq/lj3Xov1PNOtLGW608L5r2FuwP+jWq8sB2d/vNn8varn2ew06DE9xbREj/AFUZJbHfcR1Jod3qNWWnX+v6/UeWsrdcTWRk8wBsGcvuPviqVtpwllaZrNAZCMJu4jHt/wDXrO1DxLbCNYrVd7cAbh39hXOaj4j1DUZDCjSMucEfdXjsfWp5k9tTSNOXodnPe29rM8UL2gVcA7cMMdyCBz71l6nrRmj2ecduSflwo9uK417a5kH765I7hYfl/CpWsY5YhGPNY+pk6e1Jxmy1yRe9zZOswLkl1BPBPrQviK3CZDI3PBHPNYS6fDEFYQrtA5wO9XLa2aKSJ9g8o8fUHrSVLuypTXREz6+85KwQu7HuFqvFdXdxO8eVidfm2uwGV6ZXnk56itiJbWA4GRH7jkCqlylveoqLAqKmSWzlmPqPTH+NNUkyVUfRERN5G7LujbA3DDdfp61Je2Wpx6fBefKIJZ1txkEHe3THr+FULYyWd/BcmNXmjPCvypxxyB1q7f376jYiAwygmQPEzSnYpHUAdzk/hTVKPUHOeliaXStTWQRSLJJKQTsiXce/oeawprS4uJDHDMhfapCA5I9Tx0+hrZs9Uv4x5aXzox4YhAoA9zjOc1jfYWjcsk02/Od28kk+tPkitghOd/eK+oaZd6feRSviN2yY8Lhee+e/40l3Dfyi2DTXToPuxtIwX3xzxmt6O4lvEgszM0pZgi+aciP3+gNWp4pI5RaLc3UYhJQz4DxyLgnhCuRz71SQ3Ua33MK10FI4Bcz7mVT/AKvccsT6VPHpKwbp5SyITgFO2R6evQelali2qzWb20dw0tm+Tva1B2gZxhu3Y1ZOm6gtpcLNDaXdsuCXDmOQA91HQjINPlT6Gcqkl1OfmhDGL7PLeKmcTNIF2occgc5OPwrO1PUrzTJfI3S3ELfxhSuPQEZPPetV1uZ22rBCUOEURyK2xf8AEdzWzHYwz2ptb0squA8M8g578CpdNMtVuX4jA0/VLpoUaOGfHDAgZ/lUkt/LGf3glicHJLKQatR6BJaTO0quJAwJMf319M4pZzKLXyTZ3MjB8+ZK2wY6fMWNR7Mp1o30RWGtyI8bxXLI4b7ynB/PrWm/ix3aNZp45HTkMygt+J9KwobORThzGAoOyNFDBfct/Eao3dhG4bzfMWXlllToPZl7j3puEujDmg3qjsbbU7e8uG89FtN3/La3XC/8CXPT6VsXEBVBJNawXVuRhbm2yAfrt6H2Iry2CeawdFnXAb7rfwt9K6nQNbltZvNhlaNiCG2nhgfbpUxbvaQqtNW5oHTtfpGEFu8hRcgpMVdeRjg4yKwdVghcPNbghTw6kYrq9O02y1yC8uJ7iO2lxmJVYYLYyc/XjpXKzApvjf6HPerkmlc5oWba6nh/xP09rK4V1/1UnINcBuNe+/EDQzqXh6ZYVLSRDenrXgLgqSCMEV0UWmrHLiU1JMcF3cijvSRsQeKfw3PetTFakkRxUmDUKAg81Pis5HRDVFHFJUwBx8wppXHStLnK4MIF3TIPU1794TUR2CSOwztAxXhOlxmTUIEUZYuMCveNEikWNI2PAGcY61zYh6pHdg17rNyzhe4nD9sZGegrq7DTUkQ5d47JV3tOVwz+y59+M1U8O6fBt+0ag/l26jdsA+aQ+gFTajdzarMY4gIraPgKpwqiubY7N3YluNdf7ONO063ijhYkBUTkk8fMe5q9DptjpcIn1a5WW5K/NFF8x9gTnqKxW1SPTLYx2QRJGBDzsMsfpn7o+nNc29zc35Jt8rED80rf0pqWvdhyXWmi/M6jUPFKwQ+TpyuisP8Alq4Yj6Y6VzolnvZB9on2RHktzlvoO/8AKn6fbLzFZwefcNgb3GT+ArrrTwhqEMX2u6VPOOSscjZZzj9K2VNy1kZyqxp6LQ5qysRPdAw2uFOdpPOOOv5V0Fp4fg5d7gSYXcqoMFfT8zUtpd2cFm0M0Lbg2AM4PqSR+lc3e6mRK7xHH8W1F2jnitLxRl702aHiOCCKQeR8jsFLOOAePTt7VmqE3bWXaMYqvqN2WHLkjA6jGPwql9uyxyC3GM+lQ5GsYOxrrH8pMTHHddvI9DV2zsbi+jZrdCyA4Zzwqkdiaj0dLiWcSRRqwjQb2DDCknAB9884q7rt1PYacluXKRuCBgY3HP8AKkwu726k1nDbRlhJtmfGCueBWTqv2S1vNsMkieYdrRxrkJ7/AI1kC7e2tmLBtzdKzorgyTF3YyKOytgn/wCvUps0UHudCmnrcTwLJOsahwmIzk47t/npV/UbC0tolS3uSJUJ5zkYP8mHTj1rm9OkMcW+WSQYbG8jnH+NWL2SRI4gcktnax5yM1VyWnfc6N7i0urO2s3Mq20I+VY8An1Ofes2+gFnJDGxgdRDvSRTw5JPDDsw/wAKoJAyFGdc57DqKtXMH2mVRu2Ljmi7JSSe+hFYu4mRYAGJIOMdPetzVta82xFpeNJGwkDeZGeSM8kr64z19qp20VpYBXJLuRxzgn3rC1h7i4u3FujSsqliFHYcn8qE2ilFTkdLouvSWsU9ssm6ORcJkbeOgate2mjXS1inhllgbCysgwVwQQVY+veuCsrqaQQmeTKqpEaZ+6K6n+1C1oiqxXyxuG319TVKRnUp2ehevILaKRzNNBAseAYFg2nzCcdBncMEc1rXPlX8CRRTulsyGJ12BiCMYIHbp196xNC1CLFyt3taKdCpZlLEn0z2Hv2rKt7sQTNbyCaPg7FnB2ke2SMj3zVqWhk4N/I3FjuINSylxElysQk8xowiPtPBI6HI/GrV1fx6tG1tqyWyXRG63kjTAZunLDh1I7Vyl5crc4V23SRgKg37lx6Ent/KoEnkl2o7FwpKjPb2FLmsNQb3Nybw20KKpmBumbYsSrkOf9nHb9KnXwwt/bTpFF/pNsmXK5359h/Ea1bHVr+KzQhECrFiIlCzIScHkDOTjj61sae7aVPJqGpzW8Mly+VhQ5LDGAB6knqccVSSZEqk0ePXlrJDI9vNGsqKcSROOD/UGuXne6srry1jkkjJOzbzgele0fESxhvdQsb2JI7WecNDOD03gZXcR3PrXI6bpU0moK7xbR5fmDJyT1HH4g1lKGtjqpVly8xzNhq7viMOyEHoeorobad5n3uct2NDWen/AGsfbIA8T/KzKcFc9xU2oaWmlyB7O6+02p6NjBH1FZSjJFOcJeTHRK0x2RkeYf4WONwrw34p+G/7J1X7bbJi1uSSQOiP3Fe12rJKT6dAe+fWqHi3Sode0GW0cATjoffsaqnLkdzGrDnjynzT0oGe1W9SsJ9OvZbW5QrJGcH396rBTmu26PN5WnZli3wxANWPs/8AtfrVaIYqXzGrJ76HXDRaitEeOKhZMdq2fJIGCKhmhU9hUqZo6aZY8E2on1+HIzs5r3/RLWMqhcZPVvYV5d8NNFYSteuuQ/Ef09a9ZiIgiGRyeuKwrSuzajDlRa1O+yyQwttyMAf3RUF5ex29l5akqo5OT1NYVzfhb2Un7y4AH1q5Z2jXDpPdg7vvLH6e5rGEXL5nRNKFrkUNrLeOJb7Kw5ysffHv/hXT+H9EfVmZVVo4Ex82PlX6+9XfD+gSXswkn5UHnvj/AArqruePTLYWyqTFsYD7MeQ2fvEdx+tdtOmoo4K1dydkLZyWPhmJo7eBEUqGa6fDOW9MevoK5+98WRJdszW4mG5h5ivgkHIHB78896oeIfOl80zXCzzAByw+Uc9NoHTFc6bG4WUC7UQMeSrfe45xj34onN7IKdKL1kS3kiXDyPFM3XjcMZGO5/OqU8iiz2KN1w3Rv7o+lLeCRiRDgRjv0zSW1kYmLDJdgVORxn61idKSSM/7I5XdI+W7nrx61fe3GxEjXEYOdg9fU+ppUhPAl+9kirRUmIGMD5RgnHX3oG2yvp18+lXR28hhg13Mmo2Wp+F57C4RneVSYnTBKycY69B9K4G4USAYX5uxNTabM9si+QpJUlmJPeiMmmOdNTSfUfe6TPFF5UiSicZ2bGyPb8M5NX9F8KsdMu7y4MguEQyAYGwjHfuO9XLLW0ELPMhSRemVB5rPmvbi/nkUlvJJywJ+935qk0S+dq2xbtVWfSmtFdY7e52O6MBniorg6dbRyiN/tEi5VGB24b1xUN9DJnzYpHkhHy7ymBuIztx2P1qHVrL7Jdyb0/eYU4XOM4569/am2yVFX3JU1NggEsakjocYqW9tbj+zDdImdoLFAfnK/wB7HcDvWUH2SRvImVPJx6Vta44lgtbqzkkKBT8gU/uwOCc+hBP5UlqNqzVjmFumEizO46fKDyKjub5Z7Xbnknov8XPNaNzaw28BQiSOcja8Yi+X2w3YkGs1LUDZMynyyNhTIG1uh/A0tjpiovUjljaYCSxDcHBRjwgxkc/gc1Zt3m+xLdbXaLO13A+VT6H0rQutLa6tTNpzIwiCCdSCh3njB5w31p+m6PcTWyJNE0MHzKxWYfM4OMOvXjtjmnZkSkrE+n3i7B5ZO7HT0rS1G8/tFUtrqZ5J4sv8xyQeOD3rDTRr6CeZrIpdwwguwDfPtBwSF744zXUw6vDF4eSO4063dSMRSlQH3ZySccnqKpX6nNOyd46nNXCqku0IAc9B/Ot3w/pguSGkKKSRyx7e/pWTcpNJdQSsgEdwT5ZIwWAPJA9K1kuEtUYbyFXjHrS2Je2hr31hZQB/s97LIgO1oskMx/2T0IrCEX2xnSRP3kIyJ2lJlAxwoHTFUdQ1lVGFbGegJ6VW0jUHjuVkQDAOTxyT6000EYSSubFxqtxcxwWsahhbyIZpSmN7Dtt/r3rV8NgwefctIigHaSB94FvT0GaxdWg861ju7RSm3LXK7zhyTncR3J/SlhvILmzWGwa9a5cFpPuqi46Y7kYq07MHFNWRT1zT3sL2aNhuhLExv0yM9vapY5GutKmhXmZV3AHuB1q/qck1/bWMM0gmljjZ3UDqe3zd+PwrK8LNJDqcNxMii38wQykndnd7fSp6j3hd7oxYpWgQ5OVP3Se31q+k4lCSAckVpato0dvrc1tFmWxZ/lkA4/8ArVBd6f8AYUBjYNGDj6VhODSNITUmvM81+KWhC6tF1GJV8+L74Hda8mK4NfR2oQJd28kLAMjqQa+ftas20/VLi2cEbHOPpWtGV1YxrwSdyooxTt49KYCRRuPpWtjJM6q6gAOQDgVAsAlIU8EkA1pyKDnPeoBD+9TaOpA4+tYXOlo9W8N2iWmmQLHjCqBmtG6uFjDbzgVQtD5NjDGDgqozVVC1/fLByYx8z/T0rnl7zsdUI8qux+g6bJcahJfXKE7mPkxdgP7x/pXb6fZZuonYjDDOT3IqDTIAOCBg++OAK0bi4EDBXjkUnBORjb/nrXXBKKOSpNzkdVFOkUCR2xADDadvdsZwPf2PWsO/1SBNLjTT2k+3mZ0YkFZEY8DHb06e9QfY4rmNJ2u3iebnIlCgEHG7jPHPFI8NlpWopM6w7BGwiETF1WQZAZs/y/GrcmzGMIpk/wDYN5dXUc2oYgReHVZAzPjuT3HHPFc9qq3UY33KZ37sykZ/+uDxRd6xd3lxuSXcxzukPRQO59BU76mL/TjCA73AQpyN28/7IrNtPY2jGUfiK91crdRxGR1WMEAbUGQOMk9+1UndUK5+ZRzjqBmt2fQIodOtLa5cQakisXZCHV88445yOlV18M3Zt4iXiZ3XfgPnH+yfQ0mmUnDuQXAjKBhhSw5BHSqEblN+BkHpV7Vre4sPLS6UMpGNw6f/AFqrqytEQFXn5sjqKRaWg24hUxK8IBHp3zUlnAI0ZCApYHLsuSKt2mn3NxGDbQoYyCNzN3HWmPBcQnyHhdpN3P0p2tqF+lyGS1Y2nmlRt3Y/GnWcCoysQuw8EE9q6bQtGWSCSa4AI6bc8D61ZvNHtmkVVdYsjO5eQaOUh1F8Jz+nYWdFlQzRpmTy+obHf6+5qfxWkMt1BcqioZkyyAY59fr2zSz6bdwXTm1nVvLXBKDaMenvWdq811cT+fcq4UscsTnn09BTvZWJ5byTTMxo/OdjtwPpx+Vdd4Yljkt0tbtIpY1G0RTD5Svp/gfWuegQbgS3BPSpZA6TRtGdoB4Pb6Uk7amko8y5Szq1kskFtaWe9B5zvul4ZM9Vz3wBwT+FcyY3e48lMt5jZQucbhnAz2ByD19a7oOdQs1aK4ZL+LBDbs7sdiD6dq5/U7CNIZFtAvyspLO/ztnqSO3Xmqavqh058vusy0kaBlWWItGSSN44bBx+npWxe6m9va2/zxJhAiBAA3JzuVfXHc+ven6XpjYk065cPZeen7+La6wSHB4bGDkHB+lbNvpcN7dmyn+zPIgcMUJLcH5izKDgdgBxTjF9CKk431OaQE/2eNLkfz0V1eWMkKgYklenHfPr3qa8uIFvo4L8LBbIAc7QX3YXpjGfX0rTluWHmQpGojQ+WgYBWlkztAA4wMHnjPHPWrFlbRNpt2l8N1nAzMkjRqzSuOvBGQvTOPSnYzcurREwF1pMl7ckTXNt/qpUXbHjPXHv6VxN9qDTSYLcsScZ4zXS6td2q6cLewjuPMcbVVmxtbOSOOMY79KwIdEaabyFdEvWJjWOXIDYGevQHGcDnP1qZal0kldsyZg04YBDIF6kH9adEZI7vy1yrLjIPWrUAs4rS5ZvMFyp2xMpO3rzn1P8qnnsrT7Pby29y0moSAmRAp2pzxknvj0pWudDaWhvaXqB8tfM2l155HB+oo1iNb0NerHBDJGBvVBt8znsO5rBllWzRFZiJD1X3qxZ3Zd0yxKE8gGnfoc3K0+ZG5ounpqbKv2pIDtKb2zhBxzTW062sNVZbSU30yN8oVDyMcmsyVRFcyeTuReqjdnitXRZn0+3mmjkHnSjbkDoPrTT7id90y6L5G3iUfvjkuD0B9BWMk5kVkn5Vz8pPY1UupjHcBd2Mt296s3NuY4/s7kBg2cg5xQ9QUEjJCfvZEJwVPFeRfFC0MOspPtwsgxmvY5YyJw5OQeDXnfxaiVrGKQDlW61jT92RpV96B5YCM1JuFQnrTq6mjjiztGPOOvtV7SI/O1KCMkY3ZNZEcjSklAeOWJ6CtvwgBcaqpPIQE1zPRHYtztryY+WzLwo4GetanhizKw+ZIMM/wA7HP5CsOZWu7yKAH7zZb/drs7PEUahR83RR61FNa3ZtVl7qijSt1GGjKpgISWLYA96m1e4kS3iaRFmEaDelwTudgMYz7diKs2tjatAjXzNFN5m4YXOExgg1J4vWJrDdb7bySNQnnFSGRe2MdSBx0rfociackiSC1jvrO0e2uIYlSIbt5w3PXA781jeKbm10xLSNCktwZQ7uFwzD09gPTvXJM80A3W0ssZGc7ScflUZiuLqQ3NxIZZAv3mPQVnzNm6opO7ehtraWV/HPJpV5LGWYBbdhlnc9FwOSOvTpWbAtzHdJHbQmOdW2+UG5J9Qc/WtfwQVtvEEXmAq0qMqMOzYqnqbr9oufMI37iDtXJPPAH1P8qrdXKTfM4jre6lZg0smFU4HOfr/ADq7Fq5hUpbSBwpyR0x9KrabplvPbS3usTvDax52265WSdsZCBu2ePU4ol0qKDVI4rhkNpI65W2OR838KnvjofxpWY7RbsdPaarDf2xguiMOMFmGapWukRQX05uZGFmg4CYO5m/hz6Yyal122ma8vZlsntUhmWLykIIX5flwfcc8VQVmvZFiNwoRV3SHYdyqO2PWq66mcVpeOx0F74gjRtkEUaAgD5VxjHeq0msvLOkiw5KKADjjmud1CRJPOZ1WOCP/AFSgkFz2/CoDeX72NvDE0W1sLjcAQDnhvfrS5tS40FbQ6G516aKRnj+YONpOeKY2tP5Qdx8g43e5/wAmsW3D7maCNrjyFL5K/KMdz246/hVSa3KwIoZs7d3zdM+tK7KVKN7Ha6Nq0NxGd8mXb5VzW7qVtaXehyQNGfM4Kdse9eceHrmK2uklmDbo+cf1rq4daSa4TkAenrVRldGFWk4y0MCaxe1nEbksBwAT2qykaSR+VjDHoSeM10tzBDfYuUfYUGGO3gfWsVZ5rXUEe3zEFXCu6Bj9SPWlaw1Ny9SPUNOudJs7PUA6GGTKsFkVtpzx07VHda1Be20MF1aecQSrFiAwBxgqfb39aXXtSF28CRY8hWLNkAO7epHQfhxVEWwEAmkXBEilieAFJ5pN2dolxV0nPc35bWy0tI4r6wvJIrkEwRWpPMq8EMByRyDitizNtotuZEtryRpxsSSPDRyhh2I5XHPHbvT5by7gtLaa3SK5aNHJjYgMgI4dD3PJrGivLWz3S2Or6g4Enntp10g2PKDn5iOVBPOFzmt00jjd5bjJLJ9Vjs57VFtkCfZ3E64KruPKNjGTkg45OBVq+0qW5vpXs99vY2MKCNol3knnO0dGOeo9Km8OreypHLdXdzA91cbTMGOSxycAdMDiprfWwmmajY6sVuL6CcxoqJuEu7lX4PCg5P0FCsyW5J2XQxrqzFiJrm3tvsl0ojJhyCsqliDIrdWRh1XtVfxL4fMEassqW9nM6sUScmJZT0bJyQD069sV3FzHp9xqAluni1JkiWNLYRBv3pXPmJ/dUjr2xXPTWNxa288u3SIrOWJVaGQs6GPJwB23bumOp+lDiOFR3Rxuo6fptpcN9tupVWRdymKPIV+6sP4lPUEVUuUS1jjmtIZI9vErbtyM2eCp+nOK19yM7ttEw+6jSjcIfxA5HUVU1i8QwRxTxBWQ/N5b/I+Dw23sSKiyOtNuy3OWvFe6uiZAyvt3DIPzf/Wq9p8RZSkKs+Bk+vvT7u8mvJvKfhJCAFQbTtHqa0dNfyLHykXZhs4XnJ6Ek/Sp6lzdo2JCvmLHITwOMYpt5e/ulSLAVatOBB5UTocsuSMVg3Q274wPmBzn2pmEVdixu88r5BLHoa6O2062h0MXt3K/2p5Coj7bRXO2VwAVZvvHrWoJxdqVBYxxjIHvQjSafyKC3A2Txk8q2Vrgvik27Rxnrkfzr0K9tkEDSjGTjjHevP8A4njOiLxk5rJaTQpW5XY8lox7U5V6VLtHoa6mzjUTSkuZJGUs5O3p2A+grq/h/OjalMWGHZcEjp9a4ksBnmum+HspXW8ddyEYrGa907Vueq6Fb5upJnGT0AArq7Jc6jaIAOZB3xz2qnYWcel2dpdGQSK4OQR/q29D7c1eiZZoWeDcZ0YMoVc8euaiKsrEzlzaoz9Vv72K7nSQMCx2qSvH51p+F71jcqjysAfkLY5Bx2/xq7tg1ZZY5praLUflJhlBCXPoCR91s/SnWtlFo6Svc+QFOcQ5JCEfz9qtK2pMpJrltqczfWtvHqNzGjHAkICDqf8AAU+1tpW+5GpwCcbeBVeZ1fUZ5pCSrOSuwZ47VrwLHLEPsyzdf3pc4UHtgA8mktS5tpIrQLHZajYXhZMpOvyKecHg1o67ojf21CHkjVrhmKKibtoB6nHPPPTtV+Lw61xbTSJMsrupRkKgbD1V/rxVmyurPV2RLyES3gi8qSJ24lwckqccHj8aq3Rkc73j0OcW2cXM8txcp9ot28qOKRduUK5BBPT/AOtVizjstK/s+8uYbrMKsrRqm0yPnh1Y8cjqR61tTWJ02EWkKLLDKS89xjfKIwRxtJ+UkYGOmKsXaNcvNbW9xJPeh2uQWYEwgD5m5O3bj5cAdafKHtb+hz8U2oT6hPDIiRXF1IZHV84ijAyM+gGazi8dnPO4nDs/ysB/Eo+nvWpeyzx6V/aEf2nFwgtY5GHyhQck57Z9B1rMiS1XTL1XkQXTyosYwSWQKckfUkcVD0OiFv0MO5ne4m/fHHOEXHSkJUq6TPtRum1QSW/pVi4ijCt57uZVA2r97J9/wqa1hkmMfl4xH98t0HsKzWrOy6S0GK88dn9njfMLYOMYzj/9daXl+dpxOx2u0HyFTkAY5yKr2UvmXKi7dlhTlNq8g9vrxmuptbOK3uc3SmJHGEOcHPoR2q4xuc9SfL6nJmCH7NDsnzdM2GRey/3mPapd4jmAQH5cAe9WNRgVLmbyCCpOSQMVQgcLcI0pJQZIDdM+tJ6D+JHSrqcUIVljKRuMEE5Bb2rajnsriH98SgK4GO5rhJY2vZHaW5hVIExGkjbcgnJK+/epLe4kiMpR8xxAfLJ94+nSq5jGVFPZ6nY3OkxzWrXKNFFcW+CJH+4R/tVhX9xLO8z3ECI/lrHsU/KB2IHfpVrQ9TIXM0iyRBxGVDYetoafp/8AaGmyrNC8Fw+XXed8eOgx6dQT78VSV1oY3cH7xUsNJaPSkMa77u55TBOV9Meo/KrenanpkkkMOq6Y76lENrlVBDD+8eeMep7V193EJHJjZhhSYfLkHPb8Rz+lQT2o8sGW3+0RnhohGOF7nd1A46HiteS2xyuspfEY08d3fh764SO3s7WBhaQow2g7fvHsTnp2rBtbZtQhg1DTMrqdjhJVjwZVx3Cngj19a7y3vbSHBXadpChIhvAVuRjjjiub1bw0JrhtQ0w3VjdYLPGh2FgPTHqMGiUeqFTn0ehhLrGraVeaadQhCW0cpkEUcIRgjZBx6Zz0PFWtR123lXVQtlI+m3m3YHYAKehKqTw2ccDvU9jpeu2tuClw15IxVxbuMoSR0kB6nrWVruyzk0eYw5kSUtOgO2Isr8hR2wev0qbuxraLen9dRwW106+uLLW7mVDbwr5aQrhZJCOcADuNvPrmuXh019Y1RvsSbIC2Art830rd8Q3UkPiGOKZlkuLLy4fPbOZZBzhMducVj6NdXEKX96spiWFvkkTkb2689Pak7N2N4KSjzI6WxttF8PCAXRF1M6FmgaHJUHpvOfvZ9O1ZZjtLnUZZLaBltVGSqsAazb7WQ0U73qt9tdBEGIG1UHoOx96TQp1EqySoGi+7tBxn60nJbE+zkk5PclimYasTMckDAPb8Kp3UIW8fcw/eZqxq/wDo9zvj4ySVqreK32RLhmyxPOKkpdGZk1q4mVFHU8V0FrEthbbX5d+o9BWdBfJgMwyV6GrltcpeTuZWA4wuaFYcnJqzG6tLvkCRkCPbnFeZfEqcCwWPPJ45r0q7XyoXkkIx/SvEPH2p/a9R8pT8qVNryRDdo2ObXb1GKMD0amBuMAc0/wCatWjEaTW94IuPJ8SWnP3m21z5/KprGQxXkEikgq4P60NXRsnqfRVtrypeSpcDdaucbfQ9M1uQarBpd4ApJhcgbz1I6fyrzeKXeykcg8mtOO8L/I5LL355xWClY6Z4dPY9H1KzsLsXd7HcSrqCEMuOVmXHp2PTmuWuJ5LpZPtErcjK+9afhe9lWQQuFPy5LjrgjArNlgI8xA52hyVBHX6GqepjTTi2mOghadY4hnIBZfwGTWno1v58yiWVkQEBmVT8tUoG3NH5eRtOcg9K3baNhcICUWNz8u0dhzxmnEJPobFvao8H+jTebIDuR2GBx6jrzSXOgSyYuY28ibJYFx+mPStTT0AkVggZCPv46f41pG6i3NEriR4/lbecnJHQ46H0rblT3OR1JRehztvJrhEZuFt7iEEoJJl5UjqcdT24zVfX7SNbJblJjJNG75wgHmkgEqcdsZGK63UIknsniDYaMbc9w3UZP49a5SC6itjPpt6BEjtvhkYcq/fJ9DUv3dy6cubVIq6ogliM2ozuLZoA0P2YYQzEjEYH91Rx+dcu0exT5i4LkoAc5Uj/AAzXRSyFJpbG7hkmlHyRlhjYAM8EkAY/XNZlzAsqQsfM3KS6gn5toxkkAeueaznqdlJ8ujMmViU3EruHHTJ47fSord3VjsyFYbfu55rSlEPmSEhiQ5bZjlgTnP5VsSQ6JY2tqZZN91IGkdkbdsJPyr6cD9alRNnUsrWOaczxgkqxC87wOldHa6uL+0i+14lKDaSep+pqOHVobmbyre3Hlz/K25AxJIxkA1l3FhLDM0Fqfkbr3BxTWmxLtLSSszU1gWcFjILe5+d2CtAB/D1zmsMAzLGWC+YCMKOQfxpl9HIHiedAAxIIqbSI4proQ3UsiRMfvLjj86Td2VGPLG9wiukidvOC4RsBsDhvpUdlIomeSB9hz8rlc89+O31qK5gElpLKsiCMOI1DHBIJPNGlQBJyLmTylRS+5evsPzpal2XK2adoBPrCLGR5NsBHG4X73OSx9ST3rs9Z00nShfmOKRGIV4zn5mDDHToTn8K4+1uHt5orx5WczgrKz85PoD3wK7NlGoeH5PJkkby03qu7hWHP4g4xWsOpw1rpp9A8Ox2s13dTWcNwhDsUjmk42g87R9a6GeK61G3eE3clt5nEi4GVHfJ78cY6VDo13pt/a2sSRxRzRqZYFAIC+oB785zVlV+y3Nw4kwgGQAeMnqDn+lbpaHDOTb1RBBK9p4ieGUqltLAkMRTAXcv8J9D6Vb1O4YWEsscizxKhIkUZG4HoSOPSqupgzCKTyjIyvn7uNqkY59ecGs66sJbazigtEFsHOdqE7W+o7npzRexKSdmal7Z3Ti3m+0rHDmEvICVwAwOCO+eBmuM8VZbw+HWQCW3vp1U8DYC3HHXGTXb75bi2RZUSQPhHAz6cCud1mxa90rVWChZIgk8cSqADxhyfU5FTJXRdKVmrnB+KJCdVnUyOu5lHzLgqdoG4nuSCf0qLWpUTTxbWMHkeVGvneWSyyj/noew+vfIrY8U2rz3FpqkUsboVUDav+yPl9z19x3rmpJkWW6dX2II22RkZ4zwMd6yk7NnoU7SS8gkWHyLOWYB3eXCk9cL6+1X3iwIRDtAkmOxAOMdKoaXA81lKJ4t8MG0u4PA3dM1v6d5mo6haxsUVLaMfMwwqBR1OO5pIKjsUPFttJamINgyYyQOcVT068gurf7PcDDDgZo126+03TYbKg4FYuAXBU4IpN66CjG8bM1pNPijkCK+WY4AqrLaz210UhUt79qrrcSRXCuCWIrSj1jq7r83ai6YveXmYvji6lsfD7yjKyYx1rweWRppmdslic17L46uJLrRrl5TkYOBXjEYwM1cO5hO9xwGTT9p9TSDoKN49DVMLEeadE2yRG9Dmm0DqKBrc9m0Xy50tnfhWQZ9zitKCJBdoCOM4rG8OSKdLswv3wozXRywsFD9SrZOOMiuZ7no3udRp4i0+LzWy24fKxqsFeRlLEDcTtB7VNCvm6A5jDNscNlRnA9/Slt4452bzJQqo20P2HuRVnL3ZbsbeMXCuTtUsCcjO36+taL2IjmbzN5cMWG05Ax6f4UllGY4j/qyPLAcAZ4PQj3q0zoPL+zhnkB5YNgEf57VaRk27l2wuuVVT1Hy7vX39K3XhTEQiZVY8kD+I+prnLPbHMBMJA+7kgjJz/CR6e9XHW5W4DRhYY42DHPRj7VaZjJanS+WxklDhvmAQsBwRxVXUNL+1QuipE9x1VmXhT2NWIrpkR2lI4TO48456VZEoCvIu3OzPB6cZq7JmCk09DhdSe2cXMeu5tbvYPLlQF0kI7hv0xWOdOt3tTdWd3MUKGOdCAXAz1Ga6PXmF7Em5S6Lyqg4GT1rk7uBoWlETyRqQM7G+U96wloehSd1vYqWthc3t8tvFOFdsIin5WJxWnqGiSIN/kQxIDswOgYD5s++etUba2LEbWZXyCWHByO+fWpp4y2TNdSuC/wB5mJyfWpW2xs5Ny0ZVjg+zzl4H82Rf+eQPy1oRXUUNv5scq+aGwU659fpWvp9oZtMtLaFYmKKxLJ8uSWPX9Oa56a3m0+4MccJeMnrszn1I9aq1hcym7HQ3un2uuWitZEA4HXg5xXKPo11Bbnzo8R5IY5z3pyCdbmWO0mYRfewx2/UDHWtNNUmiK2Mih0ZP4fmwfQ0t9WNc0NIs5v7KYwrMjm3L7VXoXA64Pbt+dTpEfJiPkELO4aGRzyqg4zjuc8c1oa5Es1xFBI0sX2bKyRuv3CfSrFjAl1e28EM2zyipMip91RyevpStqaOp7t2LfQSfbxFOjPJbosJ3sMY5Yt65PPbtXWeDtNmuNOl2ytFasc7Su4lQcqP61z/ii2N3NqVzb4jDOpaN5A0jA/xge+OMcDmtDwfrSJDHaMxQK4O85BU9OlaKylqclXmlT900NIEUetX9g5xHaTF07EAgHr689K1r2Bo7iWS1ch7hM/Z9q/vDjsT+tYUM7eHbqVmt1vLRpDIzggypu6n/AGl+tdZatBLi8tPKngkTcpU546/5FaR7HLUunzGbpWs3F05tLmxlt5otud3ykr67T2rT1LH2V5NwDQkHOeCPWqNndi6vJA0bRvH+73MAT6j8Klv7QvZTnzSxKttJHPrj3quhk0rktvcCO3uZnVxHGw2t035Gdy+orkre+nF9FKke6KFC8437cqWOFXPUjn5e9aK3mfD1lbysXKuMEjGF5OPpjNYNpMsguz8pEt5HDFzkBM7uP5VDZrTjZO5dNrE1/HbW2+SyuVa5syThYz/GMHvwD+BrkNXgsmnflY3JKsqglRg/wnuD1rqdVeO/0a5tC3lXFlcO0a4xgMe3tmuWvbS+aziEgG3HB2gfke9RLY6KOj1ZThZN6CKQs8jKmzswzxn8a27uObQlvba6VUunO18H9B7VU0a0/s6OS+uxzyig4OG685rP1W6uL29e4uSS7cAnrU3svM0a5pWWxmXnyvtHzE81W5DY7d6tTKXck9PaofLy5Bzk1BqMkA2D6fnUOS2B/CKnlGFOT8tVN28gj60zMw/Hdxs0V1JxkV5ZDGW7V23j288xo7ZW6nkCuWjTavPXtVrRGL1ZVMeTil8oelWdpGeOO1LsHpQ2WjLo6fWnKCTSNgdeaszPUfA1yLjRAP8Alsp2iu4tEaRP3vHTdXl/w8mAR4zkAsORXrFiNkq7sNCT82awktTsjL3Uy1olz5U8lm7ERP8Aw9jWy8sIIVNqxqOFC9vSsCW0KOJIOWRznJ6r2q7btFlWuISyqSrqCQfwPr3oTexM4pvmR2MENtcxtGzmIxRhoJ1UhHGPuN6Hjj6VRl8zbC7qVOMkYzxVbw5d3CCaxd28s5DYOC4H9aiimMMzqzO21tnzHPtj8sVpe5hytNo2be4kzH5gKlujNyPqPSrlxekRKFCu/AA5wBXOW+o7Xk2D7/3h24rUM8KRx7OpXPqaaZEo66nQwXJkiTzFRPlVSA3PHStDYWsWCOVJ+X3P41ytvOiEBQAc5BOenWuk02/U25iYkQvkZPOM1aZhKLRi6hbfOIwegwABWbeWQFqo25dTljjgH6Vs6lcImoSwoCNo446Vm3l5FHauHIKlcZHJalKxtBvQxB8obPC4wM96mSJTGzOCYkwvB7ms15vMLMB9KsRy4swjNgk81kbWHXdxcHmAiDjB28ZA4FU5dRvXwrSAL0JC54qwMsAdwK+tPsLIX9/DCMKCcuw52KBktSa7GkZJLVEts1rqGm/ZjHDDMjY8wLhm9zWRNZXWlugIJWcnypOzgHmt26NpphkaEK2AAm7qB/8AXplqr3RF1dq0hRCsaY+VPwptfeNStqtjn4/PDz7hudmKMxG4qM/1rU0KWKPbE+POnIAD4XPsx7D1rUXTY7+3SCxHlTyMMqcAZBycsenesfWdP+zeIpIliVYSd7Qq2dkY9SOnTOfeizWo+dTvHYs6gwtls4Z5fPmGWdgeGwf9WPoOnTNBgntd+oMkgiimw2cblRgCGI/HHNLfov2bTyiLG0alfMUYJJOQPcjHXvXUeH7prqORrlY/nT94hGN59SPTPX61SV2ZTlyxuW45rXVYITHIhmADN3DnHGB2+lZtisPhnU0FzIVtrhdsoI4hkPIcL2DdD6GsnU0GjahaXCW0tvbSYd4m/wCWb5xx6Kexrr7lLXXLTzWVcToBISRuXn375rRO/qczXL/hZoaWokLuwVSWyePvZ5zmnX8iJGARycj8Kw/Dcstpcy6W8hlZBvhJGC8Z9j3HQir187MFxzt3ZBP+eatPQwlG0jC1UbUBRyZBuUgH7o7fzrmUmMMVvCDiNZd+R7n/ACK6nVWSK1mniJeNVXcjfxE9foa5C+ZM5TiM8r6hvespHTT2sR6xcXNxqimyjAZwEK5yXPqap313dzxwxyps2dTu5buPwqw7rJjAGAuPXHqarybPMIUBV7AVmzdNK2g/zprpEExGV5wKrXR5OMj3qxHydy/cA71UnkDOW4NQyluQEEITnPpVUcyEg1OxOwt+ABqnIwVTzzQMguZeTz9DWZqF8lnbO7NzilubjBJOBj+VcH4o1Rp5fJQnHerSIk7IzL+7N3ePM5yOw9qYr7uvT+VVAegJqTdgDB4qrGSLitn0z9Km2f5xVa0GSOvWtTym9BUsuxzjtnoAo9BUR5NSSckD+VR4rVGbOn8EXISeSE9/mFezaTMkyxtk424OTXgGi3Rs9Qil6DOD9K9o0a4328YHAPPFZT0ZvTd1Y6W3mkkmKqwVtpxnuB2p4uswJIysxHDH/aHQ1BEnkxosh/eE7g4/lTGmNvlQA8e8jBqGapX2NTw5JJ59zNJny1yOPp/OqqyPIr9SAc1PeTRR6dDbRjMwGZSPUnPNMsihiAJHJ6Gn5EN6OQttghmJ+b9MVoW4Ylc7iSOBnoO1UmIjcYXCkcYPel+0sGYrn5V7/p+NNGb1N9nEYiJOzoD35q3pt02I1VgpJ4yea5tLiSaTaAANuMZq+jhAkse5XBI2uMHjvVoya6M1NUmLNI+5gQPnYfxe1YF/dRlAAoUE544x7VduJXvBv6n64Bqg8YiUhgPm655xz0pSuXBJFKKRdznacDoB3NaWoWklk0cTg5dQxLDjkZ4qtBEGLeWWIB3BVGfzq9rVtJD5aYmK7ckytn5jz8vpxSS0Lb1sR/Ybq9uGjhTbsXczP8qooBPJ/Cp4d2nqRESizqA7OPmI6/gKvaXdFrLUVhVCk8kaFlY7sD+Haf4c1ieI5plQnzMgttBHJSm9FccLyfKxVk/tTUizzRiIN8jPwBz/ABelXbfXbjTr6SF44SVl27sZUf41nYji0WGSFg86j95tU4Jz1J9cVDZRSXQVQCN38RHrU6mjSe+x3krRy6PcpG2bhY3utyHl27g8e+a4yOcSXNnHK4k+XDSn5NysMFSfVTxWojRaNhUvWWZgd2D823+6D2zWDdXCzwyeXbp5cc5k8peiqeqjvznNW3dIzpRtfsa8UbJFiQk7JfLQ9Cdo+X6dQfpWrpMkQjiCyFVTKTyBfuEg7Wz35B/Csm6VpL2MWcnn2Kokiux5dD0APdhyPXirelzRadqB3o/ktGQpK7hJ0wD2OMHrVLcU9YmjfXVvIXttRMYs5iIWl5/d887h1A44PbNQWEkmmz3OltHJdaa7+XDIxyI1bBBLflV67uLK6hkeOJxLIuSrAD5emV+nNULWSO3lisbp2ktyC9tJICSNq4VfcEnvVPcw6F/XpbiOGynZFF7bqJBJjaWIJDj8h0q5qdwBpD3CEEyKH47nsKqeKpTHpe0FWaCJUlVmIYSsOOPp1+lGpBV0u3hI+XCDA9cDt+FPZmW6TMieRorFIpAQzoHfPPPauZmyy/Iwy2ce3c/jW9rE5e8Y7jjjIU8ACse9CiQqgwACc+pPWs5G0NCpIxiRW2lUYcGoJ2GdyArlcYz196ZNIPkDEk9iTULy4AAHGKzZskXbR28kK3U8/hVSf7xHY/pUm7YqMAQcVWduGJJDdqkpDbkhUVfesTULgZKqavXUvDAk5IrltXvBbo7k80IG7GZ4i1UW6FEOWNcaAZXZnPzHmrd65uZjI/QngUQwrnIFaIxepEtsODinfZxjg1cSAY5BzUyWo2n1ouNFSzi+f+daXkmlghCNnH5Vc21MmaJHEkcmk2/NzUuB60gC+vWtLmJHivTfAWpG8gjhYjzoTwCeorzddveruk6i+nX0c8Rxg8j1pS1Q4uzue+M/nsCcqQcjvTWX90HYHJDE1S0y/GoabBeW+G/vAdjWpAVu2hUg7S2CAOlYs6oy0uT6gn+mYwc+Wp/So7Ygpt54PJ71NqUytf5jztVQvtQkW3ceN3qKfUhvRXJmO5kXj2ouAqRBVA9ASe/1qFjtw2ckDn606NzIpVsHGeB/KmmZWFiYrgEBmIqyrtLIozhV6EnqaoK2DtkGWznFWfOBTAGMAHHeqQSRrwgx4RcBWXg565qjfOfMCqoBX3qM3B2KMAL1qnPOFcj72Op9c029Aimanh6dYtRiMqgJk596XXbua6nLSOTvYnrjPuR2rLhnKSb0cqW4BU9PanQoXALAjAIBJ6/4Ur6WK5VzczNGxmMEyBZdoI2nHBPt9aualbW17ZTDc8c57N0U9s1hTMY1Gcg5yCD3rVsJnnszMZA8q/K4PJ46GnfoVZr3kZltcINMEaoV2/Ky56nufxpL/XvLtY4okww5I24x6YNVbgS20k7shMON3A5TnvULXQuYfs/lRuGIO4j5l9s1ndnQopu5Ylk862F07osznHk9RjHBH60uk3FvEZRdl1SRlyVBzgc8Y70+YQG2gtpI2hkRixmByCpHQj8BzU2lJIIruAo00yHzFiXuuPm6+1NbibVi1ps0NzoZgRglxZzedG+MEocgg/St6zkhm01Z55BDcSAARnoy9Acdua4XzJsC4iLKrgFnHBCngZHcdjW0HiVD9kilizGCBITgnjjPcZ5q4yMqkDr47VJbGRbKRmAyu5GDbWx2/GsyaPUrVNMuLqFI54CFSYP5g54z6ep/nUkF9OLlYYZ4o8/dn8sMY1PbnG7v16VZgeaOG1u5ZIWuI3dkV/uknI+ZR6Y3AitNzld0VdQiin1iwt47h5oiDNKWbcWIPU9uuelT6rc+ZsWPGS+Rz0qjYzm8vry+VQFlwqFhgEDrgemaddyxt5jggBFKrgdKSZLWqRl6gAm55CDg5Az2xWRMzeWhJwD39Bmrtyzyxh34DH5vp7fhVLUrhSmwYyG4GO3pUNlxWpQnZS3fjnjtUanzOABxTJBuYluAOc0towTexHAHWoNizu+UL1qtcfc5x71KjCQbvequoSbQVY9ulSMxtRu1hWWVzwo4rzjV9Ra+uDgkIDgVq+MtUz/osTdfvc1zkagIOMZrRLqZSd2NckYxxU1u5zjNV5vvKBwKmt+ufwqgsacZ+UDvVyBRxxyaz4Dk8delX4eDx+dSy1Etxxg9qm2H2ogFT7faouapHmhc9KZvOae64PSoyMV0o4XcUuaTeaSjvTsK7PRfhZ4gFpdNZ3LZik4xmvYII0tlaQMAG4QV8yabcm0voplJ+RgTXv8AoV+NS0uGVTkbR1PSsKiszem76M0I8sxYk7m559KuAfu8sTn1FU4vlBJq3bkMp5GeorJGtTUjkBBz/CRxSK33huwvc9yatzGNYo9oPzZ3D+VVmAADL0HB9TVEJkBYtMCr4PfA6VOlysaEMc8YHtVF3YEFVIUHjApjSBuWbGOeP50XKtcvF2dkIwVVt2D0/GpJoRJISOQxPPvUFo6NCoUhs5zkdO+fetDTCly0m99gQDB7Ae9UtSW2ipDFskYYXcMHnpWjlDakBfmHXPpTWEW3cBkvwEyMj0J/wonn8pngZkYDunINPYL3ZRfMzOXHQ4otnktiJYT3xgnAb6062dJ5mRpViBHBK5ya0rKxjkgjlv8AcGLeZEpI2vGCR8w6jOOlK19TTmtoyKe/a4MQO0EAqo2jGD1B9agttJW6uwLSVYnVSW4wpParl5epHPJLDFCgJOFUYA9hVBL2dpZCxZUHRU4609Oo03bTQpXsha4MUsscjRtsLKchgOwrdst+mSwSb4Q8kWfN3/dB/k3asOS18+4aeMFlDfMSwJB96sXuqeVbT2sqJiThvMXJ46YpLTUqS5kkjW02OJdSh1CNrad8vG1tKdu0kYyezEjkAVAbJbid13GF4IS/3vvgHAUf7R7DtisHT57ab5HLeYv3VBxn8far+l3Uq6h52Wn8rlWbLdOp5pppkyi1dnVJp4jkEF3EYVCK/wA5DFZB82Sc8dMEehqrq+pvq80n2fasCgo0x+849EHYe9K1vpF9KztJKlxL8xVDsjLHkrz37elUr2JIT+5UpGpwoYfN7hh61bOfrruWTOkUCqiqqjgAHJ+lUrydYo0CNnJz9apXDsu0YJ55qjPMS3PQd6TYKN2TXV7vfOSBjB+tUmDNjJJPsOlVmlPzAD5qsZPAUEEdfSovc0tZCT48rk8jrSBMRgj+M8+lNmUlsEjBHan7uQSOgpMaEmdEQKvOOtYGvXywWs8rfwqce1aM8hyxPAJ7VwPjvUAsAto2+Zzzj0oSuweiONnma5uXlY5ZjnmrSZWMY5JqhGtXVGSBWjM0hrrlu+KmjGFxTQpXJPFSIuW56+1BaRetU4Fatug4NZ1omWFbNsgwB3qGapE8KEAH+dT7D6frSxrgVJlvWoYXPMJY8CqxHNaksePeqUqYPSuhM5XG5WxRipSKaQaq5LiMr0v4bavi3+ys/IPQ15titDQ7xrDUYpgcDODUzV0EdGfQ9ueCGIwOfwqTcEOSGAPOccVl6HcR3sEDBvvDn6V085SKYKyF0IA5HXiudI6LmUkoaRuvA6mi4kZHBUYXrn3q6Uhu96BQsqr+728fn61mrJvBBXJXgjNPYLXAMGBfjA7dOaqs4R5VIUqRgGllmMT7eo9KhmXG0j7vXk0AlYdbTIrDbnnmrkUwViqnAHQZrNK70DIdxPNNkllDbX29fxoHa5rBwjqxwRkZxUt/IJJWAIXPI5yR+NZ0U+1McZ65qzfELHE6gYK5p9AS1NXw3bs92l4H2m3XK5OBu9T9KlVvtAZ+cZ5HrVm3vPI8PrFHCoZ1PPr9TXP2s8iSM2dwP3lBzmm3bQEnK7HyFlleSUYC8KBUEN35MMgK5kJ65q29zBJavs3iUHGCvWsKZ/Ki3MpZ2P3fXmkax10Zr2eool2XG1cAFzjg46cVm3F2l7qUkm1UgHKjJApLuCeHTpXK+WrHcV74qDSY4zYzzuw44G71p67FxUUnIV5Y5dQZw25Au0fKF/Dit3Rz9ntVlK7kB+dA2Nw9K5+GdIoZCUVyRhfl6e9aNvep5CRnI28kYwPxpJhUTasjQ+0xRGVRg7zuEZ52D0q3PcS3iJLvLGHPmN7cBdx9c9KzpNVcyxtcW8UqKuxMqOg5zkfzqe1lM1rOQzeXJksF+UZ6iqTMJLS7RXeQ+Z34yOarTMgzlgB3x/KmPMQgY/fxzmqjlSQSxB7gmpuTaxOHiA+YH5vu4/rT921TlhiqcybBuHU44pdz4C45POSaYrFuLJQvIMMelMdtuN2AW5pAWU9Tg+tVLmYDczdBz9aQIqandrFG7scKoJz6V5Dqt69/fyzseCcD6V13jfU/JthbIR5ko+YegrhVxwK0gupEnrYtW4y30qyqlcE9+cVHp4BfBOKuugx06UmCZXPC5x17VJE3P+z61GTliB0BqWJM44pmqNK1kGc5GK2LYjjBrFtI+c4ya1rfgDPPFQyjTjYbcClylVkyV6ECpv8AgJ/KoY7HGSRY/KqUsQDHg49a3JIvlJ796pzQDkevNapmBkNESeBxTGj4rRaPHX9KjKDkdTTuOxQKYpAvPSrLL2xzTQnOKdxWPQfhzq7GP7PI3zRnIz3FerTyGR4yrdV64r550W4ayvo5lOBnBx6V7rpN0J9LinT7yjj3rNqzGi1JLFuKqCs6jOD2H+FVZoBOPOg3JKB86epHX8auvHny7t0OSuD6YpkOCA8YxgcKPX/Ci3ctStqjJeVWALDBI60mBLhQBuPTPFJdQBZmJP7mT5lx2PoarzBk2gZI7ehHepG0nsPLGPIyCc5wDVOd2Mj4IGemKVj5bYOfXGaikU/eP3QeoNAtmWLZn8wDOQeD71NJPj5RkDpz2qGBlSIHgZ4p0uTEXPzIByVoKjK7OmuyP7MWKJwkcC9TzkHtTfDMMZKEDeWG4k96qWNwk+jyJLEZDt27u4A6VR0qaVHMabyqjr6VXUVnytG5qlzBFeykALJtyFHYVysk32jUYI84VXBYjjiqtzdNcanK3mFs8Zz+lSWylboOE4RepFG5pGPIje8RTia28lGwmPmNc6ufIW3UEs/IIPX8Ks3csnlBmU4foT0PvWZYTJHrYGATH70PUqn7sbGhJK0At4CpEi8uTT2l3xkbsbjyR1FRalfmW+8qKMAuuM45FOup4bGJI1t2yU5LHqfWkO+xJC5e5VzIdqDjNaFvchUkfoir+ZNYthlyAoLljnbnHNXiVEfloQxB+Y9iaRNQcZGZctwB1FV0dCM8ceoqGRyJfLXrjJqRE3EMcAYp2MW7Fteqkn3HFMT5pCcjJ4piYwwXOcYyaLdW3l88BTQRckupiqADJx3rC1nUFgt2kY/Koz9TV+7mBBI4HY1574u1MTzi2hJ2L94juaaVx3sjA1G4kvbp55Dkscgegqsi55NSMMEcULgGtTO1yxA2xgTViS4ypOMVS7UEk8VNikiaAknnOO9aNsB1H5VRhHTHWtC3ABGeRQzRGhbgDjOBWjCeOtUYuufyGKtxZ4xWbLRfhGcVPt9v1qvCce9Wt49KkpHPOg6dc1E0fJ4FXSvpTWjGc1aOexlywjnt9KqPEFH6VtvF0HFVZYSCeKdwRjyR4bng1GUww7D3rVa35PBFQyQDPQD0p3GypGhPXOa9k8CX0F1oawq4WePggnrXkCIVJwOlauj30mn3iSoWAzzilJCaPbob0/Z5LYrgA5X2p0jCKHZlSMYBPB+lYVjfQahbR3MTcjhgDVu6iM1qjROGyPWpux2RUu3ZYblVkHDBlB9T1qrHgx4k5HY9cfSnzwTMoE29RjKsOScVPDD9pQRJLCjH+NhjkdiOxosaN2RRvIJY1VmU4Izk8cHvVHcVypyVPc1tXrymMrdNuYKFBByMD/CsK4wRlOMikTvuSrMQuAce9WJZEEZAkB4yADWbG46HIPrUcmQPmzxTHFanYaOFXw87qwLHJI9fSs7SbuYzsig7SPmOKuanPBbWEcce7DIMgDHb0qj4Ynj8q6kmm8ttxC8c4xT6iT91szb+ONfEQSBsBhuZR2NWwJYnkVyNrADGP5VnWzomp3FyxLYYgFuv1pbS8e7u7rcx+zRnCgd2plyb+409QEc8UaxsyFRnjsKzLS2WTfIyhgxLEkc8VPNMA0YyVB9utWzKoVUt9pXbhTjoaTEpWWhli4Z2VpImib+EgcfWluI5ZLhfOkWYAcsD972+lXZ7mWyunibZN5i7wCcFPaqiyokhZdsTE8hTwfrSZXO1qXE/cRkIBub5cA9KUSbR8w78YFUdwR2kZRnPDIcE/UdDSm4KsdzKSTgYGDRYzbuy38qqZHOWbuTUkcgwckYx1rOJZmBP0wKuRDCHvk9DQJrQsxjkquNp5JNJeSrDCccA8GoGlEEfJy55rmvEGuJZxl3O+U/6uPPT3NG70FYqeKtcNpCYYyDO4wB/dHrXChyWLMSSeST60k80lzO80zFnY5JNJ0rZKyMm7skY5xTgOM8UxevJ+lTAYFItCL3FPVcnrTVX86njXLDHahlJE0MfIFaMA/HA9KrwQk4xV6NCoz0IqGUiaFSB61egHIyMGqcf3eRn61bibBqGUXYRgg/yqxk1VhbA71N5n+zQh3M8rtanKnPWpCvJxTkXpxTuZkflZ/8ArVBNF1q+FyM1FMmKAMuVD0FQCIk+tX5FyetRAA9Bj60wsUWhPbr6jvTPLIXjtwa0CntUbJgHP4U7iZe8Laq2m3mxz+5fgg9K72G7ZCBbkNE3zKD615Y6YHA561taBrr2ssaXHMYOMmk0EXY9CnnaRN+0iHHPP3T61j3RLQMwTEyAhj/erThuY5VCph4XG4e1ZdwJbW5PQoeVz0PtSNYEsF0ZbRCjr5bkKS+fkb3qtewyWkhjlC7TyCvIx7VIZI7yOby4hBMoy6A8OPaqDNNcgN5zSCMY2t6UD5dSDjORz/SllxIhdRjbwakmjMTjfgkjle9R2itPM4iQsoX5vTFMXmbWoTF7KAtgloxk++OlYTyNGkjR4BAyMHirdpcRRRy2s/EituAJOD9KzL3zFV1jUsrcgjtmgUdNBmk8xTSSZJZuPapIme38+VnCLnO3OBn1xVJt0Ns2DnykLsC2K5S0umnvC7udpPIJzVpXBu7PQobg3CiSQgJj7wqU34t4NtsnzEY3t1HviuaSZldVDsUK5IY9DVhJRnG7K1LJsW1dyCx5Y9SepNKj7n9/rioUlG3bg1IrkgKOlIq5djOcMRx1xVhULHcT78iqdsdpG35j3PYVd84YLcZ9T/SlcjUeoAcEinSXCopLHkVnX2oRWsTSTOF47nmuI1vxPJcBo7TKJ3bPWiMXLYmUlFXZt+IPEawFo4GDSHv1x/jXD3FxJcTNLKxZj3NV2dnYsxyT1oFbxgonO6vMybdTl5qNKsRqTyOlDNY6jkQ54p75HHepkXgZApzQnGVqLlpFeM1ft0DYz9aqbMHtV+1GGHpQy0aVtHg8DJ9fSrfkhqjte3GAfSrsfTpWdxogVcVJEBnnmpHQY4//AF0iL+B7UmMsKR0p3H96mxx8571Lt9qQhrL0pEX8vSpmGTQq/Mc0xIVR2xj3FRzDg4qcCo5funigEZsqknjrUSoasS8kAZ/wpu3Gc8UyhNnGRUEgHbrU/UcUxupzQQQNFnntVUxbWzjPbmtVEJHTmleALyadxE/h/VPsriGc/J2Oa6cXqmJonXfC/TPVa4aWLPI49qu2WpyQx+VOSyjgHuKllxfc3DBPHKhi+VSfkfPT2NJK/wBkleZ1CTEYJzw3/wBeoxdrNAqyDfEOQQar3ly7RCEYkQcgt1+maaZo7sWXXGmPlPbxvIowd5+8PY9qINbRnMU6rCvTy4k5PuTWNcrCrAMCpb9KqyYWfZJIEx0JP8qYcsbGtqlwJ2V3QuqH7wb5sf1p8eoRNBGI3ljQdSG/Sufe6j88rLK7qOmzqTVTXdSkVPIjbBcfMBxtH+NUkZTaSsV/EuqrfXRjtiwgXg9gx/wqtpqh5Mt90DOQKzwVBwQfqDVqK6aOPZGAP9rvWhlB9zVtLjawyGPrk81pxOSCQccdO9c/Y7pXVQTj1retiqfKp+YdSazka3LcDEMMkntgf41cjYu2AC2OuDx+JqjECTkgsM9+BVsGXbiNVVfWoYOSRcLxxDdLIAv90Vj6trywRP5RCEdB3NGou6p8vL4yWPauM1EM0rM5LE9c1UIpvUynU00Iby+nu5S80jMT61W7Uh605RkV02SOG7k9RRThQFqQRmk2axixU5PFXIRge/eqyIVxVmL3rNnTBWNCBAR/QVKyjGPbrVaKTb9MdenNWom3EcHHvUFlcJz+lW4Fxxx7U4R+n5VYjiyRwKTZSJYie31q/G3IPNVkjzzzVlFIHSoYybIJwKfEoJ6YPpSRp0/wqzEo6DtUlEsUfp3qXy/enwqOKn2ewoQj/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple moist papules are present on the glans penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Keat A. Reactive Arthritis. In: Fitzpatrick's dermatology in general medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw-Hill Professional 2003. Copyright &copy; 2003 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25651=[""].join("\n");
var outline_f25_3_25651=null;
var title_f25_3_25652="Tetracaine (topical): Patient drug information";
var content_f25_3_25652=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tetracaine (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/30/29155?source=see_link\">",
"     see \"Tetracaine (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/31/2547?source=see_link\">",
"     see \"Tetracaine (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9564873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pontocaine&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9564874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ametop&trade;;",
"     </li>",
"     <li>",
"      Pontocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691606",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain from skin irritations.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tetracaine, aminobenzoic acid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any pain during care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12317 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25652=[""].join("\n");
var outline_f25_3_25652=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564873\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564874\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024782\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024781\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024786\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024787\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024789\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024784\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024791\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/45/27347?source=related_link\">",
"      Tetracaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/36/17987?source=related_link\">",
"      Tetracaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/18/13603?source=related_link\">",
"      Tetracaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24148?source=related_link\">",
"      Tetracaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/8/38019?source=related_link\">",
"      Tetracaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/8/43138?source=related_link\">",
"      Tetracaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/30/29155?source=related_link\">",
"      Tetracaine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/31/2547?source=related_link\">",
"      Tetracaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_3_25653="CT transverse process fracture";
var content_f25_3_25653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    CT transverse process fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 507px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH7AfsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxLagBZWJfuuc0LIVP7slR3RhQq9yEyec56VI5z357nqKAFDFQxDjPchcikkXeV2Lkk8Y6UAbDiLBB6470KSmTsyD15waAAJKDjaSO/tSkKoATDBuoIpOWGASuOcZoXAUAHcp6ADkUANCpGQy7SfQ84oBhkTghe5qRT5QyF575HWo38oMSUYA9KADDhcEjZ168mlUBMEIoYDg5phjQBWGM579qXbAScZLDkc8UAOYb2+ZkVu5AxR+8cAcNjovcikXay4YAHOeTTidighDsPGT1FAB5kQJWMsoxzGy859qerLAwaMM2TwrDg0hPRmDAgfePWmqRjzAJXUnueBQBfXUSAMSoFP8AAOxqyNUYEKGRRj5krGKB9zhA3PPtSqhClxhgO1AG1/aMewh5TgHIIqM6ijArEHx3+fispkYIGGxSRxmoySxw2z5uAyjg0AaElzkkkYdRyAaotNvchl5bqe+KjkYhciLzGBxuBwcUK2VKAEk8g9xQA9LiSGdCTtH07e9b1re+cjbn346BRisBWAi2rhiep6sKdG8iukisxXHXoaAOpTaATIpPcEtwabKGCu8cgIPGD0rGgvZAoabCJ0GTU0d8vlsFmBXrux0oAvmcoMyeXjHVeaibEpBR9p7Niq/2pMbdqtnndimRuqqSBtIJJYmgC2rIcpIUYnr2pJI9x3BGx04NVGdDlhIBx82BUTXSLhgWEgOTzwaALbhGBMeOnIY45rJmcudwdt5PfoaS5YtJ5hYnvikAym5v4R069aADPDCbcWU5Hapk45Bxk5AI5FJHEki/vC4I4AcHBNOMLhlzHn5cZDZoAizK8hO/I9QOTUiRCbfgkMecYqe3kVgi4ViOAOhWrMduzYbcApzkGgDOa0nR/lysWMlGNAg2oWEZUddxPetPYob+J8cc9DSlYdpLxFF/u7s0AZjpKrDJBI9O/wCNRDaxKunzDlgvWtdokBx8rxMOWPG2oZLOPhlBC9nTmgDOkTEwAYY28M/8qaFVssFZXH5VYmhjZAryybc56dKgkRF+6ZCGHIz0oAC2ciQn2AND7VYhZG6Z+UcCmIu8ZWPfJnAL8ZFTNGwQqAIkzynWgCNZYiTt2k/3sc08yBFIVA+O/akxwpjABBPIFIygkFQ4I5JY4z+FAFhCJP8AlohI4wowB9aY67WJLK3ODzwaaCMYXc3sBgZpCzbCsm3GehHT6UAO3bi2xcIeielNDsoznao6CmqhRNxUnPUnijflxwdp4AXvQAGJY8kr15yDxmljZt7FSzew6UmBn97tXuBnpTWVXwHYkdQBxQA7cyt/rPMPZSOKu28IU+aNqMBwTyKrWkTphSdxJyAegFaccO5d8imNO/v9BQBMGcAefHvz0KHpSxjGCctjJAxUsaAR5UMAfvc849qcxKttiHyAdD1FAAoZckSYHUg9jUhRipLPz2YntURDSDcV3N0KkdqXcjELubI7EdBQAI7bh/CSeo5zT1O2X/VKZO+TxRtY7Qx2K3TFIEK/KAF/2ieaABpCPldDIc8KDgCmjcAu7aRnkdxQylWbaQD7dTT8RjaWByDx9aAGnHO5jtU8ADOaAikEbQAepNP42ne+GJzhelMAwXzyOyg0ARhRkgsSCfuildcscBcfWnu0hOIyI1x129BS/wDbNT7mgDmFEZygYKR13UxxtBwu5R3p5Adlxz26dKU+coydrYON+KAEjY4ACAA9x2p3yj5VGW9SaSX5yQW2KRklaYUUNhTvU9CeooAc0QIBbCsD1Hel2qxG5TvX06Gm8x48pwcnvS7y4Kj5Gzy2aAHnOVAbYBzgc5qNVMkhLyA+g6YpdrJxI2/HTbSfNkqyqmehYc0AOClckyKQOcHvTCQFOCPXmjeq5RgGI/iPSlAAUFJFLY6YoAXh1AJQt64pojQkK+4EnHXilUIxH2jIX+LAxzUkqqFDiTA6DHNADAjxgkspHQEn+lSEbSpZVJ6EqePrio1VVxswXz1Ip6xTNkhA2euTgEUAMB3tgSjK9MCnJkDe6hB1LZ/pTW3EbfLCheeDyaj3AYLDgng+hoAIiiS5VxIvfIqRkZ4dmzK54wcYoL71V3CD1KinEmRvmAKddynmgBjROvPlEbe2etBVSp2rnjOFNXDlk+SVXPUAj9DUUkRAEgAJxwI/60AVI0UODtO/oMHFSZG1zIfmHSk3Fl4GQOeeCKdgMoCTMP7qsvB9qAGNJG7Kw+bJ4ycg0rvwMbEPQ49aHAMOY4kGeyjkGmsWD/KI8dSHHNACrMQ4/etIwHZcU8OJELFnkA6g8YpilGIVshOenarKWTSqoi3n5eGzxQBVWREBOflHBAOc06K3SXiMbnAyFY4zVyK0G/aYFSQDBPXNXYYiqAIiZ6Nv4P4UAU1tHVPvptBAKHkrVmCFY3YI3DdeKl8t0P3o1OcbuvFPw2QsbxSZ4BHBzQAjBWZlSY7hzh1yKiCbmd1kEinkADBWplaUSYBj3A4KnrSqBISygktnOOCKAIFEUch3EDPPTmpN0TgjdjphT3p0ZZBztTjB3jJNDbGb5Gy57heKAGhuG2gkpxtI4FDBlZZAVxjgrz+FSfOzKGG1wfz+tIySoSRIOTyAOKAIy8i8SRp5bdjz+NGAu0RBgW5+X7tSFW5WaUgnnp1ojkRDtQsSey8cUAQ3FrI0aszKG75rPYxwvyfNZuMKPu/jWq5Acsj5cnGHGarTxyDem9ST1AGKAKRZ5AcA+gXuKcjHBDuA2MBSOlMAwxXJL9yOCKe0SBFeQMpJ4DHr9aAIgFXG7cR1yKaXjZvUdmbqKe8jI3zbGY9COwphNuDiTd83HA5oAUxHcGilIz6nrSJ5h8wxk5UdX6CkaNwx2Lk9z6CnbN2BKBtI7ng0AMKOeWfepH8R5p4/dKxUhn6AelMd2DgCIFQMALzilyFQ5RXAPUjAFACA+WpGF3MPvdcU1WDfL1PqRwRSbU+8AwUH5gpyDShiSF8o7eT7AUAaFlheiZB7N2rXtQWVX4z/ALR6VlWROUK7VXGPm6VqQbAAQmMH5mHSgCY5aQkqGcDJwcZFNePLbgdxPIVTyPrT1kJhLCMFOzHqaap3gkL5QI5C9c0AI7SNgqwHqaZDmQEebjnvwTSjlAWHAHIoWNXYBISox3PAoAkeQwv8wBB45OcGmMHkB8wBlJ/hoLbB+7VGI445JpGBVPmV2zyEBxQA6QDduAdQOAe9IrKTnBLfzqJWcOzFSo2457VLycCMYx0IFADQmEUqApJyBmlaNwSX/h6YOKfnGV4z6VBINjHJznkknp+FAE24RgYY7m4wpzSNKM8kn3xTCdm3y1y3r2NIVg/j3K3cA0Ac2zbSfLaRT1ORSowZsFiD6g8UAFMYcOo6k0hlVwy+WMdSRxQAsjPwkqrtHIINKxIwEf5v7pFJGIgSAQCR0Y9aYGIHDNx2I4oAVXYblkiwexHahwsig7Nrp3z1pWdt3IcHHOOlIu525TZnoe9AAXUxcAx7uOOpp8eFUBw7ntu7CgllbG/5e2V6UjggAvI2PboaAFYxg4KsB3z0oDIM5iGSOCDTMEgupO70PNKSvDSbeD6UAO3M6YPzjHSmxqEKkDY47Z7UqqGGBtcZ5KnFD8EbARzwGoACsjfcVXP1wRUb+ZGRvYhQMEZzipTIxwqmPJ/DFCq4J3yoM9BjNACBmIGFHHQtxkU7dKjKJolCgZDetOVkVPLOCxHGTzmmx7kYMQWYDBTqKAEMijO5UDkZ4PSgM0wG0KqfwlT3pVKhyUjRX6+tIRlw2Y1PVscCgDRsdyD5ADuOBhc81LcQBg28MjdyvGKpW0xJIErKScYQVedmJ2F3IYcE9aAMya3k5I+ZR0xwagVSwIJKN1GT0rXaONEUMGLHg5qjdKiOfMK7B8uCOaAKyhBtDO6/Q9fel8xQ2N749duanKoy44KDoMdqiCgSj5HRP4cGgB8B3EkRdRwWHFX7WLbFtMS/L2DcGmQoWkLSEoD8vIyDVuQBQHDIB0wtACcsTiUqRxtXvRM2WRQ4yeMSU0iMMWQK8Y+8ehzTpAsMR3YMZ524yRQArZblCAemQM0pjHlKBgx5/h4YGmowZx5Dltw6Yxio5MpguRIB/CDzQBKjLhsQgP0DMck1GEkZjuG0NyvYYqXbG6/uWCu3PX7tDusmEeN2Kjpnj60AN3nfgxkgfdbPSl+6myRm2kZUqOSaWPHlgCJdgGN26k3McjmPjhj0NAChCq4iZxJ3LHNKxZFKuq4+vSmb/wB2Aw4J+8etSeYzLgeW4/nQAgdUBXKtIB1HanI5ZSMhWAxkr1pkjBY+Nq55IUZoVmdhjAA6bh1oAVSUV8LjBGDUd0qZJDMWB5fvRiT+JsPn7ntSlGA3LHmMc5U85oAz2Dlcxvuz6jBNRx+YoOYsIOPmNWZpPLJdl3noAD0qGWRWBCnMjDOPSgBu1GY+cSQDxgYIFIx67SxJ4AYUxpXJ3/vCTwUVeaeu3y9waYDByzjpQArzFI9jBUk65zmoyyow+0kN3ytNUxswYrlj0Zh1pN7StgEAdPlFAEgaOPPlqSDznPSomaRiWZwV7IeB9ai5AI3DLHqwIqxj5tzFZGPGOwoAarHIJCqx6ntijzkUsSfmIxsB604Mpyi73I6gjgfSjES8SlY5O7Dk4oAsW7SNgEAA4wMcVsQgqSBhSR9wdKw4Xw6rEzzH+6eBWtZs5UAiRn9F52/jQBbD7VJYjdnnPAWmMdu2TcASf4e9PLkcuqkDsR1p4JKArjJH3cUAJvR/nIAC8Af1pinczJGCV/iOePwpTkIPNUOB0C9aZKMgMiNhe2elAEsZjjO1tygDggcmmLgSbm3BV4BJyTSgghmHzKBwp7UgkZQSwRAehPrQBKWO7EmAnfA5NIAy7sBhg54ppJyGcpkHAKnrUZMgBLhlVjhQDkmgBzSF5D5ceJT2PTFQNnPy8sOWHfNSgHaVfI2/3utIWwWKMRg8kDJNADTLJ5Y8zCDupoDKBg4/KomVGcrJvbgtljSIh2j53HtQBjXChz86sWz0HFMPlZwG2HHAIq7KzTLgoobOOvNU3VUJXYS1ADinyc4YHuBTGdThFIA7hulLHEQu5ZmXnkGiUSq/zqpX6UAOAZRuGB+NMLu3LN8o/OlQlRnKEeh9aZ5o+8+No9BQA5RJg/M2wj5t4/lShdwCxgkDkZPFIJPOxgkr/d9aEZFlClGU4wFJ4NADtoUn5PnJwAT1pCQrKWjKnqTnNIo3Nyo+h/pSqMDPl/KPU0AN82LcCxVO4wKkimUhlOX9iKFlPcoFx9wrn9aNq4JYndjO0cUAK7Ix2yJsU9cDvTXeP+Au3+6OhpqAqMuG2dznNKyrz95VPIK96AGlguVKDd13dzQXWRgwIRxxnPWpgoIBKFj6nrTCFBKDAJPO8cUANYLkjy2LZ/h6VIyfKN7RDsVPXNJIjCPDOAB/dqFfmk2lkdjzjHNAF6yhBYl5Am3ngcVpDyy2RJkgY3DmsWAPCSeFx2Y8VorLIqBsxAeq0ATgKZvlJk9sYIqldB2fbJHnup/xqWW6R8qpYyj/AJadOKoK8kMuVfcwOMk0AXreAsOihl/u9DT2s/Pbcxww4DHoKlBeVQJAgY9dpwDUZYH5dkmAeNp+UmgCVYQq4lmkB7KvIpyoG3NG20DqB1NReYiY8tiPUHtUpnDONsmGxxsWgBjhigPrwEAoXzo+T8wPJ3DkUpkCyAK7hgcinTNIzguWDMOpHSgBm85LNBvIOQ6HmnxIjNvYbWOeMUjHB+ZgXI4xxTAoXJD4ZucA8igBv7yOUlfK2kcgdTUxxLy8LHA6K3aoXJMhCDkfeb0oZ/lHzKxHQg4IoAlDwIVYqwROnHNKEjkIdSu5v4XOPypV82Qg7ucY3FcCmtblSfMCEkZU55oAleOWMpuT5z3IyuKY0Zfp5SEcECkRcggvJgHBBNDfK4O0kA9BzigBqKyNuCscHCstPYBz5iEbv7rc0p5OFVTu98VCUILCSLy8HopyTQBMGVvlO4Y6nHJqtIyqx2tIecAL/WpjJyqq+COhPUfWq00xZiAPMOeq8GgCpcSFJB5C7W7q3NV3VUVWdpCSe3epHY7iZlaFyflJPNCJEQDJM6kHgYypoAsKTsBUsQeMjg/jTJivKuxDjnrxTW8xCPKJDHjCngioWVtrEAbyeQeT+FAEjv8AMokzv/2hgU0hmULuUBT0TrTYNqtiSZ2Rv74yQfatPMYj4Usx45GCKAM7kLguMryQ4qPf5TBpMKp6YFaE0ayNlY2XIxvIqtNA6Algd/8Ae7UANMpdcw5RfVh1qMKvLSZY5zuApyDdxI+Sv3VPAq8tqrjcSxYL06CgDML7WwgOD3HUVpadcRo3ll2CgcuTVcw7WkjjJ5+83pTTCwA8tXZR/E4xQBvJMpG55gyA+nWnhsMChDPnIIrKtrwnCyMhUcEkcVpROECnDEdMoOKAHgjeBIQSRztpzFQ27DADAC+tMYqgPl885LY5FOcKS2HkPcj0oAZJKW3HaUBPUUm1mZGc5Y8AHpTd7cqy7VH3T3NOWTcQpjZwvV+mKAJDlCMRquKFfghiXPXpwv0qLKLs2fM3Xk8Cl+0Jkguxbofl+WgBZCzDLBguOhqAu+Dtdhj0qZ50ZSpy/PPbFVLi5C5DKBgfKsff60ASMOhXlj3akEakfO77u+DVUXIlBBLE46YxipldtowUx9aAMN7uISYYFT3z1qxEyzgGJxnHQ9awdWMkRJU5IPDHtUWl6qUlAuH56A4oA6Dy0XdlSX7ktxUofIyRx2I5FRoY5kWQGMk+9N8uIY2Agn0PWgBVaKV2Gwl/UcClSLa3IJUjj0p4SIIEBwp5zUZDBDsDEdh60ADZC5CoPYnkUoM2RtZQuMA4zTQygEBSrHkkjNO8woTtwfagAbd5YzlyD9KcWjCgH5X9G5oIZiMY2nqo70xchyIwMjqGGaAJGzzmNvfYM5pOG6oQc9AKaLjZkESL7r0qxDJGSD50jIBnAHegCFUDZ+7tJ6elOLeQQhiJTsMVoJGGVh5agHoPWopVaHcd7xbugHzUAUSd7FFwv+9QpbYwLgoDgkDOKc29g25GfHO4jGTSBWC7xsibqSvT8RQA0MGUsMyKODjgink4TORIPQjBH40iXEcjsDHksPvdKZs+ZtuGPselADhIHGCkQf8A2uuKWSYJ8rEZB4GKaEByJMSL1xjn8DSMojO0JlW5IY5NAA8iSZALDI6YpIsrlmdSmOR3NLtEaqYnJYHuKJCzMrkKDuxkCgC+tzF9nwABwNueoqrE+Zf+WoUngqeM1CWVyx3MGHfbSq0ispLYBPXHBoA3InTyxGXLrnJIWlKYO5TtGONo/nVa3uEMaoQcZ+6vc1PvWKQ/wqefmPWgBfLO5jgyIR97HQ05UbPDPIcY68KKYAHBYsw55UcCkEUZGRKyqf0NACr8vyzKzc8Mo6fWn4CybnVWJ6FTzikZlUA+Wzun3jnG4VDLgFSsSorc5DZNADpfIG7fw2fvd6qtNswC6lx6DpSNcbd21Xck8hx/Wgq7tgRjPds9BQBZjuVnU75pJEbjAwuKcEwFBJxzhgcmqjRYBCGMHHGaZDcsuUOEYcs3Y/SgDRVJAARE3mD+8eooKTJ84BCjk896qxXQEm1H83HUOcVItykXzOuUzhgOaALHmAn8OWI6fSkLMxIQspxySOSKhku0Me+IEvn5cnj8qie4nLqkki887j29qAJJnVRnGM988k1TlR52IwUwQTs7VYRRIxLgEkcheuPWntCrfNDu2jtnk/WgCqltbjdvd3Gf4znimrhiEjDMD0Q9MVcIjdiGZg+PuY61WnKQqFVzkfw4zQBMAsYOQsLYxtHQ1VkOXHys6nsoxj8ackcjbdzEjGTv4xUJeVSq5eTOeE4AFADTujOVAZjwT6VLaqfMy285HVjzSsAoOMKoGdpHAP1piTqs+4IpBH3/AFoA2huVV2LIR79KqXaPKpGQCe+eKjS5VxuwyDOAA3WnSrJNHwFCr2bigDPTAkKu6si8DHU1eaZ1jXMaKMbfnbnFUzGygbfmf/d4FRZTeUn+bPIU80AacC+YgL42g8BTViVY3XL+Yz9snismyYIzlQVBPBJrVadERMJuYLyR3oAzLhDHNlh34HbFSW128bfNkpnse1Rzybt205I5+bqKrso3Fk2j3J6mgDai1B5U/dLt9PenqNzBmk/e4/vcVhrJJgFSQe7DofaljcbtroQSPWgDfDNgh8bjxtpTsZuS+B2zVC0ZmcKjEN2J6VcEUiMpj+ZueWPWgBXnbZiONPZiMYpglVRyGJHXjjNSBVZFaVH8wnI9KUgs37w/P6L3oAiMzOCQU/Ac1mX8k0YLqMAHrjGa12V4yMgAdsDmmXS/aABIwA68igDmxOzSD5wPY96urckKBtQe1SvpPz7o8P3zjhanXThtHysffFAGFrtoXDlUdePWuSMLljkEgHBPpXoclvHMo3y4yOFp9poVoZA8joAe2KAMfQITLbEeWwPqwxmrUilCf4TnoR0rqGjSCHZGFZO3y81i6gibjlyGPbGaAKDhhjAJJ9OaUPICOVHHymnmJ42ycqcYznrSkYBDR/N2OeKAG+ewIGd2RyAOtJ+767XBHXNPcRbvmDo+OijNIBs/1czA9cMKAEUTgArIu0dwKGDno4c9SelDMxJwAfpwKbiTdtdMgfhigCQSbMhmTIHKDvQrH74Cxn+Ek8GmBHjJYrujJ605I1wzx4YddrcgUATRTFCSJCQeuBkZqR2kkUHehQcEqears24EAEHGDtHFRMoB3RIrHptzg/WgCVl2sX/eFe2DyPwpoZJhuDFG7h1wDTAQnzO0ik9dvNMLRSybWkLY6+ZwKAJSEKFp5l29gBxSQeVgAAdeDnANKEC7Cijrxt5FNZQXVlWMgZyCeDQA5/mZP3udvYdPzpHQkj5cIoyWz1oJmJ/dmKOIjB4pm/nbMrNgfw9KAHg7M+TJu3DkH1pBIyEKVJTvuHQ1LHZtMwJCFCM7R1FWEtCI9jqdjH73XbQBUiQSSAJOx3dz0q7NZIY8m4BOOU9TQkUCFti4IOA2OtWSIS288bT1xigDNSQwqCoKjPJI5FX4b1FCmVNz9FJ5qperGxykjq+ec8g1Xi3oxwjkr/F2IoA2WvEfaN+GzjleKVpkI2vJ83dgv8qxzOHIEYJ5wQK0kVvLyVZh0DE8igBzXYaQsJGfPy524quSzucAqVPUDqKcxcsoTABPJNHVD5jTuAeNoxigBokKIFaRhuP3mFSNBHlmZsqeSAetMeLyhncuz+6/U0kzeaoG5VP+6eaAGyzDOyNWbcOgFVnDlh8iFwMYJqwI5pVWMxkKDwQOauCzIQBYZG3ckkc5oAzgUAIdMnOCoHOaSVnwrqXVBwVUVuw6RdsBItvcbf7+3NSjw5eSEsqybj3AwCKAOZjljUEBBv7k+lW4vLdSFOR0G6rc2iXkROYWUKcg9c1Elg7MA8eXXqBwaAFDJGoZTuOMfKOcU9H3AspG0nGDximyWnkZUkrkfK2elV2M0PG0EHnP9aALU8qBABIhbp05qHy38wsQXQj0x+tSRSh0BW4UsD1ZOFphhG48SyBeS27AzQAbVCADj18w5quWQABZM/QYqR7cMvMfyk5DBuRUTBYUZSS2eMYoAjlulVAoaRgegVc4+pqDALYLFBj77j5RU/lvjhHx3VelQupVVL8cfdzmgAick4SRSBxu6E/StBxIEUM5J681RRVzt8tg3Xca0bNAqnKEjHzEnJoAHiaRVMkx56IoxmqZtpNriJGznnI5rUKEkBXLP1HoBQ0cgyOUBHIzzQBm+XIpyw6DABFKiOhcncjH+8OK0mdNi+b86DgEHmncMnBGzPO7k0AYf2bMjCN3Zz+RpSjK65TnGMEZrZKoig7gD/cApjxkuQ68Hp7UAY21y37wFIgeuKRw8YIXiPPG7ndWzLAgb5WK9gOoPvVaW0RXDSNlT1IOaAKUEkisAJPLwehGa14JpCy/cYYxvPasWVVhB2S7M9UYZJq9ZTgAbxu2nhfSgDRRppT06HABPUVMjJHlVXa/eoxMrBeenQdKQOpPyEkehoAkRwGbkhyOAaacMCGwV747UvAzujxx60xXyhEUZKjqvegB7biFCyEt6AcUbJD1mAPpmnPJkbSpHFVzECScD8qAGLGFXPAH0zV62eIRkNjB7Ec1nbXGCcAdcLVu2lGAWA69xzQBYl+Vf3eWXqQeKxb6M+YeBGOuF5NbktwOceX0xisq73MWZecDnAxQBlONrcqxbsWPFA4BDMSxPHoKadzMy+Y5XrjFLvaNcAr83bvQA51XpI759UqOMAAmPzGHueakDbm4Vs9MYxT9sZKAPscdfSgBNwdBhWB7KaQzSZYAAL/FntQyEn54Q3cMrdKRfkG75vwHWgASNmwSWVT054/Kgo+CQPl/2T1qTLMRtGM849KRoQo+6nmA55OKAIyNxyyzKey9KRFVGDKdrHs3NOcsp3h949M0shdwCZEj/ujGcigBA7LOG4Gfl+UZ/GnnbyGVc9nIpiIOgWTdjjHApSJo9qyJhcZ5GTQA0ytEcjyySccng0CWGUbHjVT0DYpFkLceSpGeB3FOBUg/LuzwBjkGgB2HKKq/MFHXtU9tatdn5P3QA5J71HDYTOFbLkBuUzitYRrEu1eQOitQA+CIBSIghbGOTjNOYxxkfKFdf7hyDTXiXaAV+bqFzgU0GNCUk2YHYCgBxk3Zw6hepyKjMCyBvKLSKwyQTTggDkrsz1B3UjiT7wC7RzuUYNAGbd2bgkoflByy98VT/cyOQxmRe2DzW6jFmJmyFP8AerLvAk12UVxGBzle9ADIUTzI1QPuJyHHGPrV3eFGFky56rUMZZWZWII7VYjDSAgsm4D/AJZ9T+NADfJjG1t7EHtnkGnNHMof93MqDHzg5zVmCwkkbaECsQPlPOa6rTNMghi33WQ45POQPwoA57T9HNwxYfNxx61trotvCo84nHUDAPNWri5Cp5di3lhTkEJgtTBcTxRKzeTMzZHHWgC1BFaWwG3Yz8EkDtVptRtIsfZkUyAZHmYrnDcsXaJpFKsPlVB0PvT3ljw2Y1YgAEjkigDprXxBcRR7YQq56EDNC65crIQZAxY8hhxXLSvmNQkpVV6KOKPOxHw+yQc+tAHQJq9xG77oUbcMY25p0d/bOm+aOMS9CSmCKwYr11QiRSzZGCnpTkkctK8hJI5HHGKAOha30/UFYOsOSONo5Nc3q3hSdIWlsoQyjqu7qKnS48g5Uh93REXkVci1gNugj3nA5Vjg5oA4RrWSAsJFMbjkxleKWIqGdiTkct6Yrvp0tZ7fy7tGjfGSRyM+5rLv/D6lN6cpjOV9fSgDmdiyRYGzPXBODioGtQGVYwcdSScirc1u8BZnjUc/Lkc1GyOUwyLH3YZ60AUtqqMfvTg87TxVaQxbgERynViByKvyJ8oOxlJPCg9qdbwqknXap456GgCGyhbO9yVRucnkmtAxqQhZgqnrg8496Tyimdp8p+inqDSRKi7t2WkzgnsaAFZlRQF+XPQn0pu3C7nVWD/xk9KlQ7V3Da7AYy3QCmsFVQzMvPRByKAGMSRlY4iAOCOxpwDgFiFZ8che1MclTvPc8ECnL1JDqXP8QFACBlGN253HPSnJubcYzg9MNTlRxsOVHUnJ60GJsqSTnr8lAAARny0RpB1btSoihWIjVmIwx7CmEjlclR6Hgk0JGpUkSOFXls96AKc1vkswzyMYK9fpVEQvHITEMP8A7R4rcdwuNrkHtkZFVnsklmh+0mWKEuBI8ah2Vc8kKSATjsSM+ooAbbTCRlMoJIXBIq1vXAEaEx4wMjk1J9g0CFsnxHq5I/6gUf8A8mVZvLaGyh0yezvJby2vbd50kmtBbOm2eWEqUEkg+9Cxzu6EcCgCn96QnGFHUA04unRA3X+HqKcQWII5fsR/Wmk7Xw8W6Qj+HrQAeYVkBYg8cZqRZ3wN8iq3cbaidiE2rgZPTvUbK4JG1jQA1VRm+Rgr4+YqakDqpx5bsfX1rNsbcG4ZpAycdVNapcIvHAHfvQA7zN0fK4B64HNZl6zzE5ZlUdKsm8BzwRHjrVK4kSXrnDdAp60AVXDgbg3X0PSml9oH/LRTxuA6U0pt/wBUuWz0Jp0UlwpZR8mOdpGRQA1GHIAlGe5NPdCFwcFR1A5NOcPt3SOnX+GlSO3TPJBbqc0ANUgoN5UemeDQ8oLFGLoe2BkUr4CfNjZ6MMk0ihFwd5x22jpQAwxyY3K5ZD6daV3JKjeBjswyaVskg/f9OcU5pMAkxruPTvQAwAH5miIx0KnANG/Zk8gnr6ilY+aAWDHB6A4pXYKwUqM9u9ADd+9OJJtvX5uKcAzf8tH/AA5qaG3L/eLFfXsKvpYxx5wHz1+U0AUBiVVziPn7/Q0scYeQbnfOeQBwfxrUW3zgsjSr33jpQIEUqo4B4254oAIYlRMCVgp79xTzuRSGYlW7P/FSyRKqhcHB9DSRrtPO4Bum7mgBmY1Qs6MV7EnO2lBBAxJvGOcrxUm+GKRsqCfTPFMY+aQsZwvbHSgBqyLwoEOCMEVJDMvl7MdOoHShiquMohbpkDp9abNJIQSUj+7wydKAINQmCxkPDuz2B6VVgjR4gRtyOqnqagRleVnCszHuTwK2NPtzKQqxIWPVu9AFSKOR1WNh5aZ7DOPrXRaboYlQ+a0TKOeMjdWhZWEazKvLjuAO9aMs0NpGUjVtoOTkfyoAbp0tva2zpGil1GANucGqU15OqZkZSHPPy4xUM1wxdpIdq7m4Q8E1Bcs7KFZHSNuSWIODQATSuJCwJdj/ABDotVpN4dcTKj9QR3pZXYfLIylF5DKcUgcKpDgZboT1oAZLc4YEssbdCdv3jUkasgLtMMOP9Ug6+9NjcuJUlVWfHCkdfpSQoJ+CSu0cR55FACu0TxoxJUqeQ3erEzCW0VEOQfQdqrCCSOEmQxnnAzzQZAEHleWrLw2D/SgBbSN9gEWVXocVK0rfdGdoOCWPFI0tzLGgiCkHhR0/GoZGkTcsqE4OG7j60ASRzMhVoyVwTu/+tRPJmZWKyDIznHemxImxGX5iG4z6U87Bc7vMfYByvUZoAtS3XlwqSrbj1IOc1oW13LDcxtIrNkZ2OcKaxkUTIS0gRRzvB6VEwSW5/dF3UAAs70AdhfaPDqkDSwxhZguSIyMV5/d6e8Ny2+Bi0bYClsZrqJtVbTbTybUkkjnDVY8PaXaa0JW1B3ilYfLuNAHFvuzlirEcFEwdtRBgjEOEk962/Enh6XR7ktEBIpXhozx+NYhlLoPOCtjgFRyDQA9ZAdpyyt/CGOBSsY89MnPJU9DUAZTJyTN6ZHSrCqDuP3c/wAYoAYzKw/vAjGAOKWJSpwFxF/eAyak/chQXZl9geBTGKZA3O8fYoOn1oAeSijh5QB6ikJ3EiMA568U8EDLIFYe56UwRK75LsB32GgBpK4KbAcDHvQr7FbajKg9epNPG9AVVgq5/4FSJI0QBG5uxLcmgBInZlJEDMynjdSsS/LDGf4fSgSGUFt24HjGcEe9CqhDbJCSBwMUAO2gsMqGJ4xmmlBjbkRKRyM5JpHLj+JQzHBKjnFGxQAFbGT3GSaAMu6iERJQ8/nitzUpceG/CYwcmwuDn/uIXlVLqHzV6FXx2H86froaPw94TPPGn3Ckdv+QjeUAMt2kZtokVk6k55FWGaNcqGO4c7u9YkU0qgAqAAOgq5DdbmAHJA5NAF5mBJCgAHnPWkDnHX9KhW4LR4LBeecdac0iZ4c496AFhwmMhXGOq9abcyKUYR7iOpB4pwVYxgPtyOMCoLhxhTHtH16mgCobjBIH4cZqGR8n5VAfsuKV5JQ+V2lev0ppYsAQwYfSgCMq2QZARz0HenCCQnBbC+uc4+tWIoyqM7tge/NQBgPmgV3Unk9BQA5lVdqqckdSOho8zeMeUM5wTSCRXBG5f90UxokKhgWDDoueKAJScsMDCDg5pNhkJwdg/LNRFXYFRgMeSSelDbgB5p3Z7g0APzCpw6qT2Oe9I0YJYqGAx26ZpsUZdsg4j9AOlPETAfuyGXOeWwaAAlVJDoSwHJHWpYFHmgxxqF7ljzUKuU+aRNrMcEk5NaWnwrgSKj8nhm6UAXEiQD91t3dvSmhySQ/38856VMcrIGIUHuaa7OzYWMMB3zQAqOGbCyMHAyQDwaHV5ISzxJtHUg81GoEinaybhxjoRQEKDfETu/iJ6UALAEZTgldo70rBQuWyq9eDk0kpMYzKSc9wvWki2SBsTGPb2YcmgBRFGwJTe+RnJFINyYUFVGMjihvN3Aqr7Ofnz/OlxIwVkiVGH3snIIoAQzOq7l2cccDrVa/kORsHPoDgVYliJi+Y5HUgVl3KhmI556E9BQBPptvHK4Lq6Hnp0FdfpEUIeMsSm0cMF61j6JA4RCQspxg4rpEU2sZX94WI4CjigCzeXauSYJxEV42heTVGSQNCxd22HgHvUMzSNGFcIFJ+6ThjUCPE6EpLsMfHzcg0AOKAuiqqs/UMzdRUEzxrJukYg9AoJIFSsqPGu1sE90GcVSnZs7OJCe4HSgB8kEc+4rwAM5Y4qOMIZF3zKEK7c+lEciKTCrhieMMOlIY0XImCkjoF6UAXI4ES3cRPwOjt1qrYcs+9kznn1ND3EixELtPGWUdDVaOaJpEaTcB/Co/rQBoxmNTIytKwByFAzUM2y6RZQNpPBUrg091jXEqhgnVyD/KnLIAE8pXIP97rigBH8tUTAZkAwcnp9KS3/AHS5LtJGDwrdMVPbyqiq4YEYP3hmoWkWYMJTIu49QOAKAIrmVreVTtQM33cHNM2xxAsjSGVjyhqZrcRDcUAXgBn60mzPzSZL54ZFzQBPvCq0QVShwWGOlNZ1ig3OilTwD0NLOQkezY3zDqD0+tQlTcOiNIGQdyMCgBkQ84mSXnHT0rRW6uLSWPbG8rSYx6KKozzwTSx26KEROCQetMadI7jMccioO+/rQB6FGItc0t7bzIwwHQD5s15hf28mm6hJFJlCCcfLniuh8O3bG9/d7lXOSwNafxAsS1nFeAfvCMEgdR70AcLGpYHySOuSzcUyV5IZV8yQNu9aaGjIRCCpbtnOTSXiEICqqH9WPSgCyifKWxGF9R1pTLhjsBbPY8A1VtGXaDM+HPTHSrQRGyThmzkbuAKAGmHcdwUxgnJApQpZWBCIo6c4NPEZQhiGkB6kHimF8nBiBA/iYdKAEwAF4ZyT16UESK+drYHUins+5ASVC5xx1NDR5VsLLg8deKAAlNp2gA/7Q5pHeRvm2GMn7pA4IpnzBsM4wOBkVIj7V6tjtz1oARdsZyWKynoT3oRiXXKAP2JPWjC7dwyDnHz0iSAyBUYEY53D+VAClZGZg/mD1C0/xEMeG/CmMqPsVyOf+wjeUmZtuS5wOMD0qbXwD4e8K/KWP2K54z/1EbugDmwA6gOxyPQdaYMqVVZCqDripSrBOVYA9KVwRHtAUKRkkdTQA9GPOG+btmnedEOHOW71Fw2MZAA6nvSYXsufwoA2bhti7mJYewqhGJZXJKBl6gjqKdLLI2PnEae1QP5cQ3rMdxPUH+lACyoyjOBt9DSLCSNxJI6gAYAp63OVweQP4iKjc/NncSD1APFACyHyyF2Akcg54pmWbkEsewHQUjFk4d8DtxnigRORlXXOM8cE0AI0bPhWRI39fWmrEFclnP0xxShQAGLD8Tk0ASMM7cKOgzQArDPClWC9j1NRjezEm3OO2DxThISFP2cDsG9afGzMWy5ib+6OhoAbmVgNyKo6Y3UwNHGWJZCR6dRTnVSDvQue+O1MTgAFRwfTk0AOQiVgFX8TW5aRBU272GR1Y8VkQgM5YgLz0rYXb8v71Yxjoec0ASGIxgYUNnr3zTVCqN4j2MB3P8qRSyvhXbJ6ntQEIfdy7fWgBzBTnMbFgPvnimHeSNzIw6nbT2Z2wzLvQcZzzThgPny2Cgc+9AEflRgApJL6nPalZEDplS7Ho/cUSPETuZOHPHzdKUTRsduwqoP3s9aAGSFwrJGAp65bvSAMhBdxkDoBmnEcsuBkdDmkVwMhZG3YxytAEUsOYjtmZ2zk9se1VVYCZEYnGeQ1T3EZRQQcp3cnmmaeSzgSOhj7E8mgDsNGhKxDyE28ZIB4NXbyd4WWORT84wMdqk0yCJbJZG3YxkFBwaqajL5koYJkHjHcUAZ80Y87944JAP3jVAq5IRshc5wDV+Rishdo1KqeN3Jqqzxsx3RkM7cOnagBBJNbxKxc+WMgY9KbCi53xSeZn7xJwRTTJGspLFmlXsfu4pm+MSK6qQzHnYKALIHlb8IJB/eI5FFw+5VjXeAfu5GM1X8wuCUySOmRg0ZlMa4Yy9yGPK0APVvJX52BXsmOc0h+YktGPbC0xdjy5dWZjxjsKkmkIAjYOAOAD0IoAeDNMpSMGSMDkLxin2trHOCZQyyr0bNM2uT8khVWG35KdcQmKIkS7nX0PNAEoIWUjcxVRjBFNudxiXqABgYOajtTui3uC3oSeakidBC+V37ug7igA3s5UTLuPrnpUUl7cgmJJCgznYq9R9ae/wAiBWb53/gPWmy26LEuWO4nGzuKAIreNnmVplcqT94N19qsahI6xNGSBH0C4qVkEMa72YAYO0DNVSyyufl+U/3zQBRS3LvvH3h69KsLtkG2RSSDwQKrsUW6KG4A7hQOtaEMkEhVQr7+hIPFAFzSY5I1LxQoFJ4YN/OuxjB1zT5LV3VQV+Ynpn2riJZFSUmEDcowcH+lb/hWaaV3NySV6DbxigDhri2jsLyWJEbzEbbnrx6iq8yGVyo8zYvI3d66DxvarDrDsj+Wnr3asGRkAK7efUnmgCWNEVcSupz0UDkU75h8jsHUjgYpY4htDMuT2Y9qEYpuWPHI5yMmgBoRgcSxtx2Q9KkZ8cR7yTxtx0pclRklSMdB1pVYmPKPtx1zQAwMRlXjRj2UU3zVJ+VXGD909qdiHGW37j/dHWnhVMfzElP1oAQFZFJKED+9SBS3KkbR90kUF0UZjiyvQHNIXYxcEbgeg6UAOUIcHG5ictuPH4UQyiKdHREIBziaJZEbHZlYEMPUEEHuKZFExG+TA9z6VKZfL+VgSvqPSgDQGtO2CukeGyvfOgWIP/ommeLb57zRfDEzJaQu1jOoS2t47dFC392o2pGqqOAOg5OSeSTVMkP/AKpjk9sdKk19P+Kf8LnK8WVyP/KjeUAc/GwLFJGJx0NIysoYqQoHGT1pN+7hXUv15pTGVO9sMT2NADWOQB37+hpMueVlVR6U5XViVkXaPYUA44VQR2oAkZzISW24I7dKjQIWyjIp6Y61HIioQf5dKX91uJVQD78UASlC2eCw/i38VGrqMhcKcYzTgzBcMPMyOuelIo/56Y6cGgBgkCrtkDrk/e7U4yKTiPO09zSklyQrYU9j0ob91zg4PtwKAG7ADnduIGcAcUigFuBz6ZxT1wwBbPPcUrJD/EQy98nFADDgHb5bIw9TnNKpc5RcFgM59KcyblDRBTjgUzy2/iXZjk4oAaswjJWRm3k9qld/MXICg989ajdY3Hz/ADKegUcilaIxkOHBQ9BjJoAmg3iTmaJwO2K2o2zB8xjGeORWLZBZJgFBHcmthImUZDI6H+E9aAHZRcLnJzgelDxIMkqwcdNrcVGynOMKPrSNudz8pC4+8elAAJpQNpUccKT2pyRlWy+WfH31OR+VHm7OdoY9iBSqJHYtv8s9xigBivtziONgf4j1FB+zrlZHOD/CPWplZFUK6lueOKapyxIeJgD91hg0ANVYmAKrtYcAsacxkchl3qQMH0NRvKRglQvPQ85pWZ87sqFPvQBFcJmEjJxnHrSaTCVlJSJGUcEr1NLOGEJ2KcYzkHrUmhSR+cCQFY/eAPIoA9Bt8tpbJGHTYM7SK595FRts6urdc5zzW5BKJLP5ZWXC4PfNc9NIokYPuYA5yKAGSPI27Znpg45qrOI1AG5wMcqOtOky6B4225OMqetTqbdoHWRdzdfcUAVkji37kyVborn+dQ3WxCUR2Bz/AAdqe0ErjzE2LGe+cml8tZLRyqKuT1PegBWC5hEUzqQPm8zHJqaVraJiZJdueOB3qrHhIwCYXcfxselTs0MgViFeRR17ZoAWBUbcwcqTwMjpUv2QyFoxJ1H3mpI1XzR5hwJB2qR4GGEi2qf727k0AQx7rdzmMtgc84H1qaYxKEfIDHnPrT2i2pm4OQOgDc1TlZnChShO75cDpQBNNBjMjcIR1/uiorV4ipHlNheUkHc0+SSMz4lV1lXGWJ+U/hTiglkchi8Yx9zjFAEVvJPLJJLdADacKxHSmO8m0zLucKcHA61JIEVi6Mc9QG71HHM+4u6kjrsBxQBFC7tKzbiEHVW5qVopZ5CcqgHYjoKkQuzFNiJk5J9KDEI43V5VfPI2nOaAIfJQB1QA7erlarwSJGWPy7if4TzUkb3DTGODlDSNGMfMULDqR1oAkto45WLuxTnhe9dDodwou0CsQ27BGOtc8XCKpCB2UcMOtX9CXF6sty2QSCu00AaPxJhWO5glf5iy45HQ1xpxIgHmsCB2XJrvfiJKstvaOEHoCe9cEXfJ2ptHXdHQBHGXAG8O0GeTnn8qtrGWUlWUL228EiorWcISXBLH+I1OwwrlXXH8K0ARDETkx845JbtSsqzqCPvepOATSwuFB3yHA6qBmlTyi+Y1ZiehbgUAOUFBuYlW/unoaJZXG0qAF7j1pGWXgOBtHPI6U0R5YZILdm7UAKHLR5BVB6EcmmOyqmcEjuPSnussahpAM9z2xS5DZZVPu3/1qAEiJ6u6hcfnSgEDA4z608MgKs6qzfSkIDh23YHp/hQApwQSoKkDkjrUuvAnw54V2sNos7nORyf+JjeVGuw4AWQ4HLelT67j/hGfC4/iNnc/N/3EbugDlxjLAbc+pFOPJ+YsD2HY0rBQVAJdsdxShlYqCeccgdqAAyH7rggemKaVPaMY/wB6nsOSoDjPfORUJliU4OeKAJFTyydjDB67ulOaPf8ALtLHue1NIJI3MuTzgmk89gp7Y4wBxQANEobdub/dHamMJQoyu9F6jvTsBjg/KeuQakO1SN7lX7gdxQBGJ2HBg2qOjZpcbgzbixz0/hpykhiUMYUDB3GnRKJHH7vkDqPumgCKRcEbnAJ7LUrIGHyDcO+aa7Rg7Q2Xz90DoajO6XgsYsdV9aAFUqpYx53ehoElxg+UeT1UjpSyIFOPu8fnTd7Y+WKRz3OeBQArcDbK5B65ApVDq25Ci567jxSCPdzKg57FqbLGVABKsv8AcHagC5p6rJI2VUH+8D1rUURRv+7LMSOcVmaYpYkABSOhNaWNq4y2fQ8UAIXVeRuOOuR0pfvpmKZj2244BoRt2F3ZYc4HQ/WgqBJlwwDcEIeKAGmLLhACW7sKGjbOJBuUHOQ3IqTylBXbK6AU1IYAfnUO3rnrQABzjEYDA8ZzzTpEG0iQB8e3So3iVciNkTHPynmmo0e4bvNIB4b1NAEjBFyeoHp1pkZ38SRqecqD1pxEbANMpYk9IzyKhiMm5wu7B6E9aAG3zNHDtUqD9aTQvLM48yPdJn7w70+6ysRjljTYB35JqDQlhF8uwgbjjlqAPTYHCaau3YrEYIxzWDfb03naoJ6kCt66j8rTsIU4UEE9TWFdSSRxliNx4yvrQBSEBRWCpG27naxwahP7o7WjO4+hqWeVG/10KoCeWzzUMjqyMyIdmce9ADrgqm3+HtjNRCQKFZM7hyd/Sp0iRiu9dzgcZPSoZ7KUMSpWQdSM9KAEnKzqd6qcdQBipIkUIsYO7vgjGKihtnYsrPxu6nirCxyJmNXR+cHcelAC5heNo2Zvl7AVXjjZTkb1I6bqswJn5TICQecd6VvtYfbAvm88luwoAzpJtsvmRkiVeu/oaeLmSYgYiVuvy9KS+t3TLTLtPbFLbBXACRblA5x3oAkvWV1UBSzAc46Cm24TLFVYsQAXLYx+FOv3hKJ5TFGHGF5/OqIkETsXYP7igDVDKipGzIVPbqTUl1aieBmt4HQqOu7k1Wg+zrF5u5Sx6DutOaV8+bHJ8v8AsnJNADLGOZZiJ5gQBypFLJGhm2xpjIzkHinsJJIt0kZ3HjI6VURXSbfE4UD+FjQAOqpKxVJEKjsetOMiwHC/Mx5561Isxe4LzAq2O1UZgyT7kkdlJ4yvNAFmG82FiMb/AOHI61btZRHMjqQ8zHlV6Cs6K2d2X5d6Dqa1tKi8y7RAI1wRwKAOm8fRrJ4asZ8bWxgg9688iDhD5a7V7nPSvTfiQJU0GyjAVF2gkV5ejEHaSMEdB3oAI3nbhgpTOA2KsCJeWYjcO1QBhGxMgKr2I9akRllJ+bcf71ADTu3jbtVc5wO9Bkjd1XftIPGDSTvtYbvlU9OKkiiTAdQiydye4oAX5uQ7kt257U7yzEMeYCc9OuBTF8oyYUBueRnmnNGANwiK5PBJyTQAuePvtk9j0p5B3gDgn3qHcxdA6rj19Kl2q5y4UEdCDQAhR3f5mCpnGBUkQ3yrGJYowzBTJOGCLnudoJwO+AT6A9KaxYBlyqntjrTA7klXbI+lAGsmjLGTt8Q+HOeo8y+Of/JSl8UW4t9D8NQQ3lpdoLK4JmthJ5bE390SF8xEbgkjlRyDjIwaxwQpLR5bsRmtbUxGfDPhhpCy4tLngdv+Jhd0AcdcbVPG7d2A6URqoH3gHPpVi6CKxw289VOMVV2IDvIKPn86AFRV3jOeDzzTyjEkhBg0xsKMnD56Z4NPXO0YZlHpmgBimFMBkJb1NSAKWGOB/dPSmrtBwRwepz0pHZjgxorqe3Q0ASb1ClVCrmmZcKytDv8AcelBU7fmIAPQdxUkSKmC3mHPTnFAFdymPnwPbHWrEYVIyrucdgvSlL7CokQEZ6daSedEAV49qj0HWgBsjDPJwOxApj5wo2jPqe9SLIrLhlIjPcU1jsUtkY7Ke9ADAhj3A5Hru5H4UbsZIDn6cA0eWWG+Ulc9s5yKXzCDhWkZOwIoAaw80YjhU9yGamqrKFYKVz1GalQqwJdQv8xSsSWHlKmO5JoA0dPyYeGHscc1aJBx+8LMO5HNV7SLZH8r7B16cmrQAJ+d2dz2AxQAjuSRt8pccZ7mmj5X24zxnmkZPlL+Vg56mlHn5YsrOvQYFADUyAMyfN6U5w0mD5G8D+7xTSQ3ybXX14poMgO0b9q++KAHpEAuVQD03HpQGk5jckMOeORSTRiRQRIwGeAe9Iq7SdxMee45oAkij8vO542B644NV0H+ktgsvoM1I0iMGVD5gPXjFVGkAlyo5HQelAFqS4aKNvlxgYLEZzVXSSv9oxMrrljzhKmlluHiO4wsvrVbRNjalFh5FO/sOKAPTNQUjT4kdioI6leRWBIzGQjzunGcV0fi1JEsYVLPtKA571yMB+U/Pt29c80AWJURpMSy7j2yO9JIvlPm3IL9x1H1qlPcSMVXKEjoO+KnsJV87B5kI60AKytPIGlZY2Hded1NklK3H7yX5ePujBNXMqmRsVU6g9TmowzzKDJg7e5XmgCJYh9t8wITD7npU6WqOMxkEMTlTwTSPvMSrDgEnikzsfDyYx+dAFeZPsyjepYZwFj60FkZ8edJGoGdvenzXbHaIsIg496oNcg3PlOh254fHJNAE1/c7VCDLkcbmFRssqQFw+3A+UDjNSTDdFmdlLDhU/rUCCdJF2qrnrz2oAlyhhExyGA+bHeqqQh2+Tknkc9PrTrk+Yf3rcg8KlLaoxlZUKxoezd6ALcVuioTKy7+5HSrEQjhwxijIYdVOKqXVyhlCyBd+NoK9DT7CNMbJY3Zie/QCgBJ4/KkEmXxnIVTxT3jV3Vkj3Fuck96uTWxXbjJQ+lMitIYpvnYsCMrk/dNAGa6yR3o3xsyjgnsKutHHEqsxYluQKjv7lkPlAorY+u6nW0jCHdKq46ZoAfBJ5YZtjJ9OhqxpQaXVI+kW5hgd6rs0jSRpGUwemK6TwzpscmrwvO+98gDFAD/AIrERxWVuJSz+WCx7V55CgAyvOO5rsfihcxS64YYwwSMbTntXIqu0ZjIKDqKAKd3videVA75NEEjxAgBWZuRirEsbPtL7Wz6ijyArEb1z7CgCq1yXk5DdcFat2wywLA8c57GkKKSBsKsO471NDI8SsI0Xbn+I9BQBK0akB40Vx1IHBFM8wAdGx1we1Kru7BgVB9OnFSSNGUzJESP9k0AMBeRfnaNFPIAHNMZ9pCqQxPY08KpIYYQY6HrSo+HxndgenSgCJWGSHx9QOlTbWj3KqZQ9880ob+EgIx6HHBpq5QkkjHfFADfKCEMExnvmte/dR4d8MHv9kueD0/5CN3WZ8pVSGznnFad/GW8PeGWVwuLS54I6/8AExu6AOdv1wMxlcnrkVnbJWJA5HXJ7GtmZjyAwyRjgVkyCQN87gr2HegBojPBcgnPSnhoQMMRnvULhS3yEk56elS7wOAq0AIdiEBsFv8AZNRib5toynPQinouzd5gRsfwrUqlNgKkg9wRk0ARAcg7WcZ4GaVUkc5BDbT909BQUCZAf5TyMnmkYs6dCVz1Xj86AJWSRn27lUj34qMRqjDL5z1JOcU35S37wnbjr6U3ER+4dzA4oAkZUPyhiAeOOc01UjUgMzjA6NzTFVwSV3Rr645p0bO2QOST36mgA3DeSFyAO/TNOWUFSrg5HTHamyYYjKspHUdqfFtUbgQcdKAGuzgLufAx8rKOv1psYMswV4yfRulSOWcFY8YY9PSpbOP96C0u091NAGnApVAGyQBwR1FTEIATvQAAdTzSAqFG0/N6g0jmDO6Rcnvx1oAbsy+VmKqfXkGh2PlnErEE9AaQYwRGp2/3fSlSKIn5Rl8fNzjFACPLNhhKhEZ6FKfG4Zfl5XGMt1pPLZRu3sEPJU0bQW3FjjsaAGvKqdGO/HIYcU8yKIwXwO+RzRuRchonlQ9z1FM2bXBC7R2oAQwq+egRhnI4quLVkcDdlT6d6s71P3yrKOfl6k1GZ3dQY4yrD9BQA4hRFgBNoHQip/DFmJtZgAdo/nBxjrVXegXEj/OOcV0vgiFJNTiuNpcKeB3oA7Xx9GjxQxow2IgBJ4JNcDFbkqVIKkHOR3rv/EJF0w8x1Df3SM1iQxsWKLAGx37UAc1NYebMGRgx7kdqnEBiQ4XI/ujg1s3Gnv8AfVVXJ4ArNuLWdSPNlUqOydaAKxXcAFbyz9cmpndxH8w28feNRxwxyNnZ5eOcmpri1wFkUyN7jsPpQBESjoCkm/b2AxVN2YsSIwnfrkmtZdPeSLBbjHDDgmqzWUiJtmiDEcZXrigDHJZZNx+6OTntSB0ebdbKRIepI+U1uDRZHi8wRP6DPSmXNjLHtD7VOMZA4FAGVcW7CRWl2nI5I7VpBQxh8mVV7dO1QLpi+YN0jjPOCetWILc26fvCoU9B1oAytTgNnO5jOVb+LFJYSE9FUAfnViaGWZ2Ocbu1JBZtL0O1x+FAD2tlkuwBHtBGfm9alnuEtchSWYDk5qKVHX5TuZ16bqqXYjJDyhgx7DpQBMbtpYs7sD+7VkKGiRpGbbnotUrBmzj5SM8BhWz5E0kYZsKo/uigCtPFBlSw/edRkdKjkkVeCpZT2xVq4WXMcbyKy45OKbIIzCIxIHbP5UAVUhWa4Aiwg9QcV2Xg94re/jG8Mf7/AKGuPJhiZY0ALL97PFbXhW8kOsRKkcflqetAGb8QnL69KzsN+e/QiudQyybuVUDoAK3/AIkwuuvSbmwWGduK5aKRnISTOc/wntQBcjeTcyzccdcUoEfQoWPr60vJIUZVwOM85FSGGTbu2ttJ6UAINgyUVsdMUvBO4bSCMAHqKWR9owJMccqR0pNsbc78vjtQA1WMmA4AIHGKYfNT5gOpxlamMaBTvfaexHUU5cqoVZCydc460AQxx+Zklxv6kU/zGi+RUbBH3sUOkTHduIcjGAKRf3Y3GR2x1WgAZwV2yAhf9nkmkVhjCggn2p8bqGLcjjoOtPgkSORHjCMVYHy5o1kVvZlYEMPUEEHvQBHgnIABB9K1NQKjw54YU5BFpc8f9xG7pH1nBwNK8Onnt4fsf/jNWdcvmvNE8MzSwW6E2M67ba2jt41C390owkaqo4AzgcnJPJNAGLsDKSg3e+KyL2Jc5VCGHYmtVXwmQ24H2xVW+G9C2Cf93rQBmMVGEdsZ6bRzTTHgkKVx7ml2FAdmQfcc1GY3z/jQBLkk5MRQ/wCwetOEfzAAnP1zikUtF8pwR1wO9R4LnEQCk+lAExAj+8yu38OaRTMVOdiKfSoxGUYBiMj+I805XXd85zjse9ABHIq5GWLduODTiJFbcQsYPoOtOEkLcLGAx96Qhl5YuCOjdcUAKZI+pLlvU9DUb7gdxHyn+6eaQqnVpS2PWhMM21Jhv67gKAE3SSZWJiPTd2pFDjnzVbPVQO9SFbgjDKJFPG7oalt4y3+ridsDrjigCupfPKKV7jPNW7OdAxEce3HdhUjwPI6gbUPQZ5qeOwCkrIT5nbaaAHRl2ysix7TyCTipCXAPygeqjnNKsACkMxbnkN/SnqGjTCpge/WgBoYHH31K9QaGEkj8CP5RnOcE091ZsnzVOOx61Vkm2v8AvEwueo6igB2/oW5I6CpCGILFVI7YNSgRyJuIB44PemsqNwVBkPQZxQA0F34AKAevU/Sgl1UbHPuD1NIfNJCzKVA6ZNBdXcKCm8cYB5oAauwMPLGxh6CpGKksVYl8ck96QssR8t5ArddpHU/WhIBIScO7Z6Ic0AJFbLLIDgK1dx4WtvJCuXUHsRxWDZacCV813R+2Bniur0qFodoUiUD2xigDTMJlduFde/rUEdjJboxJ3AngHtS3t+i3cULr5XfaO9JcXxXIf7p6bRmgCrdW8kcZEmfwNUvsDSZyykYyGXqKsXcrTMuxDk9cnrWnbbWhVcKD6igDAFjggmTcewxV9NKu3CNCeSPukVrxaTHLcI8QcjqcetdzpNiltaSzyKCgGQW4IoA4uXSrexsln1F44nK7sZ5Jrk9T8QW0cjC18uU+w6Vi+PdWu7/XplRyYgcAKelcwXYKRKCnbgcmgDqP+EjuBuUEEE45PSqUmp3GcySq3pWCQ7gEfKR3A7UojYruXcD3J70AbI1giXNwh3jow6AVeiv0ZCXCOT0rmo/MXKsdw7n2pdhDZicEAZ5oA3Gut7g+WBk8NmpYryCN9rxbmxzg96wJZk3AGRySOg7U3zio+UnJ4zjkUAdlDc2lypXfslxjDCmy2auhK7H/ANnHeuPguZfMJLkg9OOc10mjaokTL9qIaN+vPNABHHsYh1AA5x3FaSF3RD82O30rUl0GDU4vtunjkDJDGsyaMRXAVi+F4BXpmgCtMzGYwxxbgevtWde3EcEhjiGJBwQe1T6jcpDuVXfzs5JHQ1kQkTSNJIDuHr3oA0YT5sGyXDbjnIGMVp+HytrqkUaRoSWBJJ7Vz5uZpGAWMBRwADXS6RCIdlxJHjbjGeaAD4sWu+7hmQtGGXORXn9miLKF3nc38Rr1rxso1nw/FcQrgR8H3rytAIiQ+1T3BoAvgY+U7c+vrSg8HMh5/hPao4ZARtGcdcgVIGG7hR05DUAOKcExhcdDu5NMIzuDLgD+Je1Abcue3oBzQzbd3mAhT2oAFQ7t2VOOMmiRSPmZvwU80MfMUbAOO7cU+IgglmUc4PFADfLJAJIP14NODRt0cEjtTSqMQSGbB6ihlSTCkDA7DgmgB7og5Z8HPAHemsGyWbAHb1pQhCgnhRxxyaC2Rz09+9AAnVSGKY/ix1rVv2b/AIR3wxsILm0uv/Tjd1kMZcY3DZ6AVqagFPh7wuuCWNnc8e39o3dAGdvG/DEZA5x2qG5xIuFBBPdacdqblCknvihSHUiNQnt3oAx7hHjly8ny479absdvmO7n3rQuYI2BIK5HHWqf2SU/dQkeuaAI0gwgCuWA/OrCJsTDMoB9uavrDglWxz370v2MZzgHHGSaAMwwxeXwpYk5ppUbsMpA+nJrVaAd/lPcL3pTGqEElsnpjk0AZRgPRUVO4z1pFt3GVDtG3UEnINaZlcx42ZIOCWHNKjCP5hEGPc9/yoAzxaSYBlKMP9kc1Olkr4AHXqBwatKsZQyMD5mfpTnYsSTKF9QaAIUtGQ7S2MdPM6AVP5LDG19xHZTxSGQ+WMqGU9zzmoyd2diYPcCgCTpkbwFzyMdKQRxheWIH97PJojJC4zjPUyClONzbQGx2PSgBMtuwEyn+9Tlk4CgSNjnDUR4PG3p26U8wyyNkEvjjaeMUANKJgeYjLnkAdqq3kUbZwwEn1qw1vc7cb32/SkaByn+rBxwSw5oAzIrgxrtcuzZwGq08wXCuM8fiKnt9MuDKWO0LjPJrRt9KAYNKPMH97PSgDHXzJCVCsUPTmtSy0xpF4jCd845rXja3tvle3XI7jvVkahujKx7YhjAJFAGadNEQxJtf03DNWYbCJF3mFokzjerdali2vKJJShfttP8AStS33M7RrC7I34gUAN01lSTEZJwMZPJrWhLFceZEcnkjg0unafGi70ByTy2OlRkCOVzGqnHPzjrQBBdhILzzfN37eoxmrMuq20lqQqKjgcEVjahdKVLGMoxOAEqnLsFqHYNkdQOpFAElzeusoMLjOec1e+3tbnduVsgHHasNUN3KCEaMe/pRPLKzmF402rwG9aAPS/DWoNcFW3Rx9ASO1ega3E7eFZ3iBYqh6d68U0OcW8qQmRSx7DtXufh5ItQ0IwtcHDJgjvmgD5J1ZjJfzqSyvuOc8GqyoG2lpSV6Ed66r4jaO+j69cgj5WJ2k9a5LzSMMAoUjr3zQBLHJs6Bto4OetIZjjATcndgajUniSXexHp3qRAgUtsZATn6UAOCMw2+YjKByvemZV8IWAUDB9qf5e6TdgMp5yvFOZS5yxRR0xjNADEjaIYjK4P8RPJqRHdQTs+Vu59aR0jPzMm3b0I6UxmBP7t8e1AEoyfmVQoHp1NQ4Pncxjd2zTigI3K7F++KRCzFkIOP75HWgD0j4X37SSvZz/MjjAxU/ia0NpetGMoCcjHauZ+Hxki8RW4hJ3bhkdq7/wCIoSO9D4ZcLkn3oA8w1AIZm3yNz0471mxspVhlmGeMVeeb7VdlnX5f0qDafOCJ5aoTk0AOsrdPODsSxU525rpTfyyQFIQoAGBiseSJIAG80Zx/CM1Hahi25JmCk8gcYoA7LRJftOnz2dxG43qcelef6lYGG9dCpG04BaumF8YJIQjsPfvU+u2kGoWpm8w+fjkCgDklhMaggnOM4B4oRi4BKb8fpVV4TA7IhZgRnBPSnJdADYPlcjg9qALZVz0wHPHy96TDqSCCCT35ojZgMHa3IIIPSklkjYkSOSf9nvQAhHljMqhs9x/hTlZZh+7OzHZu9QPIckRR7DjvzSNMBGpb5fc0AW1252mQn0AHAprKNoOxvc1VWckAZGPWphcEBVdwaAJFAjI8tnYkdD0o3oFIZGJPYc4qPaXB2s4yM47VIi+Y6RytFbqSF8xy21fdtoZseuAT6A9KAGPME5CEkduma0NUuAnh/wALYwC1lcnHfH9o3lPOjQSDjxD4b5GBmS+/+RKk8SafHb6N4Xiiura92WM48618wRkm/uiQPMRG4JI5Ucg4yMGgDGN3jBQYz2NQyXIAJXKjvnvUU9sVy2Pm7DNRtbSS4PYDqD0oAlURv879T6cA/WkFpM3KyFQegB6VALeQtwpZR1JOAak2+spX2z0oAvh2csQSpHZu9SADeFk6HsKG4x+93Z4xt5FIVmUZDhT/ALQ5NACh41f5GbI7dTQWIAI6n0600iQH5wEB9OrUojA+4NnvnmgBplIB2ISe/qaQSyBstHj+dS7ZD0KFegzwaaWC5x5gfoTjIFADgVxuK7j15pCbdeJQd57HkU1RI3I2Fe2etA2s5TG7HUCgBcbRhF47c0rSzKnzRhB0yOtHkuw+RV49GppG3O/zHkHoaAGb2c/dIPZnHWporRpLhELJk85U9Kidm7SSL6Lio45TDITnn+dAHTx6eqqCwLP6kdaWVChwkXIHBFZ9lrb8Iy7VH96rsmqRyAh8pjmgCKR1bIZGyvXHFM3xsp8vc3qx7VG16u0+WcsTxuFV3uowSCQr92UcUAWd8cLYVhL9aGcyYGVVT71mPdDJBBA/vKKrpcsThZnz7r2oA6EukeF5bHJJ6VWlv1ZtoQlegUVjm7Uko0xPHPYVCySSKAjMOc8HOaAN21ubZXJkQxt7c1t2eqQKQpWRR7NXEL8g+bKjpwc5p++fzA0cihR6mgD1nT9WtjtUvkD1qzfKt9E32dlDAdTXlsd1LBJvilycZINdd4e1L7WjLgggcg0AV54JIpcSZyOp61nXMoaUAswA/ixWpdfLcvuTaufvq2cfhVeMiV3jflMddnNAEkLI0IKTjGME4qF7T/SFZrgBfU1et7KAR7o3Gz0rXtbAXvlxwwoWHBzQBkWcIjkMobntJjrXrvw01OXKxXMQYMOHxxVDQ/BjSxp51sY48fe6iuy0fRo9LkXEiMB2XtQBxnxp8JNqVo19aogKjr3NfOP2fyZik0ZwuQc19vSw21/G8dyrNkY46V4T8Xvh+trNJeafh16lNuMUAeMp8jgxkgY70O7uWJkLj06ZqI+YrMhQqy8ZzT0WVsB0UqR/eoAcJcMFEb9Pu9qcsSk7jhCf4Qc5oETsP3BEZA4J5phjblidzA9QMUASMCiBdygZ4zTmdBj5ATnBIqLaxRSrjPQqw7UkjOHPlFARxntQBJvVenyH1HORSFlwQZdwJzxUaiZjtQLuPYDrXX+C/Bl5r19EHhcJkbvlwKAN74QeGZtS1ZbsLuiiOT81afxJuWfW54wh8qNcMucjivX7DR4PCOjQ2ljbqJ5Rgn1rybx7p5S6mG4q7HLUAeZ3dwphDQR4ToQRzRpbeZIRKq8dPlp97FJbkIGDBjjkVBG4hk+TdwcGgAvp5DKY1kwnYAVLp7g5CqGY9SaqyCKWcsyuX7c8VetnRXAcIoP60ASkOyBggWSPuT1FLYX8iStvK56HNReayrIdoCvwCTVS4leGLczKDnggZzQBsX1ha6hCXgl8ufumOtc1c6ZNE2xh8meRjmrNreSBw6SNkcknitq31G2uExPgSj+Ic5oA5URFGG3eT3OKDEMszxnA6EnFdUJrFziZyPTC0+fRbK9QPBcKx9CaAOUEh2/I4PHKmmqwkGVABHBBPFbl14auly6xMyY4xWS2m3Nu2DBt579KAKpkUE7c7cdQKW3UPJgNgZ79aSeOdTuKlh7DAFQ4lDfNHkE4znGKANhIioJL5UdQTTgoJ42/Q1nxzeWoXaQw4z1zVxZRMQvfHUjFADmQIy79ofsT0rT1FVfw94YBfn7Hc4A4/wCYjd1lF1UBQhYAdGFaeoSE+HvC48rcPsdy2R2P9o3fFAGZtXcMsMDqKcwiXkIRjnA70SsWQbtpGc4xSK20EEkk8gigB4AJDDlB1HpTWCFiTHn/AIDSBujDKNnkmkcuWJ3t+FAEjuOWjUocdjTFaXILn/vvvShVyAoI980CPJYNnJ7k8UAIZIwDlgW+nSjAJ/uqP4m604ogYY4I/iPSkVI9x/e729D3oAQqGKnJYdvan+Wp5d2HsDSeWxbhWGPU/KKjWBGJ3q7nruB6UASlFPJnwcfcxUbZCkbcDvt701ig+XaT7+lKrEAeWwyOu6gBNi4JXKD60h3KAwzgc9etI8ZmHyqAR1BPWq0toSx8yYD0UGgCUXW8lWV1b1xUQTzJ+HdVPPNKIZWOS2FxipIIinEiFh2YnmgCdIfmBLqR2LU7aoJ3Sjd9aGMez95Gy+nOaavkt2A+o60APJcqFRkcd89ajaVYyQAyY7EcGmkDzPkUq/qKmw+B84djxgigBhZnX55lXb02jtUTRmVTtchScZxg1ZMRLbWKqo7+lNZigO4B8d80AUZbeOFSSSwH61HBMp+SIsiDrUk8sb9I/wBaW1CM+5lwCegP3qAHojFgRnywcfWkuLUE+Z90A8L61b3DcQscigU3eTJsKFfc0AV1RgBuQkf3hWr4TuHg1ZPL34Y4IJ4qoXwx8p9zAdKd4fYz6zEqggqc/L3NAHc6pHb/AGgySjHutZwZInMsMzutamqTpM/lblU45ytY9vEqynyXJGeeKANWy+zPAoZSZm54bFeifDTRI5p3lYNtznnkV53b23nzBHjD57rwRXtfh23/ALA8MPcDzVHl5ywzigCz4o8Tw6QRaWuDMRgBOcVgRpr2ooZC4QOM+lc7o4l1DU59VupVIB+TNdZYaozk+ZOFXoOMUAZek+KbzQ9YWx1dWZScK+7FWfHfiS3khZcPtZepIYGsz4gQW1/prSZi86PkNnk14/qHiBmtRaSSrkZX1NAGX4k0+J783Fqzojnp2rH8otkEkAdxWiJ4juDhnYcgc4qrLIDIvlxhc+jUAR5yCP3px3ApTIwYCOWUseqMvAqSH7zEISR1+cUOF5P3CepZs0AVXkC/6zf7nsKZ5oLYCABuCQOTVjy0H3GBY9c9KsWaO8qtIFYj04FAHRfD3w3LquqxGZZDGGHXivrLwtoVvpVlGIEXcAOuK+b/AAhrCWV1CobbISNoJr6f0KRJ9IgnmAXcoOd3WgCS/sftkqM+3cOntXjPxM0lzqLSqoYKD36167fa7aW7MBJGCvYmuU1PXNH1MvFN5HmN8oxyc0AfOt3GwG5Yld1+9k1h3gaJ8llRn6AV7B4l8HiONpo1LKxzx3rhJtBbLB0AI6ZoA5aztbm6k3IiqBwc1qw2LIQzplvXHSui0vRcAEhRjgkGtGTQZmdfLEjJjnBwKAOLkthsOOWHc9KbdwHyESRAP93vXcDw27RlCFA6gjmn/wDCLRKAZ5Aie9AHmE1o3KrHmM9yearGF4z0xj0GM17Quh6MIwDPHn2rIvtAsJtyQMjEdCTzQB5eTIQAVJPvxViCSeF1dHRccFRXS6n4WeNSYleT/gXSsR9Mu0jZQpIHQYoA0bTxBd233ssOmCa24NUt7yMeZEpPUECuSuLSVbdnkGH7im6WzCTZG+EzyKAOpubKwueFiI7kk4rC1Pw6ceZAY9o/hBycVbZAikl9zY4Oafb3Uig7QACOpHNAHPxafLCoG0nPqOlJc2kwjAOc+wrfF2XkClCSepIrW0/T3u2x5TGM9s0AcAPPhk2SA4K8bq278n/hHPC2No/0O579P+Jjd1e8VWttb4/dhCOMZziszVQF8NeF2HOLK5AI/wCwjd0AUtx25Z1JPcUDeXwFIA5DVTRsMeuG4J96sq4YbXbOeMA0ASFgq5c9fxqHzISclGJ+tOUYBwnT19Kl+XsU/KgCPI5ATzCe3YUYHAA+b0PSnCNguAxAHGR3oKlQdxLepNACgHb1UqOoHOKYpBJHl7COhNBjZ+AduP7tSCKR1G90MfTB60ARlC44DOvcFuM0u2RSSTsQe9PMcWQAdox0oC4wASQOQD0oAasiseGXI9BTvL80DeyZ646UFvkA8pcH+7UTKrHJjJb0B4FACtHGvDSKx6ZHamsAAMMM9AcU8bvu+Uo9eaFChipb/gNAEewkDLbl+lOkX5NqOAvqaXeQwYZUngZ6U6XzeSsSH3FAESBl27cFR1561IzFgMID9BTcZBMwUZ7KeKcdyrhQxzwAD0oAPNfGFVUHfd3pMswyyKQOgDUHd/y0IAHXNMMaMCyng84BoAGfevzKOv3c01hyv3U9KfhgcRqRxyRTt8iHktn0KZoAheCTduWNWPqDSMGkQFkA29F7ipS7tn5t7dQNuKaTMPmlhA9MHg0APDuAFV+c8rTnkIX5o9xzwy9RTPNVEKvGMnkYPSkVgBuVWz7UAErq3CR4IH3s4rZ8IwpHJJPM7Bh0YVkBhKwV1cZ68VvW8UlvYbIdrbuSG4oAsTNJJeF/M3IeferUSCRQSZRj1GCKzrPzcEME3DsOta1ktxNcRrHgkdQwoA7bwJpK3N5GWJkI7nvXQ/EzVXt7eDSNPEokkwGAfim+G3ttKs5Lqd/LkRc4HSuTs7saz4llv7ht6I3y+1AHV6fZva6OkTRqZNuTVIzyxfeiU47inanfqIdqTZHYr1xXG6/rcNlDtjkkDHqc80AUvHmrbwE88jn7oGK86eMNKHjDFs5wRVrWNX+1zFxJIT/tCskXO5SdrNnowagDTQMSdodSOvFUrtSisxQgfSpLW66B1aMY4OaszOXiJVifrQBjMWf7zR7R1yMGlVwPkXyyB681NLE7sQxIPuKktkEYJyhxwcjmgCzBbb14JP0HFWlZoV2xgE9htpitlOAwXuYzzVSe6eJ8qwwOznmgDXtbqS1uYpG2hgQcelerD4pSQaGlvsYbRxtrwxLkzEkHeaa8rA7SHHPrQB2mt+MtTv5c+bhD05waxbbXLi0nEjXIVlPOASayvPwCuFVfU9aHLHbvJx7LxQB7Z4P8c2+qab9j1CRw5+65q3raRrbko6sO3FeF2krRTAiYk/7Fdbp+vyvCYZJGeMdM0AbdvftFd4RW8s8HBrZn8TW1jGxZPrk1wl3KC4aOY59BWNfyzOdpyAOpzk0Ad/8A8J7H84hQqPUDiud1nxReXb4EpEXYiuaBKhV3rjvuNG0AA/M6/wCzQBcXUrhjk3BYf3TxUkerXFudwlw+eO9Z0kuwDPA9CKerMillPDDOAM0AdFaeKZIyPMYSOeCSK1ofEFneALOnzduMCvPxM5fr17Y5qdJXY7Xk2gdqAO8uLdbqFhahWHp6VxwU2eojzS3B5GMU631GS2JMRbnr82K29M8KX/iTwp4i8UwFxFou3EQ+7P8AxTZ/3IyrfjQA+GW0lUvuAYij7Mko3RyMq+grlRPJGPuBcDjaeKcuoyrku7E9sHpQB2ltp8ShTLcAc5INab+IdL02zaBVWYupDDzGTI7gMpDD6ggjsQa84jvZZAcyHBPc0hG7O5ov5mgDXvNb0iaU+b4btJRn+PUdRY/+lNN8S3UM2j+FntrOOxhNhOogt2kdFxf3YzmR2bJxk5Y8k4wMAZIjaQfLz/tCtHVI5G8OeF8ZyLK5yPf+0bygDAmYMMbG2Z7mlg2A4DYHUGppInKjoCemajCOxIZBuHTsKALak7fvk+4p3XnDn8Krj7Qg+cRgH0NKJj3z+dAFoAkc5IHPPGKacBiV3fQ808FBgvuIoLCMkqdgx0NADQ53ZG7OcnIpS7Bt+UJ7elN80ZA3Pk+g60Oirjcu7uOelADVmeQ5Cc9CcUp3dGViB6nillkDjoyfTvSfMF+Zhj0I60AHzvu2KAvfJ4/ClO5VUAoo75NJjP3sjHOB0pcFlAKLz3PNAAC+7lQAT0FA+ReTznnApSXI2FcJ3YUjbUYgNkfWgBVwRuO/2OOKVmUE7S3P8PrTNwZhtEme/PFGfKGfLcPngnnNADhjhVUKOuDQVYH5sYPPFNTzMnBYnOcYpjXDb2VmceoxQBKcOxO3JBxRsROu5h2KjpTN2cZLbT2xzTkcbAFYgD0oARmyuFBBzndnFP8A3hA2uA54PNNeRWUfdA9cdKUFAQcK7H8KABzNHgMWOPTBNRhs/MYnK9y3SmO6BvlSVXPVs8VKknB++4xwM8CgA287hGvPAIoBkY9lA4CtSq7MTtRsAd+lNYuR97cPQigCS3VVlG/awJz96uoMSSQoPlIx0B5rkiPJAZQnXOG7Vq6drUbAROiZHdaAOhsrLex2MNx4CleldWsC6Rp/mu6lwM9K4q219bXBjcls+lQ654hnvUERkJX/AGaANDWPFZntjaiTYxPJp/hrUls0YtcKQeRnnNcSX/eFs4U9mGaU7cA4b1yDQB6Dq3iuBowInXzsHhV4rhNVvbq6l3NEZFPYdarSSZbDByAO1KzF0Hl5A+vIoAoyW7OrMA8ODyrc5qsbWJSCwk3dRtzitf5mwGT5ccknJNCyMvyFdoz1xQBmmIIMorZHZ+lXtPbzIyB5ZweQalu/LdAGdj7gVnQxeVKd4k2HoRxQBoPh8CSIqwPG30pBshXcJAhP95afGzKuA4IHQtzVO9uWddsXluc9Mc0AQTXDTSFUOcdCnGac9qzgOyDd79als45i3zrHEvYr1q1NJyFXLNjHNAGOImV8hGQD+KlZRvyrNnv3rQUOwZMLnP8AFTY7RzIcOG55AoAoGICT5vMYn+HFWYlLNlcptPQtxV/yXGBI2wdgOaQWxQFgYyvtQBTaR2bAVMd9vFT20jI/zkqnYjmoJF3v864APXkVaQhV3HAU9xzQBZaUlNo+cdu1VJYycFFYMOSA3UVMzSuhOAT2zxVcj94oLiM9sUABIyNiiMjqSMk1KgkAwrYU9D3qKNSsjFsg+uan3EkquWbHQUABEhI/eZz2201kYjG0/XOKl3E/xfN0wO1Iwj/i+8RjrQBA8TEhWBJ9VqCQbcb0KYOB6mrmwrwkze2P61DLl22nBx196AG+cGCgK0jdFAGSx7AD1J4r7W+HfhiHwx4F0/RLhY2lEO68BwQ8smTJ9RuJA9gBXxVbGa0u7e6spfJlt5VmjbAJVlOQeQehwR7gV2ui313f/D/4l3V7dTz3LnQy0s0jO5P25+rE5oA5/wAc+H5vCni7VdDdn8q1mIt89Wgb5oyT3+UgE+oNY0Zfbyq46dOtXtWu9Q1W5im1K+nvHhhECNM+9wgJIXcfmIBJxk8ZNVfKK8oHPrnnFAEiIMZZArjjjpSx7MfKefcUBJRhhgr9cE044Ochhg9zQAowwzvPHJArR1Ik+HfC5BA/0O5PP/YRu6zArZJRgD1xWtqAz4c8L5/587kf+VG7oAxVeUAkjd7jnFTKxcksBt68jmljJV8qRjuBSnLndv8Aw9aAGl1LFWRfakaPJPyr+VOKEEbGUheSDSLnHLEGgAOB1bHpQEPALHaTz3pW29MknPQdKaSvIVufQdBQBIcA7EBJPTA7UwRnlmyV9fShbiVV2xIWJ9KEkucHfGSP7pOBQA5cgBgy7uxPYUoD5JDDB6k01V8xS0wVO+Qf0pgZMEBjg8cUASmVtuFaID+VIDIEO6RNp6gU0pHuyDzjuODTR97KoPqRQBJkkEK646U0q/QKjEn7ooC7/ldBnt6U4JtOMqvoaAERWIPKjH8PShMoTuZweg9KHZ3yAVLDjngUm6QqRIAvpjpQAx/mj+9IeecHBNOiK5GJGGOoYZpjbmx5eD/ez/SpI2ZclRj60AKwZm+WZzz/AHaOFGF5PfjrTiQ6sWYhumaTbIoUB1cA9hyKAGqcsflwPX1pHRC+D94+vansFkPzFGbHc4oRYoj80e4465yKAImi2REEhlPvQm1QPk4xjHrSuMt+7G0elP2SMeRyPegBkg53FyPRRS5yMPG2euQeKVl+Y4fPtinRhx8uMgc0AQlGePEm7npVARyLIRHuCn0HStPcQmMvjscc1EIpNuU3EZ53UALEZcKu9So4ORzT0yG2qx4PUUAksFCEY6kCgphztUgZzQBIrKhZJEBb6UxijEbVI9d3Sn/MV+dVIPQk4IpnBG3nP50ADBSw4Ke46Gn+SqrvkI4HUGhWHKhGJ96FSTJ2heOxNAEaMCpVckHuaaEAPLZI6nNOYFWXeHJI5I6UAop27B0696AHtMQmwIHU9CaguIxJHtKKG68HrT1fbIT5m3PTjNSMyhCyoxbp92gCnCp2lV3IR/eqQQMVyTGzdmHBqO3YO5yCc/3quKqrwyru/wBmgBiEpGQ4G7sMVBHbiRtzBs5yfmqaUOxJJJx37U8KcA792BnC0APS2WMBuAPemkpk44x07A01F3D5QSR2Y05nQDOwqc/dPNAB5hYkLux9OKiG2UssjMPYcVIp8xeQSRzxxikwCwyTkeoxigBqW8ROSWOB0606OJQCVkKge3WlBIk+Tac+lLwHG5Dk+nSgBpVmY7X3mlmSRR+78vnrmo23hiA6jHJ21HMquQA3WgCRBlQXjO7PY5p+51O0NgDngc0RLJCBhl34xxT2y5+f527kUAMGAScjOeo60AjABZSfakbC4YZPqMUMxyAF4PfFACuAQQiAZ6nNRhdr5DLhhwBTkOXxtBI6gHrTysifdiVR39RQAiq6pyAff0rp/DmW+GvxJyBn/iR/+lz1zCBmcbn2n0zxXUeHxj4b/ErJH/MD5H/X69AHLOg2j5OenFC7k6EqO/vSAEAASMRQeMYO7PUGgB4LNk4OB60qwvcSxxxhGeQhVDSLGuT0yzEKPqSAO5AqLO4sASPanou1dp3HHIoA0R4a1bcSINPH01vTuP8AyYq14gs5bLQ/DVtc+UZRYzs3kXEc6/Nf3bY3xsyEgHnBODkHkGsQB87lcL9RWrfFf+Ec8MByd32O55H/AGEbugDHRAMAHAx0p/O0YCnPTmnK654X5hwT600kN/dBHc9qAEUMHICgjr16U1trMS27PfFPClUJ2dehzTfKZucigB/lLGOT/wABzRg4w+0L6CmiMlRgeVGO7dTS/Kexf8aAE5GNoCj1B6UMW4ZpAV7c5pQq/wDPMcccGlGNgyoQZ7UAMDSu4Gzex4z0FSnepwUVcdPeld40H71+R0x3qLLugMSkL35oAk6c4BJ7HtSFymQZWLAdAOBTcPtyWwT603MgkBBBQe3NAD0UnojeuaQoxyrknHSlaeXPyLlT3B5piphQ2WHckmgBxRNu1mlyOAAOKZIuwYJKE9Aehpxl29JZcHsRwajjbzWIjLAnruGaAHrHuwWbcB2WgMNxOScddwpxUCPLIwI6MlPVHZuGBI9RQBHvlbhFQITnJpflP/1uOaeQoPzde22mPvB57e1AAylBnfGD6EZpxVUTcyFWPPByDSbCVxkg47jrUUcXPDP9TzQAqtzuWMA56k9KcyouTliD3BoUMMgKR/WlVcj5lB9+mKAGh8cRB2PuOlKhV8hvNXI7VKGVSqqxBPqajJAOGbezcYHagACKufL83fj+I8UqnKgMp+uaQRp9xyynsQelPUqmRvVseo60ANeZQoWIuB3A70RyLjHzsw7GgnPIwPT2pQAF4I9vU0ANJTcTKBk9M0pk2r3TPpT22YKtyf7rCgExj/VKyk4yTmgBvlsSdrnI7560jHaCSGPvSEMzbnXGPTtSoXOQoBwcEk0ANUowO3f9KcYU65II96c0bAnGBjvUeCGx8xXvnpQBEIMzFt20dRipn5ACyScDuacUV1wenYdKSKJGDKVCEjqTQBDChichpeDzgDNT7gF+T1601FWLKqWD+o5BpFZCxypLHrQBGjs8pJ5UccGrCKJBgFsegOKihk/ebkCkA4xjpUjsAp3KOvUGgAK8DL9ug6ihRjGHB96RZFyCB16N3pVMZX5zgmgBTtHAX5j1OaRmIHXg9qavlkZDOGz0NLhGBAD4NAChHKjbjFNkT5cgjPfmozwxXe5wM4Ap8YUKCY2YgcFqAFjRCScKuRg5PNRlBG+SGwOmOc1I6NIpbAVe3saYGJYKSevGKAHMwPVWye4FCPtccHk96dt4JWR2X+7jpTRz8oLjHHzCgBzMwyN2PpUMu4LtG7H161NGCARsPHc9DTWJZiGRV7Bs0AMiKsvIx2681IdyMDyc8c0gj2xnL7uemKCwwf3ZOfQ0APCb16Dj1rpPDY/4tr8SQRj/AJAf/pc9cs7Hjy1fA9TXU+HD/wAW2+JRG7n+w+vb/TXoA5s7fKA+bk8YFMyAPlUZ9DShiVC/d9DQAVG4upbpjFADsELnPJ/So3DZIeZTnkCnDG0fKS3XNIBGo3EAt3DUASBf9ncMc+lad8v/ABT3hcDHFpcgf+DC7rIzySAQfRjxWpqG4+HvC+OCLO5PH/YRu6AM1oPvHc3PUntS7Nq85Kn+6Ov1prZOd6tz/ETxQC38LcD8KADzDkkJgqMYNMx7uPan75AnykMPpTTuzyCT7GgB5HcnzMfwmkYuRuVQp9PSpDhDkYz6Y6U1irfMXIGeeOtACKH4JXn0XimeaSTlDg/xen0pZGLv8oJPqelG1i2HKM3twBQAIuF+VCy9fmHNLsz/AKwsdvQDgU12VCQjSM/cjp9KegWQAy7toHQmgBCA3+rGPU56UhVwAA2QOtSKVV8YVVx2NKG6+UozQBFs+bgENjrTnikBHzKVA6E0jNKpIx8vf2pqyCR/9WjZ4BJxigB6/J/Hg/nTQ8ROUzjPX3qTC7SS4XHZecmlAOMqF2jvQBG5dG3CQ7j0UVGryO+SuV9QamYHb8mD264qBAFY7tw56DmgCTy1Q7jv+vXNOaQAZjDhvU8imsWJBjLbR609Nw4O0HrkigBN7AgyKZG7DtQ+cHaCjHpg5oL5LfKDz24pigbt25l9qAHJ5hHz8pnHHBpSDsG4jb2yaepB+8d30PQVHu3KTt3DPagB+CMDEZb1zQCMkOm3nkimlI88YV8Z2kdaUBsHCFeOaAFKJj5Qd3Xk9qNgZRtwSf4cVHhmJK4Kj3waXzHC4wU980AK0RZgSFwDzzTmz91FAb1PFMYZIJIz2280794du5jtz3oAGVz94BzjnJojD4wu0Y7UBFDF/mzjmhJAQc4P07UAMUSqTukwp7YpcdVMfy/3s07fvbIBA9aim25JRiPb3oAeFD8Nk4+7mlbfgqCAB1zUcDSHiReh/Cnvhj84HPoaAFYKfm389xSJ5YccsRjpSo6kLuKgZ/SnMEHzLu64BFAEUWTKQjYHow4qbAwVcLuA6jvUTkZ4ycdqeCWxtAGO5NADUAQ8YVyeOKeM7hkLn6daaAEOSfzNIGCDdvOPpQA7GQScc9z2oiUcBgpHqaiaRS27JOTxu4qUY8sk8kmgB+xS5IGfTmmNgKVZ3b6jpSiHeCTyR/DnBpxQkYLFM9FNACDHylWPoeKQg7sK5cD9KaV28J8re54p7oGQ5KBv9lqAG4DEM2QR2zxTWVTlokYsO+aaBn5WXI+tSBQoG4ZB98YoATMm45+UjsKQs2SOdh7GlUMGA3AJnrUjhCw3/MPagCJi2ANxAPYU3yV3b2J9hT8LtZehz9TUaShGAZsn3FAEqj+8cehPQ0gQg5AAx79aUylhkFR3wRQxWVchlzQAyMbj8zdTxXUeHwF+GvxKGG4Gh5B7/wCmyVy0ZbBHBHX6UyW3hmnWaWCF5UA2uyglcc8GgCcBNvOVP+10pp3EhVIDd2x1FKmc5YblHUUuE3DL/higBse8H5iWWhgjMWb5COMHvTjjvuA7Yp0LKJFeaCOWNWBZGZgHHcEqQwB6ZBB9CDQBHjdyF4Hc1q34b/hHvDDAgf6Hcgkn/qI3dJ9v0vkP4b07B6f6fqPP/k1U+vzQXGjeGZILKCxiNjOiwwvI6Li/uhnMjOxJIycseSegwAAYoyOhzzTGdR8qDc3fdUmAgyGJzQQduVQc9TQADeVO305ApVQkA9PaowqqcqNp7804SMR9/HtQBDbT+YgwGY+vapwGPJU8dz0rPS5CE7CeeqqKvQ3JkCqY+R70ALuLE4/1Y7e9LtZhhseWOgxyKlOOoUHIzgnpUDh+MgbD3z1oAUOqNjgt6VGyF2DYPXtT1gXjdtGfQ81JtIJAG0LwBnrQBGwIUEMu70IqJJXzkAZ6E9Kndd5zIcqB90darTINuVVsD+8aALEZYjJdSR2FOZgI+ik1Tjm5I2Yx3qdGjKFh9/OMHpQAwrIx3Oqrg8KO9ShWOMjao9+9OVm2/IAD70xw+Qp27uuc0ADBG+VcsfUGpPKJUMzY7jFRqqjGMluh4wKXjOBMB2AxQApkONqvg0bljbqzmlA2A4UH3pIy8YO/nPHFADpCu/LIT39KAyuucEDtQp2ksUP/AAOguGIYIPwNADMEt8y/LT9oGVSNsEZODSl1VAWJBJ+7R5y4yI9vHegBhQSbQVkU4yST0oCMi8PIR12k0NLvBDZjxwSO9Ojkh/uuxPGTQA1Q5A2xKR3yelQzvskGVXHpVhnU8oV246U2QxyLhn574FAAoDqPKjTA64NIN42kgEg9zUMGFbaXbB5yBip2wFIRS7UALk53Ehqd5hK8ABT1IFMiRgpDKVPTJpyxbVyXDduKADqo+b5ffiqkzFGOOVJ61bkVSwGWZx+VJheQwI9xQA2P5o8MxORzSyQwlcIRk9KauwZB2kY9agnEUZzuIK+lAE8SRjIlyPcClfy1UBD94ZA9agtyrEESls9qkdY2YHbk9KAHQxbVJbhvQntSyKBGxK5HqKe0a4wFYKR1zUZ+XGXkA7DFACQCIABlz+Pepi21vlXHsaqruVyCDg96f5qs/Ay3vQBFKsjz8pkHjJPSrEasFw+AenFB2E5ZV29+acwXAZQfwNAAIgxByN3TmkyckOAM9M051JcNgg+hpXw2SSue3FADHjUqWPT2NAIG3dtYdhigvg4BHHPFIrfNkbgp9qAEJ+9t+/8A7vSlwOBuJbGeR0p4fLkCVsjtSb8dXyfQdaAEYLu+634UmGzwQvqKcep+XA9d3Wk25+6BnHBoAUq6n7+f90VBOFOSA2e4IqTeV+QFyPYUwszHG5tvsOaAFtsAZJOB2IqUhfMO4L9aRQyry/T25xTiQpPAGfUUAN2ID8pUjPWlKCMjhSCOSKT+HPmDPpt4pGJKjdhttABEGUBvMX096GVSRkkEc80I/P3eo7047SoyoYj1NACh8DmXKgVDIwcYB5Bz8tTBUwcbQRzUbBSeo9RigBWUsu1/qPUVqX+D4b8Lg85s7nH/AIMbustev3W57mtXUMHw54YBHP2O56f9hG7oAyXby+iE8etNLjGE9M/SpdoPbOB3qMcD5Bz6UAAYgcruHXNM81TzuA/CpU4xgtk/pQ8T7jgqfwoAyE34BTgdOakjA2/NJtX26mon3EfMB7KpoRGYHeCBmgC5FLlfldyc4GatiMsQzSlm/SsxZFHRWGOnvViG5KHHlnp3NAF8qFxtIwepPemurcLnHemo4fqw57VL8oxs3Fj6UAIsWFJdssOuTg00HLYA/BulGxWkDbX69WNDRgccEemaAFmUkECJNv1qm0bYOyRce/QVbLAjyyCuBycUiiPGCy49COtAEUUhCbHkznp6U1BIzlSny56g9qZcFldmGdvYAcUQXBZtq4B9G4oAuOD0KEkdgaToCFh59TTU+YlnOD6A81KvzdQT7A0AV5RLsP7nH/AqEkcEER4b606RnU5EYAPHJqvuIc/IBn0NAF4s5wGySefm5ojKBckLn0xTY2JAIx061HMsquSjLg+lAE3I4ym7HQilO/7rFOlMi3kcyBj9Kk8oMD5hwRQA37qbSSx6kmmOjyYbO0DutSiIOxZThAOhphIxtXnnnFADUBJOCMAcZXrTXUbvukDqSO9SMzA8H5h/CaawaTJ2k/j0oAaEJQElsYyR6U7CeXuVgjehpBnpuIx1BpQMPlFDeuRQAgAI++3vilUADgMRnmlB3coWj9aAyjGWZ+xNACZ2jGCoPrTnyQCS+08AqKGYE4IYqOgpVkAJ4dV7c0AACblbfg9wVpk8IfcWCMuO1JLJsycbl9etKG3KA3GenFAFWJo1YDG0dxV+BEYjBbHYYpgiCd4yWPpUyjyk+aXAz25oAbcgED5ZAQOPSqsshQcByO2KsmVjtJd2GeMjFNZmc4RcgUAUFuA7bVXJ6jParMcQwxKgs392liUxncqAfUZqwSz8cN7DjFAEPlqoG9TwPSnoRkk4wOgoOYgCykZ7k5pFAc8ED370AR4BJKliPQ05lAIHK49BSyMigjJz71VkuZFym7B+uaAJXdQowMj6VIIyfusfXBqG2VkTdJL174zU5dGORIC3QjGM0AAUMRnZke/NKRg4CKSe9KU2ZA2gHptoAXPKkn60AMwuT90t6Zo6KRk5zninMvdYx171GxkwCCPTAoAV3O7bk8DkUSDIzGfwojVANwyWqQbArDkHrmgBu0H+P/gPc0u0p94MeOBTThcdzThkg/NjJ9aAFSJ/7r5I79BTZFIXBTB9aQKVHDM3r81NOWl+YkHtzmgAGCnyn5RzmnBVb+EH3zS5ULgAkfSmqVK4XIPQ0AOJXPKjimyKdp8sBWoZBGc4xnuarzXQijlZ2PlRqXJA6AdaALA5XbKpPvmtW9U/8I94X244s7ngn/qI3dN/4RzxGPmHhjxLnrj+x7n/AON1L4ktbnTtF8M22p2lzZ3YsZ3MFzC0Uihr+7ZcqwBGQQeR0IoAyXG0lxwvcA0m/jJYAYpikhQQwIPJFIJRjbkbjz06UADMD8yliDTBISOA2KlTdu+bABHJHapSQOF2ketAGMFgiOctnuaYdhJZ2k2jkLTSwXJKsWHr2FOaV8gLkk9FxQA4yjcAiknr9KTeN58wlie9G1zkOpyecCl2sPm24HuaAHo2BkfL2HtU8M0iHIBbI4JOMVUUf3tzMBk+lDuwX7uWNAGmt3lirt14wOlS+dGWAV0z7dqyELgZdVBPYGpIn4IO3Hc0Aa6MxPyMCPT1oZssMquAckYrME5VflcBQKkSdgAGcnA6DvQBbkCyZyGXHOQKjliDjAzkdCRUf2iXK5Q4xzzUgnAXDKd56EmgBjxyblyUJA5qB5GWQKJMjHOKubwD82z8ajZBgfu/fjpQA2NQUyxOewNV5wkXPXPUg1Z80J8wZcDsRVK7mklk6Rcc8dqAGC7aM4UnHuKtxX5YbXUAH25qjs3AltxPt0oRcj5cqc9SetAGvC8D/dYhj0GasFA7DacHHrWANzNtU4x+tSwTPHg8lRxnNAGw0YXguRzzjvQ7IsfHLZ6VFFcpImFxuqYfKcs2fwoAUS5Xcqcjjkc0jszDJjOM9QKF2lt3zHJ656U4TbMAl9ue3SgCMKxPAGD1yKf5bkZbbz6GlZ2KYVdwxzUafMcBRjHAz0oAHTCgFN3vmk85UPlgcjnpT3wG+UHPpmoWAd/mAJ9qAJVCuck4FIWEWSACPem5XIUqw9qHbH3VA9c0APEi53bQoxmlaWMtnG7PPFQszkEbh09KcqgKSw+bH0oAFmDHjIA7EVIXXvkN0AApjYBOCMe9AL9c474oAPNJJWTcPYihZV5AlYFevHSmuhYESsyk881Tkh2PuV22nk8UAaG4SR5BLEcZzUZn2AgkL71WiXcuSxweoxUrR+YAFXP4UATsxmjAX5sdDTbaJgN0rDJJAqFJJYFI2ZUnselO+1AIGIyTmgCPU13R5Dgv6DtVKzQF/mGT/eNMld7hwNxAPOKv2cOxdxyCR0JoAtqoCgArnpTVjKOG4IzjJFSFwwILZ44yKRlYKQMBuxzxQA3GSTkZ9hSDY2d7DK88U+MEHpz7UuSpwCNv060ANCqBkOT3A64oC/KRjcD0PpS4BPACsPTvTxG+0nJAoAjiXavC5H1pZMDkPx6Yqu88cUjE/exUb6gu75QrYHSgC2QCM/xd6cSwC7lTj86y31HrsA65NWNPjl1PVbGwtGQXN9cxWsJkYhA8jhF3EAkDLDJAPHY9KAJGmYuVVVLdfanI+1RuQbh3r0GDwR4S1HxJd+E9E17Xm8UReZBFc3cMSadc3UQJliAVTMg+SUAnIG3OZOA/P+HtJ8PHwjY+IPFd14gSPVJpE0y00hbfzJYosCWZ2myoAkYJt+VsjI3A5UAwAQp4LbW5wOafnPIU/j3q/wCLdCTQtbNvp15Ld6bc28OoaddyKFa4tJl3I7L/AAnIdSCFJKbtqhgKz7Ow1C7INjYajdq0vkI1vayTBpAu8xqVU5cJl9o52gtjHNAEcgLJhD1HBPaoYkKjLluewrUg0rVZ7q4s4ND1ie6tSv2i3i06d5YNwyvmIF3JuHI3AZHIzUNpZ3V/Gj6bYX15FLJ5SNa2skyySbN+xSikF9nz7RztG7GOaAKyqjYOCMdR60pAByuMj1q9BpWrT3NxaW2i6zLeWu37RbRadO8sG4ZXzECbk3DkbgMjkZqjG6yIGjKsjDcpByCDQBKQfKzuQd8AVEFYMc4Oehp/b5SMetMMiBcZ570APVSuDsyucEmnDbj+H8qpSXjJ8oOB0BqBpJySQeD7UARlg2VVBnPrzSEEfdzuA5PrSlNijB24/M0CH5Sxyx96AGqxGdnBPXJzmmvv3YZunbsKXBLA4x647UpQEYBYe3rQAh2qMO688+9MEnddx54yKcIxwCoU+p60hY5wrZHqR0oACGZsEBj3obKgAoB+PShg2MD7p7k9aRSwIHVscCgBSrlcyFQOwxSoG7vjPanLGxXc+Rnpmm7eRsP4igCUTuoAUhmz39Kesztneik+pquSAgKjnpnHNOJOcbTweuetAFiNkddzAZHalCE/MD14yD0qqZAp5JAHOAKcrhQTuOPYUAWCCrfKpZR6/wA6VgFI3orZHTGKhV2IOd2M8A8Uskxyd56DHNAACCcLARzgc0FOVMigY6AGn+ZkYCjj3pm8EklQBnjmgBSIlbIB6UixqQWH5Yo8xmXaFU4PGKDI6jaFzk89qAHREdQuOewq0LktHgqwPYGqTTEDIDBhxj2oDksGznt16UAXllCkH5MDr9aX7QxXgoAOTWaWkycMoA6ZFK+R1YHA7etAGgZ/lJXk55AqMzn5iVAPY56VQ2ht3JUD1NN2JuJVjgfjQBdFwCxLHJxjNL5+Ogx6VSCjg53c+lKzEKCx2454HNAFo3JAGSSDxmozPkj58Y5quMsoxvJ689KBwD8pHGeRQBOs5LgAnJ96BO2/DMSPrUQIJ4BJBFISN4AU45zigCcXDE53H6VJ57Fh82O1VQMoCqkHvzTlA+9nIPT2oAtLOxYHYSentT2uGUjjaO4qhEQrfec54xSyOfMwAwYflQBdE4Z8hGB9e1L9oK5ySc+hqkxwRgnd1wTSIF8vOORQBeSSN2JZsYOMUTBtmI1VgDwc1QVtqc9DyBT1JwWUgN6ZoAseXjBfjmrlsY/4doPvVCOdiNkwzzwadvG9SuVzwcigC+XO3J5x6U6P51xtIb17VROR918+mKcDKqg54PoaALoMqHqhGabuH8XBzniqRmmADbc4PY02S5lbA8tQO+aAL7SxopyMHoSazpr59rR7CCOhzTWIbBL4PfuKA5bB4P4daAK7O7AYBJPXimN8zfOCo7VdZwDtChh6ZxzTAyHC7U65weSKAKuRkE7cH2rS8M2f2/xVoNmJrq0+06lawefbvski3zIu+Nv4XXOQexANV2IVQpX3yBSfupAyEFgeCH6EelAH0VpXiy61745eIvDLeHLPTJLuO60+bVLCAxarbwrHhLl58H5G2RlMqAPMiwzYG7yLUruM/B74a3h8tYLdtWt7hk4S3lkuI5UjbsrMnzKp5K8jjmodR+IvjPUdDk0jUPEV7caVJEIJIWSLdJGONrSBBIwOMNliWGQ2QTmt4a8Z+JfCqXEXhrWp9PhuGEkqLFFIjMBgNtkVgDjAJGCQFBztGADc+Iha3vfClnKhS6s/Cel2t1C4w9vMqysY3XqrgOpKnBwwPcVf0rXNR0f4LXp0m+ubFrvxYLeaS2kMUhjGnpJgOuGX5o1OVIJAx0JB8/1K/v8AU9RutR1O7e5v7mTzJZ5DlpG6ZOOAAAAAAAAAAAABTjf3y6MdKlum/sv7Z9uMARcfaPL8rzN2N2dny4zt74zzQB6rf+JNZh8W/Cq3g1S+hjv9P0K8vPJnaM3k00qxSvOVIMxaOKNfn3cDjGTmLWdb1LRfBHjU6Tf3Ng138Rr63mltpDHIY/JMmA64ZfmjTlSCQCOhIPmk2r6nJe6RdyXzvc6VDb2+ny+Wn7iO3bdCoAXDbW5ywYn+Imm3Ws6neWdzZ3l6Zba51B9YmjKIA946lXmyFBBKkjaCF54UGgD1HUPEmsweLvhTbQapfQx3+n6Fe3vkztGbyaaVYpXnKkGYskUa/Pu4XjGTnzzxnNIvjjxQqrnGs3+P/AmSqMmtalNd6VdyXrNdaTDbwWEmxM28cDboVAC4baxzlgxPcmqN5dXF7f3N1dymS6nle4mkIA8yR2LO2AABliTgADngCgB6yuQQzBcHtUbBSO+frTCQ/X88UFVYn5uAKAHqyjO1cfWnhpAMK3y9qgx0yWHf60Zzyr4HpmgDomtY+QQm71AzUf2Xoqj/AIERXLSeJb+1dRLaMB/u1btfGdvIdsysp7k0Aa8lmEXHOOwHc1GbZtxG0bz+gqxb6vp9wu77QoParMckMvCMGHc5oAw5rZt2Twp796j2qOAhOB6dK6NoA3zZAx1z0qI2iNyMnux6CgDA2MxGR8vbNC7YyVBBOeua2XtA3AY88kY4FRjSk6qMN1xQBkFQTlmJ9yelNc4yE3Agdq0ZbDa33s5/Smmxf7+CV7k0AUeFdckk96E3c/Nz6EVO9ufvINxB7imtbuBud8d6AIiW3EswHYDFB3bm2v8AN6ClMe4ZbJbPAApGGGxtOfagBpLOmcgknnPakGwglmJAPHvUqJlSwHfGD3puz5R8vQ9M0AIQrfwnnuDSMCoIRAPfNPAxzxj0FHl9WG4AdaAEC4jyOMd6GbLAAqffPSn7G28qSDzTFQgFuFB9aAGsSWxuJHtTiS2CuCR1FCZJ2hsc9QKceAFU/N9OtACBMKc5XvgGggKPmJ/GgxtJjKnrzzU8cDPgbGJ65NAEBBHbIPHHNKQwABK9MdKvQWRPDDbjk1cjsIwOUJPrmgDGiSTeo9+oFSPBIoI+93PFbMVusWATgZ9KkZYi2A6MM84oA59I5CcbCD7mh1kH3jgZwQe1b8kUbAbV79c0gtkORtBPXJNAGAY1B4BwaGVE5Jbkc4Fb5tUz0jAHFIlsD8pUfhQBgLCjnOH9jTgjxj5FBHStyS0IcLgYpj2gAxjBoAw1DHJ2nrxg04k4OeuK1HslyuAQ3p2qvJYkP69elAFFVXBOBketKhAJ+QgHnpxVhrQ44GVHOarbDu28/nQAm8EkYPPbFBXIwSQR2xTvLIAPH58ik2kPuz2oAcYxnOd2T0NNLY4LkMD+FOkOQRxnsKYhySSo+b1oAkEoVQQcE8E4606OQ7c/3e3rUQHzYVtvfGKcNxAOSSec+lADjOqnnH0FP87cOcFe+ahIBdQOT3pNmxiCu7I9aAJvPj3H5Rx2pQ8bcogwR61XYBgSgCnoT602MhcAHnPUCgCyphbgBM9eetJuCHdwB6AdaaNu/OP0ojRSSw3FfQmgBQ6OOQwAHc0okKHB2Yz3pJY0x8qsMc5pm2Mr975qAJPNVixwR246GkSUEZwADnGajUjGCcjtmlAXaMLgYzn0oAVZAW9RTSxL4Y5X0FJuR9xDFT6mgqw5BGPUUAGF8vgsCDxS7UKgHhvWiRSfmIzx24NI3zI3GM9M0ANBxgFfbNObjHrjBFIuGUHGOzCgqcHnoKAHgtuwpBXrihlOQ3BPf3pqtjIBBXPH1pXG0ck8c4oAaMEcbgKTy4zyVINPyCeTg4zTdrdnOKAOZh8U6igCyGKZe+9M5qZdesZj/pmmR/WM9TXN0UAdYlzoE4G0y2z44JHAq3bWcTgtZ6ynXgFua4iigDvvL1pADDLHOg6YapDq+rQYW7tXdR/dFcJDdXEJzFNIn+6xFX4PEGpQ9LlnHo/NAHZw+KiMiW2ZBnpira+JrSXh3CtjJxxiuPi8WXI/4+La2m+q4qX+39NnAFzpmCfvFGoA7iDVrGfBR16cbjVpbiGQ7VdCfrXnxuPD83e5hJ6DHAqxDbWEnzW2rIhxwrNg0AdwYo8Doc9MHij7OD1K7R0HrXJLa6gwH2fU4XXthqkRddgOVxL6EGgDpfso52qBj1qu1kAwwPc4rG/tbVYAPOtGYHjIpR4oliDCW1kUDpkUAbItS3OFIBx7ikOnrwQee2ax/wDhMLXGZItpz6cmg+NLHGNrEdTxQBsiyHy5wOPSpfsyepx24rl5/G8eP3cDHjAHpWdN4zumfMcQC+hNAHctaKcgqSPrUf2Jd23AIHY1xieNbkY3QLx0w1WU8csq823NAHWGxUcBAc+lKLCMcsMHFcifG7drc4+tVZ/Gl44wkSLz1zQB3y28aOCAnA5zRNcWsKHfIi+uK8vufEepTgjztgPZRWZLczzZ82aRs9csaAPTr/xNptr92VXYdl5NYN343JJFvbD6k4riaekbv9xGb6DNAGxc+JdRnYkSCME5+Wqg1nUAf+Pp+ue1Nh0q9mGVgbHqeKnbQr4AHy16Z60ASw+JNRixiRWx6ir0XjK9UASRo3r2rGk0i+QZNu5HtVOSJ4ziRGU+4xQB2MfjeRVG63yRUq+OQSN9u31yK4aigDvI/HEfAaFxg1o2PivT7hsSEo3vxXmVFAHs9veWlyMxPuGM/eqUIJD8xyOteMQzywnMUjof9k4rVtPEmo2/WXzB6MKAPUTF2HTrULWas27Z75xXHQeN5AAJrfIxg4NXIfG9uSBJHIq9MUAbwtFyX2LkHB4qF7VTnANVbfxfpshG87c8HcOlalvq+n3YBilTn0NAGc1tIASoyR3HNQmCQEsVY4roEEEgXYy4PbNDW4ILZHPYGgDnTHuywBAFSwW7N24I61tm1UDjAGcUscKKPlGR3IoAwvs5Qk7QcfypkuMcMRjpxW+IRjOMg9qryWayk8bVNAGKNykeWcnPQ9KMbeSp75Ga0p7Pg7QeDUf2MqctgjoKAKETbxtK8KehNMJG7kDB6AHFXZrRg4ZAdw7e1Ri0O7lOR60ARAOBkNkemaHZWI3LhiMVL9mdCD0A7+tAgZiRg5agCIqseAR7HvTS2CQAcH2q2tlJtZ/L5780n2aQ+vHFAFYhdvzbc9TSGPK/uzlc5AzVo2cpfAAB+nWp49PbgNkAdqAM9T8pzgtnpSANyMYHX1rXTTUJJUY7E1J/Z67Tg5IGMigDFUI74CnIHOKcykYXBBxwTW5FYRFdynDD14NP+zx7icg/71AGPHAXGev+ND2kucjke1a+6CJSWZFz6GmSahaJkecOeaAM77C8mPlHyjPvTxYnA4x9TVhtbso+BJn6VD/b1p6qfegDyiiiigAooooAKKKKACiiigAooooAcjshyjFT7HFWYdRvYT+6upl/4GaqUUAa0PiHVIjxdM3swBq3H4rvgQZkgl+q1z1FAHTjxPBIf9I0q3bnJKnBpv8AaeiTZ87TmQnuuK5qigDpUTw1NndJcQsfYkU8aVoMmfL1XYPVuK5eigDpz4btJOLfVYG9M00+E7grmO7tnHs1c1Tldl+6xH0NAG4fC2o5+RYmHYh+tMPhjUhn5I+P9qstbq4UfLPKPo5o+2XOMfaJsf75oA108M3nPmvDHj1apf7AtYF3XeoRgDqFrBeeVxh5ZG+rE1H9aAOkjuNCsfuxPcuO9RTeI3AK2ltDEvuMmufooA0ZtYvpT805HsoxVcXtyDnz5M/7xqtRQBoQ6vfRHK3Dkeh5rQg8QB/lv7dZVIwSvWufooA6RbDStRI+x3HkSn+B6oXug31tk+UZU/vJzWX0NaNjrd/ZYEU7FB/C/IoAoPG8ZxIrKfRhimV1S+KLe4TbqGnxvx95O9MdvDlzz+9t2PYKcCgDmKK6L+zNGbldTxnoCOlOXQ9ObIGrRZ7UAc3RXQyaFZqMf2rBn3qNNEtTw2q24P8AOgDCpysyHKMVPqDW62iWW0ldUgyOcGoxpVlk51SEYNAGfFqN5Fjy7iQY981dTxHqSqF8/IHqKsrpGl/xaqmPbFOOkaRnA1ZMfhQBB/wlGp4x5q/lTo/FOooeXU/hiphpGj4BOrL79Ke+jaMpI/tZDxxyKACDxhfRn5lU1p2fjJXkJnXBPrWY2laGv/MVBPtR/Z2gjg6gTQB19rrtlNksynI9atjUbTqJB9K4VbbQo84vX6ds1KJNGjHF5Kc89DxQB2wvLWT5vMXGOxp7XNrwPMXPvXDm40XjbdS5PsacZtJYr/pzjrng0Adqs1oSR5iEAetK0lqzjZIo78Vw5OmFQV1Ej+dOY2IOV1QcjnmgDuZJ4FGPMVvfNR/2haIpLSoSPeuJf+zQP+QmW56Zphl0ZR89zK5B7A80AdjJq9nGCfNU/Sq7+IbRRhQzgDqtcodV0iPlYZpCOxGKa/iW3Q/6Np0YH+0aAOlbxGz5MFtIR9KY2p6nNxHbFQRxxXLy+Kr4/wCpSGIey5qpL4h1STg3bgeigCgDrx/bEhO8qg7EmoXtrk/8fF+iD/eripL+7l/1lzM3/AzVdmZj8zEn3NAHYvHYRsTNqoLegaoWutEiY75ppT6gGuSooA6htZ0uPJjtZHPYmmnxDa54sBj61zNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan of lumbar spine in the transverse projection reveals an acute incomplete fracture of the left transverse process (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25653=[""].join("\n");
var outline_f25_3_25653=null;
var title_f25_3_25654="Staphylococcal scalded skin syndrome close view";
var content_f25_3_25654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Staphylococcal scalded skin syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A wrinkled appearance to the skin, bullae, and desquamation are present in this patient with staphylococcal scalded skin syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25654=[""].join("\n");
var outline_f25_3_25654=null;
var title_f25_3_25655="Ramipril and hydrochlorothiazide: Drug information";
var content_f25_3_25655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ramipril and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/3/22581?source=see_link\">",
"    see \"Ramipril and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4845310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Altace&reg; HCT;",
"     </li>",
"     <li>",
"      PMS-Ramipril HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4893395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4893421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Not for initial therapy. Dose is individualized; may be substituted for individual components in patients currently maintained on both agents separately or in patients not controlled with monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Usual dosage: Ramipril 2.5 mg/hydrochlorothiazide 12.5 mg once daily; titrate to maximum ramipril 10 mg/hydrochlorothiazide 50 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4893422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4893423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Maximum dose: Ramipril 5 mg/hydrochlorothiazide 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Hydrochlorothiazide is usually ineffective",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4893424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Altace&reg; HCT 2.5/12.5: Ramipril 2.5 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Altace&reg; HCT 5/12.5: Ramipril 5 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Altace&reg; HCT 5/25: Ramipril 5 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Altace&reg; HCT 10/12.5: Ramipril 10 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Altace&reg; HCT 10/25: Ramipril 10 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4893426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer in the morning without regard to meals. Administer with",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     glass of water. Do not chew or crush tablets.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4845314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of essential hypertension (not for initial therapy)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4845305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Altace&reg; HCT may be confused with alteplase, Artane, Altace&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4893406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Observed with ramipril/hydrochlorothiazide. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4%), dizziness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Neuralgia (2%), back pain (1%), weakness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchitis (2%), cough increased (1%), upper respiratory infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute liver failure, acute renal failure, agranulocytosis, allergic reactions, anaphylactoid reaction, angina, angioedema, arrhythmia, arthralgia, auditory disturbance, bilirubin increased, bone marrow depression, bronchospasm, BUN increased, creatinine (serum) increased, dyspnea, eosinophilia, erythema multiforme, exanthema, gastroenteritis, gout, hemolytic anemia, hypercalcemia, hypercholesterolemia, hyperglycemia, hyper-/hypokalemia, hypertriglyceridemia, hyperuricemia, hypochloremia, hypomagnesemia, hyponatremia, hypotension, impotence, interstitial nephritis, ischemic stroke, jaundice, leukopenia, liver function test abnormalities, maculopapular rash, magnesium increased (serum), metabolic alkalosis, MI, myalgia, orthostatic hypotension, palpitation, pancreatitis, pancytopenia, paresthesia, pemphigus, peripheral edema, photosensitivity, polydipsia, psoriasis, rash, renal failure, shock, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, toxic epidermal necrolysis, tinnitus, tremor, transaminases increased, urticaria, vasculitis, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4893401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ramipril, hydrochlorothiazide, other ACE inhibitors or thiazides, sulfonamide-derived drugs, or any other component of the formulation; angioedema related to previous treatment with an ACE inhibitor; patients with idiopathic or hereditary angioedema; anuria; hemodynamically relevant bilateral or unilateral renal artery stenosis; hypotensive states; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4893402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs. Consider discontinuing therapy if symptoms of hepatic dysfunction (eg, fever, malaise, muscle pain, rash) present within the first weeks to months of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with bone marrow suppression including rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hyperplasia. Patients with collagen vascular disease (eg, systemic lupus erythematosus) and/or renal disease are at a higher risk of developing bone marrow suppression. Monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Collagen vascular disease: Use ACE inhibitors with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Hydrochlorothiazide may cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic dysfunction. In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal artery stenosis: Use ramipril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use ACE inhibitors with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Patients with renal impairment may be at increased risk for hematologic toxicity. Avoid hydrochlorothiazide in severe renal disease (ineffective). Contraindicated in patients with anuria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers: Concurrent use of angiotensin receptor blockers may increase the risk of clinically-significant adverse events (eg, renal dysfunction, hyperkalemia). Concurrent use with telmisartan is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [Canadian Boxed Warning]: ACEIs can cause injury and death to the developing fetus when used in pregnancy. ACEIs should be discontinued as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4893410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telmisartan: May increase the serum concentration of Ramipril. Concentrations of the active metabolite, ramiprilat, may also be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4893413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4893397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4893399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4893400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4893425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4893428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; BUN, serum creatinine, and electrolytes; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4893540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Altace Plus (VE);",
"     </li>",
"     <li>",
"      Ampril HL (EE);",
"     </li>",
"     <li>",
"      Cardace-H (IN);",
"     </li>",
"     <li>",
"      Co-ramipril (BE);",
"     </li>",
"     <li>",
"      Cotriatec (FR);",
"     </li>",
"     <li>",
"      Ramace H (IN);",
"     </li>",
"     <li>",
"      Ramicard (DE);",
"     </li>",
"     <li>",
"      Ramipril Comp (EE);",
"     </li>",
"     <li>",
"      Ramipril Plus (IL);",
"     </li>",
"     <li>",
"      Ramitens (IL);",
"     </li>",
"     <li>",
"      Triatec Comp (CH, DK, PT, SE);",
"     </li>",
"     <li>",
"      Triatec D (BR);",
"     </li>",
"     <li>",
"      Triatec HCT (IT);",
"     </li>",
"     <li>",
"      Triatec Plus (GR);",
"     </li>",
"     <li>",
"      Tritace Comp (IL);",
"     </li>",
"     <li>",
"      Tritace Plus (BG, KP);",
"     </li>",
"     <li>",
"      Tritace-HCT (AR, BB, BS, CR, DO, GT, HN, JM, NI, NL, PA, PY, SV, TT);",
"     </li>",
"     <li>",
"      Tritazide (AT, BE, CZ, MX, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4893416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/3/25655/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/3/25655/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/3/25655/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73-8, 95-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/3/25655/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/3/25655/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/3/25655/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, \"Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/3/25655/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10248 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-DEDEA7E9BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25655=[""].join("\n");
var outline_f25_3_25655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4845310\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893395\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893421\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893422\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893423\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893424\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950140\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234289\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893426\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4845314\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4845305\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893406\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893401\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893402\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299981\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893410\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893413\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893397\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893399\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893400\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893425\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893428\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893540\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4893416\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10248\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10248|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/3/22581?source=related_link\">",
"      Ramipril and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_3_25656="Fast-track protocols in colorectal surgery";
var content_f25_3_25656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fast-track protocols in colorectal surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/3/25656/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25656/contributors\">",
"     Rocco Ricciardi, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25656/contributors\">",
"     Graham MacKay, MBChB, FRCS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/3/25656/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25656/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/3/25656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25656/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/3/25656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H117219187\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced recovery, otherwise known as &ldquo;fast-track&rdquo; programs, are evidenced-based protocols designed to standardize medical care, improve outcomes, and lower health care costs. Fast-track protocols for colorectal surgery patients were developed to reduce physiological stress and postoperative organ dysfunction through optimization of perioperative care and recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/1\">",
"     1",
"    </a>",
"    ]. Organization and effectiveness of a fast-track protocol requires participation and commitment from a multidisciplinary team, including surgeons, anesthesiologists, nursing staff, social services, and hospital administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117219210\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially, fast-track surgery protocols converted many operations performed as inpatient to outpatient &ldquo;day surgery&rdquo; procedures. As experience developed with these protocols, the principles of enhanced recovery were applied to increasingly complex procedures to reduce hospital length of stay and expedite return to baseline health and functional status.",
"   </p>",
"   <p>",
"    The goals of enhanced recovery protocols include attenuating the surgical stress response and reducing end organ dysfunction through integrated preoperative, intraoperative, and postoperative pathways. Discharge criteria with fast-track surgery are similar to those of traditional care, but fast-track programs meet the discharge criteria sooner [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117217484\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fast-track surgery consists of a protocol of evidence-based techniques to reduce surgical trauma and postoperative stress by minimizing pain, reducing complications, improving outcomes, and decreasing hospital length of stay while expediting recovery following elective procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117217498\">",
"    <span class=\"h1\">",
"     ELEMENTS OF FAST-TRACK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fast-track protocols include three elements combined to form a multimodal pathway:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperative strategies",
"     </li>",
"     <li>",
"      Intra-operative strategies",
"     </li>",
"     <li>",
"      Postoperative strategies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Separately, individual elements result in modest gains, but when used in a complementary fashion they can decrease postoperative stress responses, thereby reducing duration of postoperative ileus, surgical complications, incisional pain, and decrease recovery time and hospital length of stay [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173017798\">",
"    <span class=\"h2\">",
"     Multimodal fast-track protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multimodal fast-track protocols are an integrated, multidisciplinary approach for enhanced recovery programs, and include the patient, surgeons, anesthesiologists, pain specialists, nursing staff, physical and occupational therapists, and social workers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As an example, a multimodal strategy includes perioperative opioid sparing analgesia, epidural analgesia, laparoscopic approach for the colorectal resection, avoidance of nasogastric tubes and peritoneal drains, aggressive management of postoperative nausea and vomiting, and early oral feedings and ambulation. An example of a fast-track protocol is included in the table (",
"    <a class=\"graphic graphic_table graphicRef57175 \" href=\"UTD.htm?17/38/18028\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117217507\">",
"    <span class=\"h2\">",
"     Preoperative strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative pathway strategies include medical risk evaluation, patient education including stoma management, and eliminating mechanical bowel preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117219358\">",
"    <span class=\"h3\">",
"     Medical risk evaluation and interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fast-track programs require optimization of medical comorbidities, including cardiovascular, respiratory,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal disease. Social and behavioral factors, such as illicit drug use, tobacco smoking, and alcohol dependency should be addressed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=see_link\">",
"     \"Overview of the principles of medical consultation and perioperative medicine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117219366\">",
"    <span class=\"h3\">",
"     Patient education and ostomy site selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education, including discussions regarding ostomy site selection if needed, routine postoperative care, recovery milestones, and a review of signs and symptoms that warrant a postdischarge surgical evaluation, helps patients adhere to a fast-track program [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=see_link&amp;anchor=H21062994#H21062994\">",
"     \"Surgical principles of ostomy construction\", section on 'Preoperative preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117219374\">",
"    <span class=\"h3\">",
"     Bowel preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, bowel preparation included fasting and a mechanical bowel preparation (MBP). Most fast-track programs have omitted bowel cleansing, favoring no preparation other than a preoperative enema for left-sided resections. Evidence in support of this approach is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125365066#H125365066\">",
"     \"Surgical oncologic principles for the resection of colon cancer\", section on 'Bowel preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11858731\">",
"    <span class=\"h3\">",
"     Fasting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasting policies are in place to reduce the risk of aspiration of gastric contents during a general anesthetic. Measures to reduce aspiration include gastric volume reduction and acidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11858738\">",
"    <span class=\"h4\">",
"     Solid foods and nonhuman milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practice guidelines established by the American Society of Anesthesiologists (ASA) are based upon randomized trials and nonrandomized comparative studies for preoperative fasting from solid foods and nonhuman milk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/6\">",
"     6",
"    </a>",
"    ]. The following recommendations for elective surgical procedures with general or regional anesthesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sedation analgesia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fried or fatty foods or meat &ndash; ASA recommends children and adults fast eight hours or more following intake of fried or fatty foods or meat due to prolonged gastric emptying time.",
"     </li>",
"     <li>",
"      Light meal or nonhuman milk or infant formula &ndash; ASA recommends children and adults fast six hours or more following ingestion of a light meal (eg, toast and tea), nonhuman milk, or infant formula.",
"     </li>",
"     <li>",
"      Breast milk",
"      <strong>",
"      </strong>",
"      &ndash; ASA recommends neonates and infants fast four hours or more from ingesting breast milk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11858745\">",
"    <span class=\"h4\">",
"     Clear liquids",
"    </span>",
"    &nbsp;&mdash;&nbsp;For otherwise healthy infants (younger than two years), children (age 2 to 16 years), and adults, the ASA recommends fasting at least two hours from clear liquid intake, including medicines [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Clear liquids include nonalcoholic beverages without milk and juices without pulp. This approach to fasting helps avoid symptoms of dehydration, hypoglycemia, and caffeine withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11858752\">",
"    <span class=\"h4\">",
"     Carbohydrate rich drink",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many fast-track protocols prescribe a carbohydrate-rich drink two hours prior to surgery. This practice has been suggested as a method to convert the patient from the 'fasted' to the 'fed' state, reducing postoperative insulin resistance, and postoperative weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/9\">",
"     9",
"    </a>",
"    ]. Evidence to support carbohydrate-rich drinks in elective colon surgery is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117217514\">",
"    <span class=\"h2\">",
"     Intra-operative strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of perioperative strategies, including evolving fasting policies, anesthetic choices, fluid management, temperature regulation, nasogastric tubes, and surgical approaches are included in fast-track protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1376659\">",
"    <span class=\"h3\">",
"     Anesthetic choices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced recovery anesthetic techniques are central to the fast-track protocol for colorectal surgery. The introduction of rapid short-acting volatile anesthetics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    ), opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    ), and muscle relaxants (eg, rapacuronium), and monitored sedation drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    , and remifentanil) have facilitated expansion of ambulatory surgery from minor to moderately complicated procedures, and reduced the need for extensive postoperative monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/2,11,12\">",
"     2,11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1376667\">",
"    <span class=\"h3\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative fluid management for fast-track protocols must be balanced between avoiding hypovolemia and excessive fluid administration that can result in pulmonary compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. While fixed fluid regimens are appropriate for healthy patients, goal-directed fluids to maintain maximal stroke volume can improve outcome in patients with significant medical comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The lack of reproducible resuscitation data in fast-track surgery precludes guidelines for procedure-specific perioperative fixed-volume regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/17\">",
"     17",
"    </a>",
"    ]. Intraoperative fluid management is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42729?source=see_link\">",
"     \"Intraoperative fluid management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1376675\">",
"    <span class=\"h3\">",
"     Temperature regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in body temperature that occur with exposure during the procedure and alterations in temperature regulation with anesthetic use can lead to coagulopathy, adverse cardiac events, and a decreased resistance to surgical-wound infections [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/18\">",
"     18",
"    </a>",
"    ]. Data from a randomized trial demonstrated that intra-operative hypothermia prolonged the duration of time in the recovery room compared with routine thermal management (mean 94 versus 53 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intra-operative hypothermia is most likely to occur when procedures are longer than two hours, in older adults, those with little body fat, and those with comorbid illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/2,19-22\">",
"     2,19-22",
"    </a>",
"    ]. The authors monitor body temperature in patients undergoing general anesthesia exceeding 30 minutes, and for local and regional anesthetics exceeding one hour. Rewarmers (eg, Bair Hugger&reg; Therapy) are used when body temperature is likely to fall for a prolonged period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173017481\">",
"    <span class=\"h3\">",
"     Nasogastric tubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasogastric tubes (NGT), once a mainstay of colon and rectal surgery, are associated with patient discomfort and a delay in time for oral intake, and are not included in the fast-track protocols for most elective patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. The authors do not use nasogastric tubes in elective colorectal surgery. The indications, management, and controversies associated with NGT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=see_link\">",
"     \"Nasogastric and nasoenteric tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173017457\">",
"    <span class=\"h3\">",
"     Surgical approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1376691\">",
"    <span class=\"h4\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimally invasive techniques are central to fast-track protocols with advantages of a decrease in inflammatory mediators, improved pulmonary function with oncologic outcomes comparable to the open technique, faster return of bowel function, and reduced hospital length of stay [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. In a population based study of 138,735 elective colorectal procedures, patients undergoing a laparoscopic approach (n = 9895) had a significantly lower 30-day mortality rate compared with patients undergoing an open procedure (1.7 versus 3.4 percent; Odds ratio [OR] = 0.46, 95% CI 0.39-0.53) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients undergoing a laparoscopic procedure also had a significantly lower one-year mortality rate (5.3 versus 12.2 percent), 30-day postoperative complication rate (12.4 versus 14.8 percent), and one-year postoperative complication rate (13.6 versus 15.8 percent).",
"   </p>",
"   <p>",
"    Laparoscopic approaches for the resection of benign and malignant colon and rectal lesions are reviewed as separate topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1376712\">",
"    <span class=\"h4\">",
"     Peritoneal drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal drains are not included in fast-track protocols. In the elective setting, drains do not reduce postoperative morbidity, mortality, or ameliorate the effect of anastomotic leakage. Data are limited on the use of intra-abdominal drains in emergent settings. Further discussion on the use of drains can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H27#H27\">",
"     \"Principles of abdominal wall closure\", section on 'Drains'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26522?source=see_link&amp;anchor=H791235782#H791235782\">",
"     \"Traumatic gastrointestinal injury in the adult patient\", section on 'Role of drains'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117217521\">",
"    <span class=\"h2\">",
"     Postoperative strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention and relief of pain, nausea and vomiting, and early nutrition and mobilization are the primary components of postoperative strategies for a fast-track protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/11,12,35,36\">",
"     11,12,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173018177\">",
"    <span class=\"h3\">",
"     Pain management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pain management, including patient-controlled analgesia devices using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , oral analgesics, such as nonsteroidal anti-inflammatory drugs, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173018227\">",
"    <span class=\"h3\">",
"     Ileus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative ileus is a main cause of delayed patient recovery and is a specific objective of enhanced recovery regimens. The pathogenesis, clinical manifestations, prevention (eg, reduction in opioid use), and management (eg, nasogastric suction, reduction of opioid use) are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"     \"Postoperative ileus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173018235\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fast-track programs incorporate resumption of a liquid diet within a few hours after surgery, and can be supplemented with high-calorie drinks to minimize the negative protein balance after surgery. This is in contrast to the traditional approach where oral feedings were withheld until signs of bowel activity (eg, bowel sounds, flatus, bowel movement) were evident.",
"   </p>",
"   <p>",
"    Postoperative nutritional support is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"     \"Perioperative nutritional support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link&amp;anchor=H23#H23\">",
"     \"Postoperative ileus\", section on 'Delayed postoperative feeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173018243\">",
"    <span class=\"h3\">",
"     Mobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early mobilization is a key element of colorectal surgery fast-track protocols as well as contemporary management of all postoperative patients capable of ambulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/37\">",
"     37",
"    </a>",
"    ]. Early mobilization is essential to reducing the risk of postoperative pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and venous thromboembolism. An overview of the causes of venous thrombosis, including longer surgical times and immobilization are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263425324\">",
"    <span class=\"h3\">",
"     Early catheter removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;To aid with early mobilization, urinary catheters should be removed as early as possible, a process that also reduces the incidence of urinary tract infection after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263004035\">",
"    <span class=\"h3\">",
"     Early discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of fast-track programs is an accelerated recovery and return to normal activity. Hospital stay (typically &le;5 days) is often used as a surrogate marker of recovery but is not the only focus of the protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/40\">",
"     40",
"    </a>",
"    ]. In comparison, the mean length of stay of a traditional practice is &gt;5 to 9 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117217535\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from observational studies and randomized trials show that fast-track colorectal protocols are characterized by reduced hospital length of stay (LOS), earlier return of bowel function, and earlier ambulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. Contemporary postoperative hospital admission stays in fast-track protocols range from three to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/46,48-54\">",
"     46,48-54",
"    </a>",
"    ]. While previous studies suggested an increased readmission rate compared with traditional practice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], a systematic review of later reports identified no significant differences [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/47\">",
"     47",
"    </a>",
"    ]. Critics of fast-track protocols cite selection bias for younger and healthier patients; however, fast-track protocols have been effective in patients undergoing complex procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Others have suggested that improved outcomes may be due to reduced surgical stress response and not simply reduced inpatient stay because of changed expectations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279836948\">",
"    <span class=\"h2\">",
"     Length of stay and morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary postoperative hospital LOS is defined as the date of discharge minus the date of the operation. The following randomized trial and previously published meta-analysis identified a significantly shorter LOS, but with a somewhat variable effect on morbidity rates for patients managed on the fast-track protocol compared with the traditional clinical practice approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter randomized trial including 156 patients found that patients in the fast-track program had significantly decreased median LOS and fewer postoperative complications (5 versus 9 days, and 21 versus 49 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/46\">",
"       46",
"      </a>",
"      ]. The effectiveness of the fast-track protocol was attributed to fluid restriction and epidural anesthesia.",
"     </li>",
"     <li>",
"      A meta-analysis of three randomized trials (n = 128 patients) and three prospective studies (n = 332 patients) found that patients managed on a fast-track protocol had a significantly shorter primary LOS and lower morbidity rates (weighted mean difference [WMD] -1.56 days, 95% CI -2.61-0.50 days, and relative risk [RR] 0.54, CI 0.42-0.69, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In-hospital morbidity rates may be lower secondary to the shorter LOS. Further prospective trials are needed to assess 30-day morbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279836967\">",
"    <span class=\"h2\">",
"     Readmission rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early discharge (LOS &le;5 days) is the goal of fast-track protocols, and should not be offset by a higher rate of hospital readmission compared with traditional practice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/40,47,55\">",
"     40,47,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether early discharge is associated with higher readmission rates and the optimal discharge day to avoid a readmission has not been clearly established. As an example, a retrospective review using the United States national Medicare data (MEDPAR database), including 477,461 patients undergoing a colectomy, found that the readmission rate was significantly higher for a very early discharge, defined as LOS &le;4 days, (21.3 versus 15.7 percent), suggesting that a threshold had been reached at 5 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/40\">",
"     40",
"    </a>",
"    ]. However, the overall rate of readmission for patients managed with early discharge was comparable to patients with a longer median LOS (16.3 versus 15.7 percent). In addition, a meta-analysis of six randomized trials and prospective studies found that a higher relative risk of readmission for fast-track patients favored the traditional management approach (RR 1.17, 95% CI 0.73-1.86) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A US-based national consensus panel identified a list of warning indicators that should be provided to patients to educate them as to when they should contact their surgeon or physician following hospital discharge for a colorectal procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/56\">",
"     56",
"    </a>",
"    ]. The warning indicators include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wound drainage",
"     </li>",
"     <li>",
"      Wound erythema or changes in the skin around the wound",
"     </li>",
"     <li>",
"      No bowel movement or lack of flatus per rectum or ostomy for more than 24 hours",
"     </li>",
"     <li>",
"      Increasing abdominal pain",
"     </li>",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Abdominal swelling",
"     </li>",
"     <li>",
"      High ostomy output",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dark or no urine",
"     </li>",
"     <li>",
"      Fever greater than 101.5&deg;F (38.6&deg;C)",
"     </li>",
"     <li>",
"      Unable to take in liquids or solid foods for greater than 24 hours",
"     </li>",
"     <li>",
"      Shortness of breath",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279836955\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fast-track protocols for elective colorectal resection may benefit older adults as well as younger patients. If readmission is a surrogate marker for delayed recovery, then the MEDPAR database review [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/40\">",
"     40",
"    </a>",
"    ], which was comprised of patients over age 65 years, showed that older patients can be effectively treated on a fast-track protocol. A prospective study of 87 patients aged 70 years and older reported a mean hospital stay of 3.9 days and 90 percent of patients tolerated early postoperative feedings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/57\">",
"     57",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H892222\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the fast-track protocol to be financially justified, the increased cost of a laparoscopic procedure must be balanced with savings from a shorter, realistic hospital admission and any costs of readmission and complications. Prospective trials to analyze the costs and benefits of fast-track programs are in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279837494\">",
"    <span class=\"h2\">",
"     Other outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to shorter hospital length of stay and low morbidity, several other favorable postoperative outcomes have been attributed to fast-track protocols in observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced duration of an ileus [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preservation of lean body mass and exercise performance [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Improved grip strength suggesting an overall improvement in muscle function [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Earlier resumption of normal activities, a reduced need for daytime sleep, and no increased use of primary care services [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117217570\">",
"    <span class=\"h1\">",
"     RESEARCH INITIATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research directives of fast-track programs include optimizing patient care using cost-effective methods. As an example, perioperative strategies, such as optimal goal-directed intravenous fluid administration to avoid fluid overload, continue to evolve. Postoperative strategies using improved pain management with opioid antagonists may reduce postoperative ileus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/64\">",
"     64",
"    </a>",
"    ]. Advances in surgical technology will also augment enhanced-recovery protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25656/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the effectiveness of fast-track protocols for patients undergoing emergent colorectal surgery should be evaluated since these patients typically require longer hospitalizations. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1377177\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced recovery, otherwise known as &ldquo;fast-track&rdquo; programs, are evidenced-based protocols designed to standardize medical care, improve outcomes, and lower health care costs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fast-track protocols for colorectal surgery patients were developed to reduce inpatient hospital costs through refinements in preoperative, intra-operative, and postoperative strategies. Organization and effectiveness of a fast-track protocol requires participation and commitment from a multidisciplinary team, including surgeons, anesthesiologists, nursing staff, social services, and hospital administration. (See",
"      <a class=\"local\" href=\"#H117219187\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H117219210\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the fast-track approach for patients undergoing elective colorectal operations (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H117217535\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The elements of a fast-track protocol include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Preoperative pathway strategies (eg, medical risk evaluation, patient education including stoma management, and avoidance of mechanical bowel preparation). (See",
"      <a class=\"local\" href=\"#H117217507\">",
"       'Preoperative strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intra-operative pathway strategies (eg, fasting, anesthetic choices, fluid management, temperature regulation). (See",
"      <a class=\"local\" href=\"#H117217514\">",
"       'Intra-operative strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative pathway strategies (eg, pain management, nutrition, mobilization, early discharge). (See",
"      <a class=\"local\" href=\"#H117217521\">",
"       'Postoperative strategies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/1\">",
"      Kehlet H, Wilmore DW. Fast-track surgery. Br J Surg 2005; 92:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/2\">",
"      Wilmore DW, Kehlet H. Management of patients in fast track surgery. BMJ 2001; 322:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/3\">",
"      Polle SW, Wind J, Fuhring JW, et al. Implementation of a fast-track perioperative care program: what are the difficulties? Dig Surg 2007; 24:441.",
"     </a>",
"    </li>",
"    <li>",
"     Kahlet, H. Modification of responses to surgery by neural blockade: clinical implications. In: Neural Blockade in Clinical Anesthesia and Management of Pain, Cousins, MJ, Bridenbaugh, PO (Eds), Lippincott, Philadelphia 1998. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/5\">",
"      Carli F, Charlebois P, Baldini G, et al. An integrated multidisciplinary approach to implementation of a fast-track program for laparoscopic colorectal surgery. Can J Anaesth 2009; 56:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/6\">",
"      American Society of Anesthesiologists Committee. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology 2011; 114:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/7\">",
"      Brady M, Kinn S, Stuart P. Preoperative fasting for adults to prevent perioperative complications. Cochrane Database Syst Rev 2003; :CD004423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/8\">",
"      Brady M, Kinn S, Ness V, et al. Preoperative fasting for preventing perioperative complications in children. Cochrane Database Syst Rev 2009; :CD005285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/9\">",
"      Svanfeldt M, Thorell A, Hausel J, et al. Randomized clinical trial of the effect of preoperative oral carbohydrate treatment on postoperative whole-body protein and glucose kinetics. Br J Surg 2007; 94:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/10\">",
"      Noblett SE, Watson DS, Huong H, et al. Pre-operative oral carbohydrate loading in colorectal surgery: a randomized controlled trial. Colorectal Dis 2006; 8:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/11\">",
"      White PF, Song D. New criteria for fast-tracking after outpatient anesthesia: a comparison with the modified Aldrete's scoring system. Anesth Analg 1999; 88:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/12\">",
"      White PF. Ambulatory anesthesia advances into the new millennium. Anesth Analg 2000; 90:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/13\">",
"      Lobo DN, Bostock KA, Neal KR, et al. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet 2002; 359:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/14\">",
"      Brandstrup B, T&oslash;nnesen H, Beier-Holgersen R, et al. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg 2003; 238:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/15\">",
"      Wakeling HG, McFall MR, Jenkins CS, et al. Intraoperative oesophageal Doppler guided fluid management shortens postoperative hospital stay after major bowel surgery. Br J Anaesth 2005; 95:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/16\">",
"      MacKay G, Fearon K, McConnachie A, et al. Randomized clinical trial of the effect of postoperative intravenous fluid restriction on recovery after elective colorectal surgery. Br J Surg 2006; 93:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/17\">",
"      Bundgaard-Nielsen M, Secher NH, Kehlet H. 'Liberal' vs. 'restrictive' perioperative fluid therapy--a critical assessment of the evidence. Acta Anaesthesiol Scand 2009; 53:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/18\">",
"      Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med 1996; 334:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/19\">",
"      Lenhardt R, Marker E, Goll V, et al. Mild intraoperative hypothermia prolongs postanesthetic recovery. Anesthesiology 1997; 87:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/20\">",
"      Carli F, Gabrielczyk M, Clark MM, Aber VR. An investigation of factors affecting postoperative rewarming of adult patients. Anaesthesia 1986; 41:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/21\">",
"      Kurz A, Plattner O, Sessler DI, et al. The threshold for thermoregulatory vasoconstriction during nitrous oxide/isoflurane anesthesia is lower in elderly than in young patients. Anesthesiology 1993; 79:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/22\">",
"      Kurz A, Sessler DI, Narzt E, et al. Morphometric influences on intraoperative core temperature changes. Anesth Analg 1995; 80:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/23\">",
"      Nelson R, Tse B, Edwards S. Systematic review of prophylactic nasogastric decompression after abdominal operations. Br J Surg 2005; 92:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/24\">",
"      Lewis SJ, Egger M, Sylvester PA, Thomas S. Early enteral feeding versus \"nil by mouth\" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ 2001; 323:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/25\">",
"      Nelson R, Edwards S, Tse B. Prophylactic nasogastric decompression after abdominal surgery. Cochrane Database Syst Rev 2007; :CD004929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/26\">",
"      J&oslash;rgensen H, Wetterslev J, M&oslash;iniche S, Dahl JB. Epidural local anaesthetics versus opioid-based analgesic regimens on postoperative gastrointestinal paralysis, PONV and pain after abdominal surgery. Cochrane Database Syst Rev 2000; :CD001893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/27\">",
"      Lourenco T, Murray A, Grant A, et al. Laparoscopic surgery for colorectal cancer: safe and effective? - A systematic review. Surg Endosc 2008; 22:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/28\">",
"      Novitsky YW, Litwin DE, Callery MP. The net immunologic advantage of laparoscopic surgery. Surg Endosc 2004; 18:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/29\">",
"      Kehlet H. Surgical stress response: does endoscopic surgery confer an advantage? World J Surg 1999; 23:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/30\">",
"      Shea JA, Berlin JA, Bachwich DR, et al. Indications for and outcomes of cholecystectomy: a comparison of the pre and postlaparoscopic eras. Ann Surg 1998; 227:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/31\">",
"      Fleshman J, Sargent DJ, Green E, et al. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg 2007; 246:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/32\">",
"      MacKay G, Ihedioha U, McConnachie A, et al. Laparoscopic colonic resection in fast-track patients does not enhance short-term recovery after elective surgery. Colorectal Dis 2007; 9:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/33\">",
"      King PM, Blazeby JM, Ewings P, et al. Randomized clinical trial comparing laparoscopic and open surgery for colorectal cancer within an enhanced recovery programme. Br J Surg 2006; 93:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/34\">",
"      Mamidanna R, Burns EM, Bottle A, et al. Reduced risk of medical morbidity and mortality in patients selected for laparoscopic colorectal resection in England: a population-based study. Arch Surg 2012; 147:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/35\">",
"      Kehlet H, Dahl JB. The value of \"multimodal\" or \"balanced analgesia\" in postoperative pain treatment. Anesth Analg 1993; 77:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/36\">",
"      Souter AJ, Fredman B, White PF. Controversies in the perioperative use of nonsterodial antiinflammatory drugs. Anesth Analg 1994; 79:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/37\">",
"      Zutshi M, Delaney CP, Senagore AJ, Fazio VW. Shorter hospital stay associated with fastrack postoperative care pathways and laparoscopic intestinal resection are not associated with increased physical activity. Colorectal Dis 2004; 6:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/38\">",
"      Kamel HK, Iqbal MA, Mogallapu R, et al. Time to ambulation after hip fracture surgery: relation to hospitalization outcomes. J Gerontol A Biol Sci Med Sci 2003; 58:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/39\">",
"      Wren SM, Martin M, Yoon JK, Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward. J Am Coll Surg 2010; 210:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/40\">",
"      Hendren S, Morris AM, Zhang W, Dimick J. Early discharge and hospital readmission after colectomy for cancer. Dis Colon Rectum 2011; 54:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/41\">",
"      Pritts TA, Nussbaum MS, Flesch LV, et al. Implementation of a clinical pathway decreases length of stay and cost for bowel resection. Ann Surg 1999; 230:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/42\">",
"      Basse L, Hjort Jakobsen D, Billesb&oslash;lle P, et al. A clinical pathway to accelerate recovery after colonic resection. Ann Surg 2000; 232:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/43\">",
"      Basse L, Thorb&oslash;l JE, L&oslash;ssl K, Kehlet H. Colonic surgery with accelerated rehabilitation or conventional care. Dis Colon Rectum 2004; 47:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/44\">",
"      Delaney CP, Fazio VW, Senagore AJ, et al. 'Fast track' postoperative management protocol for patients with high co-morbidity undergoing complex abdominal and pelvic colorectal surgery. Br J Surg 2001; 88:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/45\">",
"      Kariv Y, Delaney CP, Senagore AJ, et al. Clinical outcomes and cost analysis of a \"fast track\" postoperative care pathway for ileal pouch-anal anastomosis: a case control study. Dis Colon Rectum 2007; 50:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/46\">",
"      Muller S, Zalunardo MP, Hubner M, et al. A fast-track program reduces complications and length of hospital stay after open colonic surgery. Gastroenterology 2009; 136:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/47\">",
"      Wind J, Polle SW, Fung Kon Jin PH, et al. Systematic review of enhanced recovery programmes in colonic surgery. Br J Surg 2006; 93:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/48\">",
"      Proske JM, Raue W, Neudecker J, et al. [Fast track rehabilitation in colonic surgery: results of a prospective trial]. Ann Chir 2005; 130:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/49\">",
"      Delaney CP, Zutshi M, Senagore AJ, et al. Prospective, randomized, controlled trial between a pathway of controlled rehabilitation with early ambulation and diet and traditional postoperative care after laparotomy and intestinal resection. Dis Colon Rectum 2003; 46:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/50\">",
"      Anderson AD, McNaught CE, MacFie J, et al. Randomized clinical trial of multimodal optimization and standard perioperative surgical care. Br J Surg 2003; 90:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/51\">",
"      Kremer M, Ulrich A, B&uuml;chler MW, Uhl W. Fast-track surgery: the Heidelberg experience. Recent Results Cancer Res 2005; 165:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/52\">",
"      Susa A, Roveran A, Bocchi A, et al. [FastTrack approach to major colorectal surgery]. Chir Ital 2004; 56:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/53\">",
"      Smedh K, Strand E, Jansson P, et al. [Rapid recovery after colonic resection. Multimodal rehabilitation by means of Kehlet's method practiced in Vasteras]. Lakartidningen 2001; 98:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/54\">",
"      Gatt M, Anderson AD, Reddy BS, et al. Randomized clinical trial of multimodal optimization of surgical care in patients undergoing major colonic resection. Br J Surg 2005; 92:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/55\">",
"      Lawrence JK, Keller DS, Samia H, et al. Discharge within 24 to 72 hours of colorectal surgery is associated with low readmission rates when using enhanced recovery pathways. J Am Coll Surg 2013; 216:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/56\">",
"      Li LT, Mills WL, Gutierrez AM, et al. A patient-centered early warning system to prevent readmission after colorectal surgery: a national consensus using the Delphi method. J Am Coll Surg 2013; 216:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/57\">",
"      DiFronzo LA, Yamin N, Patel K, O'Connell TX. Benefits of early feeding and early hospital discharge in elderly patients undergoing open colon resection. J Am Coll Surg 2003; 197:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/58\">",
"      Wind J, Hofland J, Preckel B, et al. Perioperative strategy in colonic surgery; LAparoscopy and/or FAst track multimodal management versus standard care (LAFA trial). BMC Surg 2006; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/59\">",
"      Reurings JC, Spanjersberg WR, Oostvogel HJ, et al. A prospective cohort study to investigate cost-minimisation, of Traditional open, open fAst track recovery and laParoscopic fASt track multimodal management, for surgical patients with colon carcinomas (TAPAS study). BMC Surg 2010; 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/60\">",
"      Slim K, Fingerhut A. Laparoscopy or fast-track surgery, or both? Surg Endosc 2009; 23:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/61\">",
"      Basse L, Madsen JL, Kehlet H. Normal gastrointestinal transit after colonic resection using epidural analgesia, enforced oral nutrition and laxative. Br J Surg 2001; 88:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/62\">",
"      Basse L, Raskov HH, Hjort Jakobsen D, et al. Accelerated postoperative recovery programme after colonic resection improves physical performance, pulmonary function and body composition. Br J Surg 2002; 89:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/63\">",
"      Jakobsen DH, Sonne E, Andreasen J, Kehlet H. Convalescence after colonic surgery with fast-track vs conventional care. Colorectal Dis 2006; 8:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/64\">",
"      Behm B, Stollman N. Postoperative ileus: etiologies and interventions. Clin Gastroenterol Hepatol 2003; 1:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25656/abstract/65\">",
"      Kehlet H. Fast-track colonic surgery: status and perspectives. Recent Results Cancer Res 2005; 165:8.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15006 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25656=[""].join("\n");
var outline_f25_3_25656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1377177\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H117219187\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H117219210\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H117217484\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H117217498\">",
"      ELEMENTS OF FAST-TRACK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173017798\">",
"      Multimodal fast-track protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H117217507\">",
"      Preoperative strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H117219358\">",
"      - Medical risk evaluation and interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H117219366\">",
"      - Patient education and ostomy site selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H117219374\">",
"      - Bowel preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11858731\">",
"      - Fasting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11858738\">",
"      Solid foods and nonhuman milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11858745\">",
"      Clear liquids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11858752\">",
"      Carbohydrate rich drink",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H117217514\">",
"      Intra-operative strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1376659\">",
"      - Anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1376667\">",
"      - Fluid management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1376675\">",
"      - Temperature regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173017481\">",
"      - Nasogastric tubes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173017457\">",
"      - Surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1376691\">",
"      Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1376712\">",
"      Peritoneal drains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H117217521\">",
"      Postoperative strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173018177\">",
"      - Pain management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173018227\">",
"      - Ileus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173018235\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173018243\">",
"      - Mobilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H263425324\">",
"      - Early catheter removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H263004035\">",
"      - Early discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H117217535\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279836948\">",
"      Length of stay and morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279836967\">",
"      Readmission rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279836955\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H892222\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279837494\">",
"      Other outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H117217570\">",
"      RESEARCH INITIATIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1377177\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15006\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15006|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/38/18028\" title=\"table 1\">",
"      Fast track protocol for adult colorectal surgical procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42729?source=related_link\">",
"      Intraoperative fluid management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=related_link\">",
"      Nasogastric and nasoenteric tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=related_link\">",
"      Overview of the principles of medical consultation and perioperative medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=related_link\">",
"      Postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=related_link\">",
"      Surgical principles of ostomy construction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26522?source=related_link\">",
"      Traumatic gastrointestinal injury in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_3_25657="Clinical presentation and diagnosis of brain tumors";
var content_f25_3_25657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of brain tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/3/25657/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25657/contributors\">",
"     Eric T Wong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25657/contributors\">",
"     Julian K Wu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/3/25657/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25657/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25657/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/3/25657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25657/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/3/25657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain tumors are a diverse group of neoplasms arising from different cells within the central nervous system (CNS) or from systemic tumors that have metastasized to the CNS. Brain tumors include a number of histologic types with markedly different tumor growth rates (",
"    <a class=\"graphic graphic_table graphicRef73168 \" href=\"UTD.htm?14/49/15134\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55058 \" href=\"UTD.htm?14/32/14861\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link\">",
"     \"Classification of gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brain tumors can produce symptoms and signs by local brain invasion, compression of adjacent structures, and increased intracranial pressure (ICP). In addition to the histology of the tumor, the clinical manifestations are determined by the function of the involved areas of the brain. The proper evaluation of the patient with a suspected brain tumor requires a detailed history, comprehensive neurologic examination, and appropriate diagnostic neuroimaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of primary brain tumors will be reviewed here. Aspects of the various primary brain tumors are discussed in the specific topics, and the presentation and approach to patients with brain metastases is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary or metastatic brain tumors may present with either generalized or focal signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms (",
"    <a class=\"graphic graphic_table graphicRef52235 \" href=\"UTD.htm?3/9/3227\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Generalized",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is a common manifestation of brain tumors and is the worst symptom in about one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/2\">",
"     2",
"    </a>",
"    ]. The headaches are usually dull and constant, but occasionally throbbing. Severe headaches are infrequent, unless obstructive hydrocephalus or meningeal irritation is present. The \"classic\" early morning brain tumor headache appears to be uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features suggestive of a brain tumor in a patient complaining of headaches include nausea and vomiting (present in about 40 percent), a change in prior headache pattern, and an abnormal neurologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, many patients with a brain tumor report worsening of headache after a change in body position, such as bending over, or with maneuvers that raise intrathoracic pressure, such as coughing, sneezing, or the Valsalva maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/2\">",
"     2",
"    </a>",
"    ]. These activities lead to a period of raised ICP, which uncommonly can cause a loss of consciousness (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Syncope'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The headache can be localizing. In the above series, the typical headache was bifrontal, but worse on the same side as the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/2\">",
"     2",
"    </a>",
"    ]. Alternatively, a generalized headache may result from increased intracranial pressure (ICP), which can arise either from a large mass or from restriction of cerebrospinal fluid outflow causing hydrocephalus. Increased ICP may lead to the classic triad of headache, nausea, and papilledema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumor-related headaches tend to be worse at night and may awaken the patient. This nocturnal pattern is thought to be due in part to transient increases in PCO2, a potent vasodilator, during sleep. Other possible physiologic explanations include recumbency and decreased cerebral venous return.",
"   </p>",
"   <p>",
"    The manifestations of headache in brain tumor patients were illustrated by a retrospective review of 111 patients with brain tumors, in which headaches were present in 48 percent of cases with either primary or metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/2\">",
"     2",
"    </a>",
"    ]. The headaches were tension-type in 77 percent, migraine-type in 9 percent, and other types in 14 percent.",
"   </p>",
"   <p>",
"    Brain tumor headaches are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41655?source=see_link\">",
"     \"Brain tumor headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are among the most common symptoms of gliomas and cerebral metastases. Some patients who are seizure-free at diagnosis subsequently develop seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], but routine prophylaxis with anticonvulsant medications is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=see_link\">",
"     \"Seizures in patients with primary and metastatic brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of seizures is higher with primary tumors than with metastatic lesions, and among patients with primary tumors, seizures are less common with high-grade as opposed to low-grade gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This was illustrated in a review of 1028 patients with primary brain tumors: the prevalence of seizures was 49, 69, and 85 percent among patients with glioblastoma (GBM), anaplastic glioma, and low-grade glioma, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures may be the presenting symptom or develop subsequently. In two large series of patients with GBM, seizures were the initial manifestation in 18 percent and were present at the time of diagnosis (for an average of one year) in 29 percent (",
"    <a class=\"graphic graphic_table graphicRef65078 \" href=\"UTD.htm?40/21/41307\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The frequency and onset of seizures in patients with brain metastases was illustrated in a series of 195 patients, in which seizures were present at diagnosis in 9 percent and subsequently developed in another 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although seizures can be either generalized or focal, any seizure focus can cause a generalized seizure. In patients who have focal seizures, the clinical presentation is dependent upon the tumor location. As an example, frontal lobe tumors may cause focal tonic-clonic movements involving one extremity, while seizures originating within the occipital lobe may cause visual disturbances. Temporal lobe seizures are the most difficult to diagnose and localize. In this setting, abrupt sudden behavioral changes may occur with or without typical preseizure auras, such as abnormal smell, taste, or gastrointestinal symptoms.",
"   </p>",
"   <p>",
"    Tumor-related seizures are typically repetitive and are stereotyped in a given patient. The ictal event may be preceded by an aura, which is itself a simple partial seizure, and followed by postictal sequelae. The postictal phase can be manifested as a period of fatigue and an urge to sleep. For patients with focal seizures, a postictal paresis (also known as a Todd's paralysis) may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both primary and metastatic brain tumors can cause status epilepticus, which may occur at the time of tumor diagnosis or subsequently [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who present with seizures usually have smaller primary brain tumors or fewer metastatic lesions in the brain, compared to those who present with other symptoms. This is probably because the diagnosis of a seizure is an indication for neuroimaging, which leads to an earlier diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A seizure should not be confused with a syncopal event that may be caused by an abrupt increase in ICP. This distinction is important since treatment is different in the two conditions. Patients with seizures are at risk of subsequent seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/3,10\">",
"     3,10",
"    </a>",
"    ], and the treatment is anticonvulsants. In contrast, patients with increased ICP require urgent corticosteroids, neurosurgical intervention, or both. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Syncope'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain tumors can cause nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting by increasing the ICP at the area postrema of the medulla. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several characteristics suggest the possibility of tumor-associated emesis, such as triggering emesis by an abrupt change in body position. More importantly, neurogenic nausea and vomiting usually occur in the context of other neurologic symptoms such as headache or focal neurologic deficit; these signs and symptoms may be subtle [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant rise in ICP can temporarily cut off cerebral perfusion, leading to loss of consciousness. Patients with brain tumors are particularly susceptible to this sequence of events in association with normal plateau waves.",
"   </p>",
"   <p>",
"    Plateau waves are sustained pressure waves that normally occur within the brain and are caused by activities that transiently raise the ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. As an example, any Valsalva maneuver (eg, coughing, sneezing, vomiting) that increases the intrathoracic pressure can impede jugular venous drainage, leading to a transient increase in ICP.",
"   </p>",
"   <p>",
"    In the presence of a brain tumor, the baseline ICP may be raised to a level that reduces brain compliance; in this setting, even a further small increase in intracranial fluid volume can result in dramatic elevations in ICP. The cerebral perfusion pressure is the difference between the mean systemic arterial pressure and ICP. Thus, a significant rise in ICP can temporarily cut off cerebral perfusion, leading to loss of consciousness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A syncopal episode may simulate a seizure, since patients suffer loss of consciousness and may have a few tonic-clonic jerks. Identification of plateau wave-related episodes of loss of consciousness is critical, since these events identify patients who require urgent corticosteroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurosurgical intervention to reduce elevated ICP rather than treatment with an anticonvulsant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cognitive dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive dysfunction, which includes memory problems and mood or personality change, is common among patients with intracranial malignancy.",
"   </p>",
"   <p>",
"    Most of the neurocognitive deficits associated with brain tumors are subtle. Patients often complain of having low energy, fatigue, an urge to sleep, and loss of interest in everyday activities. They may become abulic and show a lack of spontaneity (",
"    <a class=\"graphic graphic_table graphicRef65883 \" href=\"UTD.htm?32/39/33405\">",
"     table 5",
"    </a>",
"    ). This pattern of symptoms can be confused with depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because these symptoms lack specificity, they are often recognized in retrospect by the patient or the treating physician. Thus, consideration should be given to neuroimaging to rule out a brain tumor in patients without a prior history of depression who experience new onset of depressive symptoms without obvious cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Focal",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness is a common complaint in patients with brain tumors. The manifestations may be subtle, particularly in the early stages. For upper motor neuron lesions, weakness is generally more pronounced in the flexors of the lower extremities than in the extensors, and more pronounced in the extensors than the flexors in the upper extremities. Transient weakness may represent a postictal state, as in Todd's paralysis (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Seizures'",
"    </a>",
"    above). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H62#H62\">",
"     \"The detailed neurologic examination in adults\", section on 'Upper versus lower motor neuron lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A key feature of tumor-related muscle weakness is its frequent responsiveness to high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , particularly with tumors that are near the motor cortex or its descending fibers. A response to dexamethasone usually means that the weakness is caused by edema and not by direct tumor involvement. In such a patient, craniotomy can be considered to relieve mass effect and lessen the corticosteroid requirement, even if the patient is not resectable for cure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sensory loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortical sensory deficits (eg, graphesthesia or abnormalities in stereognosis) can develop in patients whose tumors invade the primary sensory cortex (",
"    <a class=\"graphic graphic_table graphicRef65883 \" href=\"UTD.htm?32/39/33405\">",
"     table 5",
"    </a>",
"    ). These sensory deficits usually do not respect a dermatomal or peripheral nerve distribution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H72#H72\">",
"     \"The detailed neurologic examination in adults\", section on 'Sensory examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The type of deficit varies in part with location of the tumor. As an example, visual-spatial disconnection syndromes can be found in patients with tumors located in the visual association cortex (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Visual spatial dysfunction'",
"    </a>",
"    below). Some of the other cortically-based sensory deficits include loss of spatial orientation, tingling, and lack of coordination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aphasia is a disorder of language function, not of vocalization, as in dysarthria or hoarseness. It is a specific sign of a lesion in the dominant hemisphere (usually left frontal or parietal); in comparison, lesions in the nondominant hemisphere may produce apraxia, which refers to an inability to perform purposeful movements (",
"    <a class=\"graphic graphic_table graphicRef65883 \" href=\"UTD.htm?32/39/33405\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who are aphasic may be confused with those who have dementia or other psychiatric disorders such as psychosis or depression. Subacute psychosis in a patient without an antecedent psychiatric history is a diagnosis of exclusion that requires diagnostic neuroimaging studies to rule out an organic cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Visual spatial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The visual pathway courses through the brain from the retina and optic chiasm to the occipital poles of the cerebral cortex. Because of its long course through the brain, the visual pathway can be affected by brain tumors that involve any of these areas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of the retina, particularly the optic discs, is an important component of the initial examination of a patient suspected of having a brain tumor. The optic nerve head can be a good measure of ICP, although papilledema is often not present in the elderly despite an increase in ICP. Although gross papilledema is easy to diagnose, evolving papilledema can be difficult to recognize. As an example, only the medial portion of the optic disk may be blurred initially in early papilledema. Venous engorgement and the absence of venous pulsations are also important diagnostic clues. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30552?source=see_link\">",
"       \"Overview and differential diagnosis of papilledema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tumor-related compression of the optic chiasm usually manifests as a bitemporal hemianopsia. However, there may be a unilateral hemianopsia with a central scotoma in the contralateral eye in the early stages, particularly when the compression is on one side. The latter results from partial compression of the Wilbrand's knee in the contralateral optic nerve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"       \"Causes, presentation, and evaluation of sellar masses\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/16/39176?source=see_link\">",
"       \"Optic pathway glioma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postchiasmatic lesions also may present with visual abnormalities. Because of the somatotopic representation of the visual pathways, the more anterior the lesion, the more asymmetric the hemianopsia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC NEUROIMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of an adult presenting with signs and symptoms suggesting a brain tumor includes both neoplastic and nonneoplastic conditions (",
"    <a class=\"graphic graphic_table graphicRef64210 \" href=\"UTD.htm?36/52/37707\">",
"     table 6",
"    </a>",
"    ). Neuroradiologic imaging is the major diagnostic modality in the evaluation of brain tumors. These studies are critical for preoperative planning, and they often provide information about the etiology of a mass lesion.",
"   </p>",
"   <p>",
"    Although neuroimaging cannot definitively establish the specific histology, the characteristic appearance of dural-based meningiomas often can allow a tentative diagnosis. Treatment of meningiomas without a histologic diagnosis may be warranted in carefully selected cases for lesions in a surgically inaccessible location. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link&amp;anchor=H23#H23\">",
"     \"Meningioma: Clinical presentation and diagnosis\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gadolinium-enhanced magnetic resonance imaging (MRI) is usually the only test needed to suggest a brain tumor. MRI may also provide information that indicates the specific tumor type:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant gliomas are typically hypointense on T1-weighted images, and enhance heterogeneously following contrast infusion. Enhancing tumor can be distinguished from the surrounding hypointense signal of edema on T1-weighted sequences (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65860 \" href=\"UTD.htm?1/48/1795\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Regardless of the histologic grade, astrocytomas generally show increased T2 and FLAIR signal intensity; however, some astrocytomas do not manifest contrast enhancement [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low grade gliomas generally present as an infiltrating hemispheric lesion that produce little mass effect. The MRI appearance of focal brainstem gliomas is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=see_link&amp;anchor=H5#H5\">",
"       \"Focal brainstem glioma\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to permitting visualization of the tumor and its relationship to the surrounding normal parenchyma, MRI is also superior to computed tomography (CT) for evaluation of the meninges, subarachnoid space, and posterior fossa, and for defining the vascular distribution of the abnormality. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Computed tomography'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Magnetic resonance spectroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance spectroscopy (MRS) is increasingly being utilized as a diagnostic technique in patients with suspected brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. This technique may improve the differentiation of locally infiltrative brain tumors from other types of well-circumscribed intracranial lesions by analyzing the chemical composition in an area of interest selected by the radiologist. Important spectroscopic signals include N-acetylaspartate, choline, lactate, and 2-hydroxyglutarate (",
"    <a class=\"graphic graphic_table graphicRef79098 \" href=\"UTD.htm?2/12/2251\">",
"     table 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      N-acetylasparate, a byproduct of the ubiquitous neurotransmitter glutamate, signals the presence of neurons since it localizes to the synaptic terminals, and is decreased in gliomas.",
"     </li>",
"     <li>",
"      Choline, a component of cell membranes, is increased in tumors.",
"     </li>",
"     <li>",
"      Lactate, a product of anaerobic respiration, can be present in necrotic tumor, infection, or stroke.",
"     </li>",
"     <li>",
"      Mutations in IDH1 and IDH2 result in accumulation of 2-hydroxyglutarate [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRS cannot differentiate the types of infiltrative or circumscribed lesions, and it cannot replace histologic diagnosis of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/18\">",
"     18",
"    </a>",
"    ]. However, it can help differentiate between neoplasm and other central nervous system processes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/23\">",
"     23",
"    </a>",
"    ]. The utility of MRS was illustrated in a study of 26 patients with intracranial masses who underwent MRI, proton MRS, and stereotactic biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/18\">",
"     18",
"    </a>",
"    ]. For patients with gliomas and lymphomas, pathologic spectra were present outside the area of contrast enhancement, suggesting infiltration beyond the borders suggested by MRI. In comparison, four circumscribed tumors (meningioma, pineocytoma, metastasis, and germinoma) showed no pathologic spectra outside the region of enhancement.",
"   </p>",
"   <p>",
"    MRS spectroscopy signals are degraded by bone and cerebrospinal fluid. As a result, MRS is less useful for skull base and periventricular lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Functional MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a region of the brain is activated (eg, the language center during phonation or the motor cortex when moving a limb), blood flow to that region increases. Functional MRI (also known as echoplanar MRI) permits the measurement of differences in blood flow though particular regions of the brain and has several advantages in patients with brain tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Functional MRI is an important adjunct in the preoperative planning for patients whose tumor is located near eloquent areas of the brain [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/24\">",
"       24",
"      </a>",
"      ]. In such areas, imaging after activation of sensory and motor areas by appropriate stimuli may permit separation of tumor from normal brain preoperatively (functional brain imaging) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Functional MRI may permit better resolution of tumor versus surrounding edema at the tumor borders [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultrafast acquisition of MRI images by echoplanar imaging is free from motion artifact and may be useful in patients who are unable to cooperate with standard MRI scanning [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Perfusion MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perfusion MRI is the imaging of blood flow in brain tumors. This is done either with a bolus of gadolinium as in dynamic contrast MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/30\">",
"     30",
"    </a>",
"    ] or dynamic susceptibility contrast MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/31\">",
"     31",
"    </a>",
"    ], or with magnetic pulsation of water molecules as they pass through carotid and vertebral arteries as in arterial spin labeling [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Increased perfusion can be seen in newly diagnosed or recurrent brain tumors, usually reflecting the presence of hypervascularity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT has largely been replaced by cranial MRI as the imaging modality of choice for brain tumors. However, CT retains utility in selected situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To detect bone or vascular involvement",
"     </li>",
"     <li>",
"      To detect metastases to the skull base, clivus, or regions near the foramen magnum",
"     </li>",
"     <li>",
"      In an emergency situation (eg, an unstable patient with a suspected intratumoral hemorrhage), when CT can be faster to perform than MRI",
"     </li>",
"     <li>",
"      In patients for whom MRI is contraindicated, either because of an iron-containing implant or because of claustrophobia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     PET scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) with fluorodeoxyglucose (FDG) can be used to detect malignant tumors with high metabolic rates. Such lesions take up greater amounts of glucose than surrounding tissues or tumors with slower metabolic rates.",
"   </p>",
"   <p>",
"    FDG-PET may be useful in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To localize the areas of maximum glucose utilization within the tumor. This information can guide the neurosurgeon to biopsy tumor locations with the most aggressive biologic behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/34-36\">",
"       34-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To permit the mapping of functional areas of the brain prior to surgery or radiation, in conjunction with functional MRI, in order to minimize injury to eloquent areas [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/25,37,38\">",
"       25,37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To differentiate recurrent tumor from radiation necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/39-43\">",
"       39-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To help differentiate high-grade (glucose hypermetabolizing) from low-grade (glucose hypometabolizing) brain tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. In patients with low-grade gliomas, FDG-PET images that show diffuse hypometabolism may support a decision to defer treatment, while the presence of hypermetabolic areas may indicate a high-grade tumor and signal the need for biopsy or treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2071?source=see_link\">",
"       \"Diagnosis and classification of low-grade gliomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of high basal uptake of FDG by normal brain tissues, the low signal-to-noise ratio of FDG-PET may result in false negative data [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/46\">",
"     46",
"    </a>",
"    ], sensitivity of 71 percent and specificity of 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/43\">",
"     43",
"    </a>",
"    ]. As a result, FDG-PET is not an FDA-approved diagnostic study for evaluating malignancies in the brain, even though it is approved for systemic malignancies. 18F-fluorothymidine-PET (18F-FLT-PET) has a higher signal-to-noise radiation than FDG-PET [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/47\">",
"     47",
"    </a>",
"    ]. But its exact utility in the brain tumor population await further clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     SPECT imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single photon emission CT (SPECT) utilizes various isotopes to detect abnormalities in the blood brain barrier. Preoperative SPECT using thallium-201 is useful to distinguish benign from malignant brain lesions, predict the histologic grade of brain tumors, and select areas for biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/48\">",
"     48",
"    </a>",
"    ]. The uptake of 201-Tl is unaffected by steroid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be a correlation between early and delayed tumor uptake of 201-Tl and the subsequent grade of the surgically resected tumor, allowing a distinction between low- and high-grade astrocytomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC NEUROSURGICAL INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate diagnosis of a brain tumor requires an adequate tissue sample for histologic study. This may be obtained by stereotactic biopsy or open surgery.",
"   </p>",
"   <p>",
"    Corticosteroid use should be",
"    <strong>",
"     avoided",
"    </strong>",
"    prior to biopsy or surgery if either a primary central nervous system lymphoma or an infectious process is part of the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'CNS lymphomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Preoperative assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood that a lesion is metastatic should be assessed prior to proceeding to biopsy. Brain metastases are more common than primary brain tumors. Although brain metastases usually present in the context of overt systemic disease, they can occur as the initial manifestation of a systemic malignancy.",
"   </p>",
"   <p>",
"    If any aspect of the clinical or neurodiagnostic evaluation suggests that a brain tumor is a metastatic rather than a primary lesion, systemic evaluation, particularly of the thorax, should be carried. Neurosurgical intervention in a patient with a presumed brain metastasis should balance the risks of the procedure versus the potential benefits (ie, tissue diagnosis, resection of a solitary lesion, relief of neurological symptoms). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surgical exploration or biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technical advances have improved the safety of both surgical resection and stereotactic biopsy. Improved diagnostic neuroimaging permits better preoperative localization of the lesion and separation of the lesion from adjacent normal brain tissue, particularly in eloquent areas of the brain. Techniques such as intraoperative MRI facilitate improved surgical navigation for lesion biopsy and resection.",
"   </p>",
"   <p>",
"    For most patients, tissue for histologic confirmation is obtained at the time of surgical exploration for resection. In those patients with large, nonresectable lesions or those whose lesions are in a critical location, stereotactic biopsy is an alternative. In some patients with a meningioma with a lesion that is either difficult or impossible to access, the characteristic appearance of a dural-based tumor may be sufficient to permit treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of benign (WHO grade I) meningioma\", section on 'RT alone for nonresectable meningiomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Glial tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with primary glial tumors, maximum surgical resection is usually recommended. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    There are two exceptions to this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-grade glioma &mdash; For patients with low-grade glial tumors, the role of maximal resection remains uncertain. Retrospective studies suggest that more extensive tumor resection is associated with delay in tumor progression and malignant degeneration, as well as improved survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of low-grade glioma\", section on 'Surgery'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Immediate surgery is generally required for patients presenting with a large mass or extensive neurologic symptoms, both to establish the diagnosis and to debulk the tumor. However, for patients with a small tumor not creating a mass effect and only transient symptoms or tumors in eloquent cortex, careful observation may be an alternative to immediate surgery.",
"     </li>",
"     <li>",
"      Diffuse pontine glioma &mdash; As long as characteristic radiologic features are present, a tissue diagnosis of a pontine gliomas not required prior to treatment (",
"      <a class=\"graphic graphic_algorithm graphicRef71275 \" href=\"UTD.htm?0/11/181\">",
"       algorithm 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/53\">",
"       53",
"      </a>",
"      ]. In equivocal cases, the clinician must weigh the risks of a surgical biopsy versus the diagnostic uncertainty. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1832?source=see_link\">",
"       \"Diffuse pontine glioma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     CNS lymphomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary central nervous system lymphoma are typically not offered surgical debulking, since the extent of surgical resection does not influence patient survival. Stereotactic biopsy is usually recommended, providing a high rate of positive tissue diagnosis with a low rate (&lt;2 percent) of morbidity and mortality. Definitive treatment is usually chemotherapy, radiation, or a combination of these modalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=see_link\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Corticosteroids should be",
"    <strong>",
"     avoided",
"    </strong>",
"    whenever possible prior to biopsy or surgery if primary CNS lymphoma is part of the differential diagnosis. These agents are lymphocytotoxic. A single dose can alter the histopathologic evaluation, and a short course of treatment may cause the lymphoma to disappear temporarily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is not necessary for patients with multiple brain metastases if there is a preexisting primary cancer known to have a propensity for brain metastases. If, however, a patient has a primary tumor that does not usually metastasize to the brain (eg, prostate cancer), there is no known primary, or neuroimaging is not typical for metastasis, biopsy may be indicated to define the etiology of a brain lesion. The importance of biopsy in such situations was illustrated in a randomized trial of surgery for the treatment of solitary brain metastases, in which 11 percent of patients had a second primary malignancy, inflammatory process, or infection rather than metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of patients with brain metastases is dependent upon the overall condition of the patient, as well as the number, size, and location of brain metastases. The management of patients with brain metastases is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"     \"Treatment of brain metastases in poor prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Neuropathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic examination of the biopsy specimen remains the most important component of the diagnostic evaluation of brain tumors. A smear or frozen section can be performed in the operating room for a preliminary interpretation of the histologic subtype. With this information, the neurosurgeon can make a decision whether or not to proceed with a more extensive resection.",
"   </p>",
"   <p>",
"    A definitive diagnosis requires examination of the permanent tissue sections stained by hematoxylin and eosin. Important information may be derived from additional analyses that include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proliferative index, using the MIB-1 monoclonal antibody",
"     </li>",
"     <li>",
"      Immunohistochemical stains",
"     </li>",
"     <li>",
"      Electron microscopy may be necessary to ascertain the correct diagnosis",
"     </li>",
"     <li>",
"      Molecular markers, including deletions of chromosome",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      or the presence or absence of promoter methylation of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT), isocitrate dehydrogenase (IDH), and p53",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Caution should be exercised in interpreting the tissue diagnosis when the tissue is derived only from a biopsy specimen. This is particularly true for glial tumors, because regional heterogeneity and sampling error may underestimate the histologic grade of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25657/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients suspected of having a primary central nervous system lymphoma, corticosteroid use should be avoided prior to biopsy, as these drugs are lymphocytotoxic and can affect the histopathologic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/48/9986?source=see_link\">",
"       \"Patient information: Brain cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=see_link\">",
"       \"Patient information: Primary low-grade glioma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=see_link\">",
"       \"Patient information: High-grade glioma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=see_link\">",
"       \"Patient information: Meningioma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain tumors can produce symptoms and signs by local brain invasion, compression of adjacent structures, and increased intracranial pressure (ICP). In addition to the histology of the tumor, the clinical manifestations are determined by the function of the involved areas of brain. The proper evaluation of the patient with a suspected brain tumor requires a detailed history, a comprehensive neurologic examination, and appropriate diagnostic neuroimaging studies.",
"   </p>",
"   <p>",
"    Although newer imaging techniques often provide information suggesting a specific histology, an adequate tissue sample should generally be obtained, either at the time of neurosurgical resection or by stereotactic biopsy, to optimize treatment.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/1\">",
"      Gutin PH, Posner JB. Neuro-oncology: diagnosis and management of cerebral gliomas--past, present, and future. Neurosurgery 2000; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/2\">",
"      Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993; 43:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/3\">",
"      Moots PL, Maciunas RJ, Eisert DR, et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995; 52:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/4\">",
"      Cohen N, Strauss G, Lew R, et al. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988; 6:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/5\">",
"      Pace A, Bove L, Innocenti P, et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998; 17:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/6\">",
"      Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998; 34:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/7\">",
"      FRANKEL SA, GERMAN WJ. Glioblastoma multiforme; review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment. J Neurosurg 1958; 15:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/8\">",
"      ROTH JG, ELVIDGE AR. Glioblastoma multiforme: a clinical survey. J Neurosurg 1960; 17:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/9\">",
"      Cavaliere R, Farace E, Schiff D. Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol 2006; 63:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/10\">",
"      Cascino GD. Epilepsy and brain tumors: implications for treatment. Epilepsia 1990; 31 Suppl 3:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/11\">",
"      Keane JR. Neurologic symptoms mistaken for gastrointestinal disease. Neurology 1998; 50:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/12\">",
"      Squires RH Jr. Intracranial tumors. Vomiting as a presenting sign. A gastroenterologist's perspective. Clin Pediatr (Phila) 1989; 28:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/13\">",
"      Hayashi M, Handa Y, Kobayashi H, et al. Plateau-wave phenomenon (I). Correlation between the appearance of plateau waves and CSF circulation in patients with intracranial hypertension. Brain 1991; 114 ( Pt 6):2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/14\">",
"      Hayashi M, Kobayashi H, Handa Y, et al. Brain blood volume and blood flow in patients with plateau waves. J Neurosurg 1985; 63:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/15\">",
"      Scott JN, Brasher PM, Sevick RJ, et al. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002; 59:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/16\">",
"      Poptani H, Gupta RK, Roy R, et al. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995; 16:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/17\">",
"      Warren KE, Frank JA, Black JL, et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000; 18:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/18\">",
"      Burtscher IM, Skagerberg G, Geijer B, et al. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol 2000; 21:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/19\">",
"      Galanaud D, Chinot O, Nicoli F, et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 2003; 98:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/20\">",
"      Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 2012; 107:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/21\">",
"      Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012; 4:116ra4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/22\">",
"      Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012; 18:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/23\">",
"      Quan D, Hackney DB, Pruitt AA, et al. Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. Neurology 1999; 53:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/24\">",
"      Leh&eacute;ricy S, Duffau H, Cornu P, et al. Correspondence between functional magnetic resonance imaging somatotopy and individual brain anatomy of the central region: comparison with intraoperative stimulation in patients with brain tumors. J Neurosurg 2000; 92:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/25\">",
"      Bittar RG, Olivier A, Sadikot AF, et al. Presurgical motor and somatosensory cortex mapping with functional magnetic resonance imaging and positron emission tomography. J Neurosurg 1999; 91:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/26\">",
"      Schulder M, Maldjian JA, Liu WC, et al. Functional image-guided surgery of intracranial tumors located in or near the sensorimotor cortex. J Neurosurg 1998; 89:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/27\">",
"      Pardo FS, Aronen HJ, Kennedy D, et al. Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. Int J Radiat Oncol Biol Phys 1994; 30:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/28\">",
"      Aronen HJ, Glass J, Pardo FS, et al. Echo-planar MR cerebral blood volume mapping of gliomas. Clinical utility. Acta Radiol 1995; 36:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/29\">",
"      Br&uuml;ning R, Seelos K, Yousry T, et al. Echo-planar magnetic resonance imaging (EPI) with high-resolution matrix in intra-axial brain tumors. Eur Radiol 1999; 9:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/30\">",
"      Wong ET, Jackson EF, Hess KR, et al. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 1998; 50:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/31\">",
"      Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/32\">",
"      Alsop DC, Detre JA. Multisection cerebral blood flow MR imaging with continuous arterial spin labeling. Radiology 1998; 208:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/33\">",
"      Alsop DC, Detre JA. Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab 1996; 16:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/34\">",
"      Hanson MW, Glantz MJ, Hoffman JM, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991; 15:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/35\">",
"      Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993; 79:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/36\">",
"      Levivier M, Goldman S, Pirotte B, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg 1995; 82:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/37\">",
"      Kaplan AM, Bandy DJ, Manwaring KH, et al. Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. J Neurosurg 1999; 91:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/38\">",
"      Hamilton RJ, Sweeney PJ, Pelizzari CA, et al. Functional imaging in treatment planning of brain lesions. Int J Radiat Oncol Biol Phys 1997; 37:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/39\">",
"      Thiel A, Pietrzyk U, Sturm V, et al. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report. Neurosurgery 2000; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/40\">",
"      Barker FG 2nd, Chang SM, Valk PE, et al. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997; 79:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/41\">",
"      Doyle WK, Budinger TF, Valk PE, et al. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987; 11:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/42\">",
"      Janus TJ, Kim EE, Tilbury R, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993; 33:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/43\">",
"      Chao ST, Suh JH, Raja S, et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001; 96:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/44\">",
"      Sasaki M, Kuwabara Y, Yoshida T, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998; 25:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/45\">",
"      Borgwardt L, H&oslash;jgaard L, Carstensen H, et al. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 2005; 23:3030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/46\">",
"      Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumours: is it useful? J Neurol Neurosurg Psychiatry 1995; 58:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/47\">",
"      Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005; 46:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/48\">",
"      Sun D, Liu Q, Liu W, Hu W. Clinical application of 201Tl SPECT imaging of brain tumors. J Nucl Med 2000; 41:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/49\">",
"      Black KL, Hawkins RA, Kim KT, et al. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 1989; 71:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/50\">",
"      Kaplan WD, Takvorian T, Morris JH, et al. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med 1987; 28:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/51\">",
"      Slizofski WJ, Krishna L, Katsetos CD, et al. Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology. Cancer 1994; 74:3190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/52\">",
"      Vertosick FT Jr, Selker RG, Grossman SJ, Joyce JM. Correlation of thallium-201 single photon emission computed tomography and survival after treatment failure in patients with glioblastoma multiforme. Neurosurgery 1994; 34:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/53\">",
"      Barkovich AJ, Krischer J, Kun LE, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg 1990; 16:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/54\">",
"      Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25657/abstract/55\">",
"      Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001; 3:193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5180 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-8A237B75EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25657=[""].join("\n");
var outline_f25_3_25657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Generalized",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Headaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cognitive dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Focal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sensory loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Aphasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Visual spatial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC NEUROIMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Magnetic resonance spectroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Functional MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Perfusion MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PET scans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SPECT imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSTIC NEUROSURGICAL INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Preoperative assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surgical exploration or biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Glial tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - CNS lymphomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Neuropathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5180\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5180|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/11/181\" title=\"algorithm 1\">",
"      Diffuse pontine glioma MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5180|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/48/1795\" title=\"diagnostic image 1\">",
"      GBM MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5180|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/49/15134\" title=\"table 1\">",
"      WHO nervous system tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/32/14861\" title=\"table 2\">",
"      WHO brain tumor classification by histology and grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/9/3227\" title=\"table 3\">",
"      Symptoms of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/21/41307\" title=\"table 4\">",
"      Symptoms of GBM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/39/33405\" title=\"table 5\">",
"      Mental status exam terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/52/37707\" title=\"table 6\">",
"      Brain tumors diff diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/12/2251\" title=\"table 7\">",
"      MR spectroscopy brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41655?source=related_link\">",
"      Brain tumor headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2071?source=related_link\">",
"      Diagnosis and classification of low-grade gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1832?source=related_link\">",
"      Diffuse pontine glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=related_link\">",
"      Focal brainstem glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=related_link\">",
"      Management of low-grade glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/16/39176?source=related_link\">",
"      Optic pathway glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30552?source=related_link\">",
"      Overview and differential diagnosis of papilledema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/48/9986?source=related_link\">",
"      Patient information: Brain cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=related_link\">",
"      Patient information: High-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=related_link\">",
"      Patient information: Meningioma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=related_link\">",
"      Patient information: Primary low-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=related_link\">",
"      Treatment and prognosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=related_link\">",
"      Treatment of benign (WHO grade I) meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=related_link\">",
"      Treatment of brain metastases in poor prognosis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_3_25658="Selection of medications for pediatric procedural sedation outside of the operating room";
var content_f25_3_25658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selection of medications for pediatric procedural sedation outside of the operating room",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/3/25658/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25658/contributors\">",
"     Deborah C Hsu, MD, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25658/contributors\">",
"     Joseph P Cravero, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/3/25658/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25658/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25658/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/3/25658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/3/25658/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/3/25658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2258654\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of short-acting sedative-hypnotic and analgesic medications are available for pediatric procedural sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Many of these agents have multiple routes of administration. The choice of drug is based upon the type of procedure, the anticipated degree of pain, the targeted depth of sedation, and the patient's underlying medical condition. Procedures that are not painful but induce anxiety or require the child to remain still are usually performed with sedation alone. Children undergoing painful procedures require analgesia as well as sedation.",
"   </p>",
"   <p>",
"    This topic will discuss the selection of medications for pediatric procedural sedation outside of the operating room. The properties of agents commonly used for procedural sedation in children; the assessment, preparation, and proper performance of procedural sedation in children outside of the operating room; and sedation in adults are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=see_link\">",
"       \"Preparation for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"       \"Procedural sedation in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6054074\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic interventions include behavioral and cognitive approaches, such as desensitization, distraction, reinforcing coping skills, positive reinforcement, and relaxation. These techniques are complementary to pharmacologic interventions and, in some children, may prevent the need for sedation altogether. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1684879#H1684879\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Nonpharmacologic interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253043\">",
"    <span class=\"h1\">",
"     CHOICE OF SEDATIVE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The targeted depth of sedation and the agents used largely depend upon the anticipated degree of pain, the allowable amount of motion encountered during the procedure, and the following patient factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/2,4\">",
"     2,4",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=see_link&amp;anchor=H1560692#H1560692\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Pre-sedation evaluation'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Comorbidities (eg, asthma, upper respiratory tract infection)",
"     </li>",
"     <li>",
"      Fasting status",
"     </li>",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Ability to cooperate",
"     </li>",
"     <li>",
"      Degree of anxiety",
"     </li>",
"     <li>",
"      Any prior problems with specific medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dosing, administration, and properties of commonly used medications for pediatric sedation are listed in the tables and discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendations for sedation strategies and dosing in this topic assume that the patient is healthy (American Society of Anesthesiologists [ASA] class I or II) (",
"    <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"     table 3",
"    </a>",
"    ) and have been evaluated and prepared for sedation in accordance with guidelines designed to maximize patient safety. Those patients with ASA classes III, IV, and V, special needs, or airway abnormalities warrant consultation with a pediatric anesthesiologist or clinician with similar pediatric sedation expertise (eg, pediatric critical care or emergency physician). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=see_link&amp;anchor=H1560692#H1560692\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Pre-sedation evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=see_link&amp;anchor=H1563046#H1563046\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to make pediatric procedural sedation as safe as possible, institutions should develop protocols that specify a pre-sedation evaluation, including a sedation plan, monitoring during the procedure and recovery, discharge and follow-up criteria, credentialing for personnel, and a quality improvement monitoring mechanism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H33#H33\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Adverse outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss a wide range of available sedatives and analgesics. Health care providers who perform procedural sedation in children should have strong resuscitation and advanced pediatric life support skills, including advanced training in the assessment and management of the pediatric airway as well as specific training in pediatric procedural sedation. In some facilities, the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    may be restricted to use by anesthesiologists or other specialists (eg, pediatric critical care or pediatric emergency medicine specialists).",
"   </p>",
"   <p>",
"    In some jurisdictions,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    is",
"    <strong>",
"     only",
"    </strong>",
"    approved for use by anesthesiologists or others with specialized pediatric procedural training. Otherwise, bolus propofol use for procedural sedation in children requires special privileging. The clinician should check local regulations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253050\">",
"    <span class=\"h1\">",
"     SEDATION FOR IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging tests that are negatively impacted by motion (eg, noninterventional computed tomography [CT] or magnetic resonance imaging [MRI]) constitute the most common nonpainful procedures for which children undergo sedation. In one observational multicenter study of elective sedations provided by members of a sedation service, imaging accounted for almost 60 percent of 30,000 pediatric sedations performed outside of the operating room [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/5\">",
"     5",
"    </a>",
"    ]. Ideally, the chosen agent or agents should have a quick onset of action that permits successful and safe completion of the imaging study, maintains airway reflexes, and has limited impact on breathing and hemodynamic stability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/6\">",
"     6",
"    </a>",
"    ]. It should also permit rapid recovery with few side effects, such as nausea or agitation. Because imaging studies are not painful, analgesia is not necessary.",
"   </p>",
"   <p>",
"    Nonpainful imaging tests can often be performed without sedation in older cooperative children and young infants who are bundled and recently fed. However, a significant number of older infants, toddlers, and older children with intellectual disability cannot cooperate even for brief imaging tests (eg, helical computed tomography) and warrant sedation to ensure accurate imaging without excessive radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253057\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful imaging with helical CT is less sensitive to patient movement than MRI and, given the rapid speed of imaging, can sometimes be done without sedation or requires only brief sedation (approximately 5 to 10 minutes). Thus, the clinician has a choice of several different agents and a variety of routes of administration. The intravenous (IV) route is preferred where maximal efficiency and throughput is desirable, such as patients undergoing urgent imaging for diagnostic purposes, because the onset of action is shorter and more predictable, and depending upon the agent, recovery is quicker (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/6\">",
"     6",
"    </a>",
"    ]. Other routes of administration (ie, oral, intranasal, or rectal) are useful in children without intravenous access, especially in settings where CT imaging is elective and longer sedation duration and recovery times are acceptable (",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). However, if inadequate sedation or serious adverse events occur, lack of IV access may impede further management [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253064\">",
"    <span class=\"h3\">",
"     Intravenous medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that healthy infants and children (American Society of Anesthesiologists class I or II) (",
"    <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"     table 3",
"    </a>",
"    ) who have vascular access and are undergoing sedation for CT receive intravenous (IV)",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    rather than intravenous short-acting barbiturates (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/20/40262?source=see_link\">",
"     methohexital",
"    </a>",
"    ) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    ). In settings where IV propofol, dexmedetomidine, or etomidate are not available or their use is restricted, any of the other agents may be safely used but increased adverse events and slightly lower efficacy may occur.",
"   </p>",
"   <p>",
"    <br/>",
"    Evidence identifying the best sedative agent for children undergoing CT is limited. Based upon observational studies, IV",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    is associated with effective sedation in over 99 percent of children undergoing CT compared with 97 to 98 percent of children receiving short-acting barbiturates or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/6,8-12\">",
"     6,8-12",
"    </a>",
"    ]. Although lower efficacy was described for intravenous etomidate (76 percent of 17 patients) in one small trial, more than 99 percent of 446 children receiving etomidate for imaging successfully completed the procedure in a subsequent observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Intravenous etomidate and propofol have a more rapid onset of action than dexmedetomidine (1 to 2 minutes versus 8 to 16 minutes, respectively) and etomidate has a shorter duration of action than dexmedetomidine (approximately 15 minutes compared with 30 minutes, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Duration of action with propofol varies by dose and mode of administration (bolus or continuous infusion) and compares favorably with etomidate. Adverse events have been described in 2 percent of infants and children receiving etomidate or propofol sedation for imaging and 1 percent receiving dexmedetomidine. In contrast, approximately 5 percent of patients receiving IV short-acting barbiturates (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/20/40262?source=see_link\">",
"     methohexital",
"    </a>",
"    ) and up to 7 percent receiving IV midazolam experience adverse events, primarily transient oxygen desaturation and less commonly apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/8,10,13\">",
"     8,10,13",
"    </a>",
"    ]. Other adverse reactions that are specific to the agent have also been described as follows (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H7977207#H7977207\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Sedative-hypnotic agents'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       Dexmedetomidine",
"      </a>",
"      &ndash; Hypotension (2 percent), most commonly occurring during medication bolus [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      &ndash; Myoclonus (1 percent) and adrenal suppression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       Propofol",
"      </a>",
"      &ndash; Pain on injection, rapid attainment of greater depth of sedation than intended [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/14\">",
"       14",
"      </a>",
"      ]. Formulations of propofol contain egg lecithin, egg yolk phospholipids, and soybean oil. Consequently, some suggest that children with allergies to egg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      soybeans should not receive propofol, whenever possible [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/15\">",
"       15",
"      </a>",
"      ]. However, the use of propofol in children with known egg allergies has been described with allergic reactions occurring in approximately 2 percent of patients and no report of anaphylaxis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H3220172#H3220172\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Propofol'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/20/40262?source=see_link\">",
"       Methohexital",
"      </a>",
"      &ndash; Contraindicated in patients with temporal lobe epilepsy and porphyria [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/16\">",
"       16",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H7#H7\">",
"       \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Drugs and chemicals'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       Midazolam",
"      </a>",
"      &ndash; Paradoxical agitation and crying (1 to 2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"       Pentobarbital",
"      </a>",
"      &ndash; Prolonged sleepiness with decreased activity more than 12 hours after sedation (15 of 28 children in one small trial) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/9\">",
"       9",
"      </a>",
"      ]. Pentobarbital is contraindicated in patients with porphyria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H7#H7\">",
"       \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Drugs and chemicals'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253072\">",
"    <span class=\"h3\">",
"     Oral, rectal, or intranasal medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that healthy infants and children (American Society of Anesthesiologists class I or II) who do not have intravenous access and are undergoing sedation for CT receive oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    rather than oral or intranasal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    or rectal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/20/40262?source=see_link\">",
"     methohexital",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). We suggest that these children",
"    <strong>",
"     not",
"    </strong>",
"    receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    . Regardless of agent and route chosen, children should undergo monitoring of oxygen saturation and heart rate as soon as any signs of sedation are present because the risk of adverse events is",
"    <strong>",
"     not",
"    </strong>",
"    lower with these routes of administration when compared to sedation with intravenous agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1683246#H1683246\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Monitoring'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Based upon one small clinical trial and larger observational studies, oral pentobarbital has an efficacy of 99 percent for successful completion of CT with adverse effects occurring in approximately 1 to 2 percent of patients (airway or oxygen desaturation &lt;0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The time to sedation ranges from 10 to 30 minutes and time to discharge is 90 to 100 minutes.",
"    <br/>",
"    <br/>",
"    In comparison, although rectal methohexital or thiopental and oral or intranasal midazolam have a more rapid onset of action, small trials and larger observational studies have shown lower efficacies for successful sedation and greater potential for adverse effects in children undergoing CT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. For example, successful completion of CT with rectal methohexital or thiopental occurs approximately 95 percent and 98 percent of the time, respectively. Up to 10 percent of infants or children experience adverse effects with rectal methohexital (6 percent oxygen desaturation) and 33 percent have adverse effects following administration of rectal thiopental (11 percent oxygen desaturation) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Rectal thiopental has also been associated with delayed effects of rectal irritation or diarrhea (over 50 percent), prolonged sleepiness (14 percent), and ataxia (13 percent). Midazolam by oral or intranasal routes achieves successful sedation in only 50 to 87 percent of patients undergoing CT, with higher efficacy in patients receiving it by the intranasal route [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/20,23,24\">",
"     20,23,24",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    While not a recommended agent, chloral hydrate was once the preferred sedative for infants and children less than three years of age and is still in use in some settings. However, small trials and observational studies indicate that chloral hydrate is inferior to other sedation options because of its delayed onset of action and prolonged effect (",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. If chloral hydrate is used, procedural sedation protocols for monitoring should be followed because there is no consistent dose below which complications do not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/2\">",
"     2",
"    </a>",
"    ]. In one report of adverse sedation events, 20 of 60 children had received chloral hydrate alone or in combination with other sedatives [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/25\">",
"     25",
"    </a>",
"    ]. Five of those who died or sustained permanent neurologic damage received chloral hydrate in unmonitored settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=see_link&amp;anchor=H1560720#H1560720\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some countries have removed",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    from national health formularies because of potential carcinogenicity although the risk of cancer from a single dose is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/3,26\">",
"     3,26",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    After a single oral or rectal dose of chloral hydrate, successful sedation occurs in approximately 80 percent of infants and children under three years of age, although efficacy approaches 100 percent in patients who receive a second dose when sedation is inadequate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/23,27,28\">",
"     23,27,28",
"    </a>",
"    ]. Onset of action takes up to 30 minutes after a single dose and up to 60 minutes if re-dosing is necessary. The onset and degree of sedation may be unreliable with the rectal route. Time to discharge is 120 to 240 minutes with the longer time occurring in children who require re-dosing. Oxygen desaturation occurs in up to 9 percent of patients and is highest in patients who receive a dose of 75 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Other acute adverse events include vomiting, hallucinations, and paradoxical agitation. Adverse effects that may persist for up to 24 hours after chloral hydrate administration include ataxia (50 percent), agitation (15 to 38 percent), and excessive sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253079\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) often necessitates sedation for up to one hour, and machine noise and lack of patient access pose additional challenges to achieving safe and effective sedation. We suggest that healthy infants and children (American Society of Anesthesiologists class I or II) undergoing MRI receive sedation using continuous intravenous (IV) infusion of",
"    <strong>",
"    </strong>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    rather than IV or oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). In settings where dexmedetomidine or propofol are not available or use is restricted, we suggest IV or oral pentobarbital. We suggest that these patients",
"    <strong>",
"     not",
"    </strong>",
"    receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Observational studies indicate that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    have comparable efficacy and safety as sedative agents for children undergoing MRI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sedation with continuous infusion of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      permits successful completion of MRI in approximately 97 to 99 percent of children when administered by experienced practitioners [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/12,29-32\">",
"       12,29-32",
"      </a>",
"      ]. However, to achieve this level of success with dexmedetomidine infusion alone typically requires dosing that exceeds current manufacturer recommendations (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/30\">",
"       30",
"      </a>",
"      ]. Alternatively, although less commonly used and based upon limited experience,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      combined with dexmedetomidine can be efficacious. As an example, the combination of dexmedetomidine administered to 20 children according to manufacturer&rsquo;s suggested dosing along with midazolam (0.1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      permitted successful completion of MRI studies in all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/31\">",
"       31",
"      </a>",
"      ]. Current evidence does not support one approach over the other. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H3220179#H3220179\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Dexmedetomidine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Time to sedation is longer with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      than with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      (10 versus &lt;1 minutes, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/12,29-31\">",
"       12,29-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recovery is typically complete 20 to 30 minutes after stopping a",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      infusion and 25 to 40 minutes after ending a",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/12,29-31,33\">",
"       12,29-31,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Minor adverse effects occur in up to 5 percent of children receiving",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      . However, major complications (eg, unplanned admission, aspiration, airway compromise requiring endotracheal intubation) happen uncommonly (less than 0.5 percent of patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/12,34\">",
"       12,34",
"      </a>",
"      ]. For example, in a multicenter observational study of almost 50,000 pediatric sedations with propofol, most of them performed for MRI, only 4 patients developed pulmonary aspiration and two patients not undergoing MRI required CPR. Very low rates (50 to 100 events out of 10,000 sedations) were also found for stridor, laryngospasm, and vomiting. However, 1.5 percent of patients required some form of airway intervention during the sedation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/35\">",
"       35",
"      </a>",
"      ]. In another multicenter observational study of 5072 children undergoing propofol sedation for MRI, rates of significant adverse events potentially requiring intervention were also low including oxygen desaturation (1.2 percent); airway obstruction (0.5 percent); unexpected apnea (0.3 percent); or a greater than 30 percent decrease in heart rate, respiratory rate, or blood pressure (0.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       Dexmedetomidine",
"      </a>",
"      causes minimal respiratory depression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/7\">",
"       7",
"      </a>",
"      ]. However, bradycardia and hypertension have been reported in up to 16 percent and 5 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. These hemodynamic changes are dose-related. In a large observational study of 3522 children undergoing MRI who received dexmedetomidine for sedation, hypertension did not require pharmacologic intervention and did not result in any adverse outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/29\">",
"       29",
"      </a>",
"      ]. However, dexmedetomidine should be avoided in patients for whom increases in pulmonary artery pressure or decreases in cardiac output will not be well tolerated. Dexmedetomidine should also",
"      <strong>",
"       not",
"      </strong>",
"      be given to children with AV node conduction delay or those receiving",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      , beta blockers or other medications that slow AV node conduction. The initial bolus dose of dexmedetomidine prior to initiation of the infusion is often accompanied by hypotension that usually reversed with a bolus of fluid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H3220179#H3220179\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Dexmedetomidine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of bradycardia caused by",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/4/43078?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      has resulted in severe hypertension. Thus, the use of anticholinergic agents in these patients should be avoided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H3220179#H3220179\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Dexmedetomidine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    can effectively sedate children undergoing MRI (99 and 95 percent successful completion, respectively), the time to sedation is much greater for both agents than with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    and the potential for adverse events is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/18,27,28,34\">",
"     18,27,28,34",
"    </a>",
"    ]. As an example, in an observational multicenter study of 7079 children undergoing sedation for MRI that compared propofol with pentobarbital, sedation with pentobarbital (2007 children) was significantly associated with prolonged recovery (1 percent of patients, adjusted OR 17), unplanned admission (0.2 percent of patients, adjusted OR 6), and vomiting (0.8 percent of patients, adjusted OR 37) when compared with propofol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/34\">",
"     34",
"    </a>",
"    ]. Overall complications were also significantly greater with pentobarbital than with propofol (7 versus 5 percent, adjusted OR 1.4). Of note, no statistically significant differences for any airway event were found between patients receiving pentobarbital and those who received propofol. Although no studies have compared MRI sedation using chloral hydrate with propofol or dexmedetomidine, observational evidence for outcomes after pediatric sedation for imaging with chloral hydrate demonstrate even lower efficacy and greater risk of adverse events than described for pentobarbital [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/20,27,28\">",
"     20,27,28",
"    </a>",
"    ]. Thus, as for sedation for computed tomography, we suggest that chloral hydrate",
"    <strong>",
"     not",
"    </strong>",
"    be used. (See",
"    <a class=\"local\" href=\"#H2253072\">",
"     'Oral, rectal, or intranasal medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    or appropriately trained providers to provide sedation with these agents are not available, then we suggest that children undergoing MRI receive IV or oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). In one observational study of 2164 infants undergoing sedation with IV pentobarbital or oral pentobarbital, both routes of administration resulted in successful imaging in more than 99 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/18\">",
"     18",
"    </a>",
"    ]. Time to sedation was longer with oral pentobarbital than with IV pentobarbital (18 versus 7 minutes, respectively) but time to discharge was not significantly different (approximately 60 to 120 minutes for both administration routes). Oral pentobarbital administration was associated with significantly fewer episodes of oxygen desaturation when compared to IV pentobarbital administration (0.2 versus 0.9 percent, respectively). However, potential differences in late effects between IV and oral pentobarbital were not reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253087\">",
"    <span class=\"h1\">",
"     SEDATION FOR OTHER NONPAINFUL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some children, physical examination (eg, genital examination to document sexual assault or routine physical examination in children with intellectual disability) or other nonpainful procedures (eg, echocardiography, electroencephalogram) can cause anxiety and lack of cooperation with the medical provider. In many situations, nonpharmacologic interventions can permit completion of the examination or test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1684879#H1684879\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Nonpharmacologic interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When nonpharmacologic interventions are not sufficient and mild sedation is necessary for nonpainful procedures, we suggest that healthy children (American Society of Anesthesiologists class I or II) (",
"    <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"     table 3",
"    </a>",
"    ) receive sedation with inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    (N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    ) or oral, sublingual, or intranasal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    rather than short-acting barbiturates (",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). Intravenous sedation as described for computed tomography is suggested for patients who fail N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    or midazolam sedation. (See",
"    <a class=\"local\" href=\"#H2253057\">",
"     'Computed tomography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     Midazolam",
"    </a>",
"    has both anxiolytic and amnestic properties. After oral or sublingual administration, it has an onset of action of 5 to 10 minutes with recovery occurring in approximately 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/36\">",
"     36",
"    </a>",
"    ]. Onset of action with intranasal midazolam administration is similar to oral administration but duration of sedation is shorter (20 to 30 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/37\">",
"     37",
"    </a>",
"    ]. However, intranasal midazolam can be very irritating to some children. Pretreatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    spray (10 mg per puff) one minute prior to intranasal midazolam administration decreases nasal mucosal irritation. An atomizer can also deliver midazolam intranasally with better comfort and with reduction of sneezing and cough when compared to direct instillation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/37\">",
"     37",
"    </a>",
"    ]. Although midazolam may be administered rectally, this route is less reliable and may cause patient discomfort.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/58/38821?source=see_link\">",
"     Flumazenil",
"    </a>",
"    is an effective reversal agent for the few patients who develop significant respiratory depression or apnea after sedation with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    . Flumazenil should",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients with seizure disorders or those who receive benzodiazepines on a chronic basis because of the risk of precipitating seizures or withdrawal symptoms, respectively. The use of flumazenil to reverse adverse effects of benzodiazepines, including dosing and re-dosing recommendations is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link&amp;anchor=H14#H14\">",
"     \"Benzodiazepine poisoning and withdrawal\", section on 'Antidote (flumazenil)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon observational studies and one trial,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    has good efficacy and a shorter duration of action than oral or rectal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/6,23,24,36,37\">",
"     6,23,24,36,37",
"    </a>",
"    ]. As an example, in a trial that compared sublingual midazolam with oral chloral hydrate in 264 children undergoing echocardiogram, midazolam was associated with a 99 percent success rate for completing the examination and had fewer patients with significant oxygen desaturation when compared to chloral hydrate (5 versus 14 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/36\">",
"     36",
"    </a>",
"    ]. Unlike barbiturates or chloral hydrate, midazolam is not associated with prolonged symptoms of ataxia, sleepiness, or irritability (",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2253072\">",
"     'Oral, rectal, or intranasal medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several small studies describe acceptable efficacy following the use of intranasal, oral, or buccal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    for pediatric sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Thus, this approach may find future use for sedation for nonpainful procedures outside of the operating room.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253094\">",
"    <span class=\"h1\">",
"     SEDATION FOR PAINFUL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians frequently employ procedural sedation for infants and children undergoing a variety of painful procedures including fracture reduction, laceration repair, bone marrow aspiration, central line placement, and lumbar puncture. For these procedures, chosen agents or combinations of agents must safely provide sedation",
"    <strong>",
"     and",
"    </strong>",
"    analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253101\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate analgesia can often lower the amount of sedative agent needed to provide adequate sedation and thus increase the safety of the procedure. The need for supplementary analgesia varies by the agents used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      has both sedative and analgesic properties and can thus be used alone to provide sedation for painful procedures. (See",
"      <a class=\"local\" href=\"#H2253108\">",
"       'Approach'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       Dexmedetomidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      have limited analgesic properties that may be inadequate and warrant additional analgesic medications for moderately or severely painful procedures.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       Midazolam",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      , do",
"      <strong>",
"       not",
"      </strong>",
"      have analgesic properties and need to be combined with other analgesic agents. Although propofol is used alone for brief, painful procedures by some practitioners, the doses necessary to achieve adequate analgesia and control unwanted motion during the procedure may approach those used for general anesthesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Options for supplementary analgesia include topical, local, and regional infiltrated anesthetics and systemic analgesic medications. The commonly used agents for analgesia during pediatric procedural sedation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H7977256#H7977256\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Analgesic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253108\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient factors (eg, last oral intake, urgency of the procedure, prior sedation experience, and comorbidities [eg, asthma, upper respiratory infection]) are key considerations for sedation strategies in children undergoing painful procedures and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=see_link&amp;anchor=H1560692#H1560692\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Pre-sedation evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In healthy infants and children, anticipated pain during the procedure is also an important determinant of the depth and type of sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253115\">",
"    <span class=\"h3\">",
"     Minimally painful",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many children undergoing intravenous cannula insertion or laceration repair, local anesthetics can be delivered topically or by direct infiltration to diminish or abolish the pain without the need for sedation, especially when age-appropriate nonpharmacologic interventions are used. (See",
"    <a class=\"local\" href=\"#H6054074\">",
"     'Nonpharmacologic interventions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The topical anesthetic most frequently used for laceration repair is the combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    , epinephrine, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37648?source=see_link\">",
"     tetracaine",
"    </a>",
"    (LET), which becomes effective in approximately 30 minutes. For intact skin, EMLA, a eutectic mixture of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/43/34486?source=see_link\">",
"     lidocaine-prilocaine",
"    </a>",
"    in a cream base, and LMX 4, a nonprescription 4 percent liposomal lidocaine preparation, are also effective topical agents. They are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link&amp;anchor=H2#H2\">",
"     \"Topical anesthetics in children\", section on 'LET'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link&amp;anchor=H11#H11\">",
"     \"Topical anesthetics in children\", section on 'EMLA'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    In some children, the distress and anxiety of a minimally painful procedure is profound despite topical anesthesia and the use of nonpharmacologic techniques. For healthy infants and children (American Society of Anesthesiologists class I or II) (",
"    <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"     table 3",
"    </a>",
"    ) with significant distress or anxiety who are undergoing minimally painful procedures (eg, laceration repair or peripheral venous access with topical anesthesia) and for whom mild sedation is desired, we suggest procedural sedation with inhalation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    (N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    ) or administration of oral or intranasal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    rather than topical anesthesia and nonpharmacologic interventions alone (",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). Based upon an observational study of 295 children, five years of age or younger, who received N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    , refusal of the mask and need for restraint may occur in over 10 and 33 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/41\">",
"     41",
"    </a>",
"    ]. If N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    is not available or not tolerated by the patient, then oral or nasal midazolam is an acceptable alternative but longer recovery time and more adverse events, especially ataxia, should be anticipated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. The method for administering N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    for procedural sedation outside of the operating room is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H2152505#H2152505\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Nitrous oxide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This recommendation is supported by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 264 young children (mean age four years) undergoing facial laceration repair, N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      alone (50 percent N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      : 50 percent oxygen ratio) or combined with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      provided clinically significantly decreased distress during cleaning,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      injection, and repair than either midazolam alone or topical anesthesia with comforting [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/42\">",
"       42",
"      </a>",
"      ]. Approximately 6 percent of patients receiving N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      vomited. Patients who received midazolam took longer to recover (30 versus 20 minutes) and were more likely to report ataxia or dizziness (28 versus 2 percent) than those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      alone. No serious side effects (eg, apnea, need for airway control) occurred in either group.",
"     </li>",
"     <li>",
"      In a blinded, randomized trial of 90 obese or growth retarded children (aged 5 to 18 years) in whom intravenous (IV) access was expected to be difficult, use of 50 percent N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      was associated with a significantly increased success rate for IV placement when compared to oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      (0.3",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose 15 mg) or 10 percent N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      (67 versus 40 or 37 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/43\">",
"       43",
"      </a>",
"      ]. Procedure time was also significantly shorter for patients who received 50 percent N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      when compared to oral midazolam.",
"     </li>",
"     <li>",
"      Administration of up to 70 percent N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      with 30 percent oxygen via nasal dental mask was performed in an observational study of almost 4000 infants and children under four years of age with serious adverse events occurring in &lt;1 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/44\">",
"       44",
"      </a>",
"      ]. The most common painful procedures for which N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      was used included urinary catheterization, peripheral venous cannulation, lumbar puncture, and enteral tube (nasogastric or gastrostomy) placement. Vomiting occurred in approximately 2 percent of patients and was associated with inhalation of N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      for longer than 15 minutes.",
"     </li>",
"     <li>",
"      In another observational study of N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      in 762 children between 1 and 17 years of age, most of whom received 70 percent N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      with 30 percent oxygen, vomiting or serious adverse events occurred in 6 and 0.2 percent of children, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/45\">",
"       45",
"      </a>",
"      ]. Moderate sedation was achieved in most patients although 3 percent of children were deeply sedated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, this evidence suggests that N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    may be more effective than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    for minimally painful procedures with a shorter recovery time and fewer overall adverse effects. However, a large number of patients, especially younger children may",
"    <strong>",
"     not",
"    </strong>",
"    tolerate N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    delivery and vomiting is more frequent with N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    than midazolam. N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    administration also requires special equipment and may be more costly than midazolam administration. Furthermore, N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    is not always available for administration outside of the operating room and should not be administered by pregnant personnel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H2152505#H2152505\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Nitrous oxide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253122\">",
"    <span class=\"h3\">",
"     Moderately or severely painful",
"    </span>",
"    &nbsp;&mdash;&nbsp;For healthy infants and children (American Society of Anesthesiologists class I or II) (",
"    <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"     table 3",
"    </a>",
"    ) who are undergoing moderately or severely painful procedures of short duration (eg, fracture reduction, bone marrow aspiration), we suggest procedural sedation with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    , ketamine combined with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    , or ketamine combined with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    rather than opioids combined with benzodiazepines (eg, midazolam), opioids combined with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    , opioids combined with propofol, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    (N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    ) alone (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Based upon observational studies and randomized trials,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    alone or in combination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    provides more effective sedation and anxiolysis for very painful procedures, such as fracture reduction or bone marrow aspiration, than N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    alone and lower risk of respiratory events during sedation than opioids combined with midazolam,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    , or propofol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/41,46-50\">",
"     41,46-50",
"    </a>",
"    ]. Although vomiting may occur more frequently in patients who receive ketamine sedation without propofol than other sedation regimens, this adverse effect can be mitigated by pretreatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    or combination sedation with propofol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H2152498#H2152498\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Ketamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies support these conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a blinded trial of 260 children, 5 to 15 years of age, undergoing fracture reduction, patients who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      combined with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      had clinically significantly lower distress during the procedure and higher orthopedist satisfaction than those who received midazolam and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/47\">",
"       47",
"      </a>",
"      ]. Sedation with ketamine and midazolam was associated with clinically significantly fewer respiratory complications than midazolam and fentanyl (hypoxia: 6 versus 24 percent, respectively; breathing cues: 1 versus 12 percent, respectively; and supplemental oxygen requirement: 10 versus 20 percent, respectively). One patient in each group had laryngospasm. Patients who received ketamine and midazolam were significantly more likely to vomit during recovery (9 versus 2 percent) and had an average recovery time that was 14 minutes longer than those who received midazolam and fentanyl.",
"     </li>",
"     <li>",
"      In a trial of 113 children, 3 to 18 years of age, undergoing fracture reduction, patients who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      had clinically significantly less chance of oxygen desaturation (7 versus 31 percent, respectively) and need for respiratory maneuvers (2 versus 25 percent, respectively) than those who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/48\">",
"       48",
"      </a>",
"      ]. Patients who received ketamine and midazolam had clinically significantly longer total sedation time compared with those who received propofol and fentanyl (62 versus 39 minutes). Distress during reduction was low in both groups. Nurse and orthopedist satisfaction was high for both regimens.",
"     </li>",
"     <li>",
"      In a multicenter observational study of 1019 children younger than 18 years undergoing a variety of painful procedures including bone marrow aspiration, lumbar puncture, laceration repairs, and fracture reduction, N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      alone was associated with high rates of responsiveness to pain that varied by age and was indicated by crying (11 to 44 percent), withdrawal (18 to 43 percent), and need for restraint (8 to 34 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/41\">",
"       41",
"      </a>",
"      ]. Vomiting occurred in 4 percent of patients but no significant respiratory events were reported.",
"     </li>",
"     <li>",
"      In an observational study of 4252 children younger than 19 years receiving",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      sedation at a children&rsquo;s hospital, adverse respiratory events (eg, oxygen desaturation, airway obstruction, or apnea) and major respiratory events requiring airway intervention occurred in 2 and 1 percent of patients, respectively, including 29 patients with laryngospasm [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/54\">",
"       54",
"      </a>",
"      ]. One patient required endotracheal intubation. Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      prior to sedation or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      during sedation was",
"      <strong>",
"       not",
"      </strong>",
"      associated with an increased frequency of respiratory events. As previously discussed, these rates of adverse respiratory events are much lower than those described in children receiving opioids combined with midazolam,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/47,48,50\">",
"       47,48,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, currently available evidence favors",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    alone or in combination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    as an effective and safe sedative regimen for children undergoing brief, painful procedures in the emergency department. There is ample evidence that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    alone or in combination with opioids can be effective for pediatric sedation outside of the operating room for these procedures. In general, propofol based techniques carry a greater frequency of minor adverse events. Clinicians who use propofol warrant proper training and experience [",
"    <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited in children, the combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    for procedural sedation provides effective sedation and less vomiting than reported for ketamine alone and less respiratory depression and hypotension than described with propofol alone based upon experience in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link&amp;anchor=H22#H22\">",
"     \"Procedural sedation in adults\", section on 'Ketamine and propofol (ketofol)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence in children supports the adult experience as demonstrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of 219 patients, age 1 to 20 years, ketofol (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      [10",
"      <span class=\"nowrap\">",
"       mg/ml]",
"      </span>",
"      in a 1:1 volume mixture with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      [10",
"      <span class=\"nowrap\">",
"       mg/ml])",
"      </span>",
"      effectively sedated all patients with an average sedating dose of 0.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for both agents and a median recovery time of 14 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/53\">",
"       53",
"      </a>",
"      ]. Airway intervention was necessary in three patients (1.4 percent), including one patient who needed bag-valve-mask ventilation for laryngospasm. No patients had hypotension or vomiting.",
"     </li>",
"     <li>",
"      In a trial of 136 children (aged 2 to 17 years) who were receiving sedation and analgesia for fracture management with bolus doses of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      or ketamine alone, sedation and recovery time was statistically significantly shorter for ketamine combined with propofol (13 versus 16 minutes and 10 versus 12 minutes, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/3/25658/abstract/52\">",
"       52",
"      </a>",
"      ]. Clinically significantly more vomiting occurred in children who received ketamine alone than those who received ketamine and propofol (12 versus 2 percent). Oxygen desaturation or airway obstruction was not significantly different between the two groups (9 percent for ketamine, 12 percent for ketamine and propofol) and resolved with supplemental oxygen or airway repositioning. No patient had laryngospasm or hypotension. Approximately half of the patients in each group received opioid analgesia prior to sedation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    is an option for brief, moderate to severely painful procedures. However, when this combination is used, the clinician performing the sedation must have appropriate expertise in the performance of pediatric resuscitation, pediatric airway management, and specific training in the use of propofol and the provision of deep sedation or anesthesia. Careful selection of patients and appropriate preparation and monitoring are essential to maximize the safety of this regimen. Furthermore, this combination has not been shown to be more efficacious or safer for procedural sedation in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=see_link\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link&amp;anchor=H22#H22\">",
"     \"Procedural sedation in adults\", section on 'Ketamine and propofol (ketofol)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for procedural sedation in children undergoing elective diagnostic interventions (eg, gastrointestinal endoscopy, bronchoscopy, cardiac catheterization, or interventional radiology) are beyond the scope of this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2255305\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonpharmacologic interventions include behavioral and cognitive approaches such as desensitization, distraction, reinforcing coping skills, positive reinforcement, and relaxation. These techniques are complementary to pharmacologic interventions and, in some children, may prevent the need for sedation altogether. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1684879#H1684879\">",
"       \"Procedural sedation in children outside of the operating room\", section on 'Nonpharmacologic interventions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The targeted depth of sedation and the agents used largely depend upon the procedure performed, the anticipated degree of pain, allowable patient movement, and other patient factors. The recommendations for sedation strategies and dosing in this topic assume that the patient is healthy (American Society of Anesthesiologists class I or II) (",
"      <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"       table 3",
"      </a>",
"      ) and that the sedation is being performed by a properly trained health care provider with institutional oversight. (See",
"      <a class=\"local\" href=\"#H2253043\">",
"       'Choice of sedative agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The necessary preparation, indications, contraindications, and steps for safely performing procedural sedation in children are discussed separately. Patient factors (eg, last oral intake, urgency of the procedure, prior sedation experience, and comorbidities [eg, asthma, upper respiratory infection]) are key considerations for sedation strategies in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=see_link\">",
"       \"Preparation for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The properties of the specific agents with respect to pediatric sedation are listed in the tables (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ) and discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some facilities, the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      may be restricted to use by anesthesiologists or other specialists (eg, pediatric critical care or pediatric emergency medicine specialists). (See",
"      <a class=\"local\" href=\"#H2253043\">",
"       'Choice of sedative agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging tests that are negatively impacted by motion (eg, noninterventional computed tomography [CT] or magnetic resonance imaging [MRI]) constitute the most common nonpainful procedures for which children undergo sedation. The selection of medications for these procedures are determined by the duration of the test and whether vascular access is present (see",
"      <a class=\"local\" href=\"#H2253050\">",
"       'Sedation for imaging studies'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that healthy infants and children (American Society of Anesthesiologists class I or II) (",
"      <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"       table 3",
"      </a>",
"      ) who have vascular access and are undergoing sedation for CT receive intravenous (IV)",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      rather than intravenous short-acting barbiturates (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"       pentobarbital",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/20/40262?source=see_link\">",
"       methohexital",
"      </a>",
"      ) or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2253064\">",
"       'Intravenous medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that healthy infants and children (American Society of Anesthesiologists class I or II) (",
"      <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"       table 3",
"      </a>",
"      ) who do not have intravenous access and are undergoing sedation for CT receive oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"       pentobarbital",
"      </a>",
"      rather than oral or intranasal",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      or rectal",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/20/40262?source=see_link\">",
"       methohexital",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest that these children",
"      <strong>",
"       not",
"      </strong>",
"      receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Regardless of agent and route chosen, children should undergo monitoring of oxygen saturation and heart rate as soon as any signs of sedation are present because the risk of adverse events is",
"      <strong>",
"       not",
"      </strong>",
"      lower with these routes of administration when compared to sedation with intravenous agents. (See",
"      <a class=\"local\" href=\"#H2253072\">",
"       'Oral, rectal, or intranasal medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that healthy infants and children (American Society of Anesthesiologists class I or II) undergoing magnetic resonance imaging receive sedation using continuous intravenous (IV) infusion of",
"      <strong>",
"      </strong>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      rather than IV or oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"       pentobarbital",
"      </a>",
"      or oral or rectal",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In settings where dexmedetomidine, propofol, or appropriately trained providers to administer these agents are",
"      <strong>",
"       not",
"      </strong>",
"      available, we suggest IV or oral pentobarbital (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest that these patients",
"      <strong>",
"       not",
"      </strong>",
"      receive chloral hydrate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2253079\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When nonpharmacologic interventions are not sufficient and mild sedation is necessary for nonpainful procedures, we suggest that healthy children (American Society of Anesthesiologists class I or II) (",
"      <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"       table 3",
"      </a>",
"      ) receive sedation with inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      (N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      ) or oral, sublingual, or intranasal",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      rather than short-acting barbiturates (",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2253087\">",
"       'Sedation for other nonpainful procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When nonpharmacologic interventions and topical anesthetics are not sufficient and mild sedation is necessary for minimally painful procedures (eg, intravenous cannula placement), we suggest that healthy children (American Society of Anesthesiologists class I or II) (",
"      <a class=\"graphic graphic_table graphicRef78084 \" href=\"UTD.htm?9/5/9307\">",
"       table 3",
"      </a>",
"      ) receive sedation with inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      (N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      ) or oral, sublingual, or intranasal",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      rather than short-acting barbiturates (",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"UTD.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Intravenous sedation as described for computed tomography is suggested for patients who fail N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      or midazolam sedation. (See",
"      <a class=\"local\" href=\"#H2253115\">",
"       'Minimally painful'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H2152505#H2152505\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Nitrous oxide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Moderate to severely painful procedures, including fracture reduction, laceration repair, bone marrow aspiration, central line placement, and lumbar puncture frequently require procedural sedation that effectively combines sedation and analgesia. For these procedures, chosen agents or combinations of agents must safely provide sedation",
"      <strong>",
"       and",
"      </strong>",
"      analgesia. Appropriate analgesia can often lower the amount of sedative agent needed to provide adequate sedation and thus increase the safety of the procedure. The need for supplementary analgesia varies by the agents used. (See",
"      <a class=\"local\" href=\"#H2253094\">",
"       'Sedation for painful procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Options for supplementary analgesia include topical, local, and regional infiltrated anesthetics and systemic analgesic medications. The commonly used agents for analgesia during pediatric procedural sedation are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H7977256#H7977256\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Analgesic agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For healthy infants and children (American Society of Anesthesiologists class I or II) who are undergoing moderately or severely painful procedures of short duration (eg, fracture reduction or bone marrow aspiration), we suggest procedural sedation with intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      or ketamine in combination with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      rather than N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      alone or opioids combined with benzodiazepines (eg, midazolam),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      , or propofol (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"UTD.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"       Ondansetron",
"      </a>",
"      is suggested as a premedication when ketamine is used. (See",
"      <a class=\"local\" href=\"#H2253122\">",
"       'Moderately or severely painful'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H2152498#H2152498\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Ketamine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/1\">",
"      Kennedy RM, Luhmann JD. Pharmacological management of pain and anxiety during emergency procedures in children. Paediatr Drugs 2001; 3:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/2\">",
"      Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet 2006; 367:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/3\">",
"      Sahyoun C, Krauss B. Clinical implications of pharmacokinetics and pharmacodynamics of procedural sedation agents in children. Curr Opin Pediatr 2012; 24:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/4\">",
"      American Academy of Pediatrics, American Academy of Pediatric Dentistry, Cot&eacute; CJ, et al. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics 2006; 118:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/5\">",
"      Cravero JP, Blike GT, Beach M, et al. Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium. Pediatrics 2006; 118:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/6\">",
"      Macias CG, Chumpitazi CE. Sedation and anesthesia for CT: emerging issues for providing high-quality care. Pediatr Radiol 2011; 41 Suppl 2:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/7\">",
"      Rutman MS. Sedation for emergent diagnostic imaging studies in pediatric patients. Curr Opin Pediatr 2009; 21:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/8\">",
"      Baxter AL, Mallory MD, Spandorfer PR, et al. Etomidate versus pentobarbital for computed tomography sedations: report from the Pediatric Sedation Research Consortium. Pediatr Emerg Care 2007; 23:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/9\">",
"      Kienstra AJ, Ward MA, Sasan F, et al. Etomidate versus pentobarbital for sedation of children for head and neck CT imaging. Pediatr Emerg Care 2004; 20:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/10\">",
"      Mason KP, Prescilla R, Fontaine PJ, Zurakowski D. Pediatric CT sedation: comparison of dexmedetomidine and pentobarbital. AJR Am J Roentgenol 2011; 196:W194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/11\">",
"      Mason KP, Zgleszewski SE, Prescilla R, et al. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. Paediatr Anaesth 2008; 18:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/12\">",
"      Srinivasan M, Turmelle M, Depalma LM, et al. Procedural sedation for diagnostic imaging in children by pediatric hospitalists using propofol: analysis of the nature, frequency, and predictors of adverse events and interventions. J Pediatr 2012; 160:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/13\">",
"      Singh R, Kumar N, Vajifdar H. Midazolam as a sole sedative for computed tomography imaging in pediatric patients. Paediatr Anaesth 2009; 19:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/14\">",
"      Green SM, Krauss B. Propofol in emergency medicine: pushing the sedation frontier. Ann Emerg Med 2003; 42:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/15\">",
"      Hofer KN, McCarthy MW, Buck ML, Hendrick AE. Possible anaphylaxis after propofol in a child with food allergy. Ann Pharmacother 2003; 37:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/16\">",
"      Rockoff MA, Goudsouzian NG. Seizures induced by methohexital. Anesthesiology 1981; 54:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/17\">",
"      Rooks VJ, Chung T, Connor L, et al. Comparison of oral pentobarbital sodium (nembutal) and oral chloral hydrate for sedation of infants during radiologic imaging: preliminary results. AJR Am J Roentgenol 2003; 180:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/18\">",
"      Mason KP, Zurakowski D, Connor L, et al. Infant sedation for MR imaging and CT: oral versus intravenous pentobarbital. Radiology 2004; 233:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/19\">",
"      Mason KP, Sanborn P, Zurakowski D, et al. Superiority of pentobarbital versus chloral hydrate for sedation in infants during imaging. Radiology 2004; 230:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/20\">",
"      Malviya S, Voepel-Lewis T, Prochaska G, Tait AR. Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children. Pediatrics 2000; 105:E42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/21\">",
"      Pomeranz ES, Chudnofsky CR, Deegan TJ, et al. Rectal methohexital sedation for computed tomography imaging of stable pediatric emergency department patients. Pediatrics 2000; 105:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/22\">",
"      Glasier CM, Stark JE, Brown R, et al. Rectal thiopental sodium for sedation of pediatric patients undergoing MR and other imaging studies. AJNR Am J Neuroradiol 1995; 16:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/23\">",
"      D'Agostino J, Terndrup TE. Chloral hydrate versus midazolam for sedation of children for neuroimaging: a randomized clinical trial. Pediatr Emerg Care 2000; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/24\">",
"      Harcke HT, Grissom LE, Meister MA. Sedation in pediatric imaging using intranasal midazolam. Pediatr Radiol 1995; 25:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/25\">",
"      Cot&eacute; CJ, Karl HW, Notterman DA, et al. Adverse sedation events in pediatrics: analysis of medications used for sedation. Pediatrics 2000; 106:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/26\">",
"      American Academy of Pediatrics Committee on Drugs and Committee on Environmental Health: Use of chloral hydrate for sedation in children. Pediatrics 1993; 92:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/27\">",
"      Cortellazzi P, Lamperti M, Minati L, et al. Sedation of neurologically impaired children undergoing MRI: a sequential approach. Paediatr Anaesth 2007; 17:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/28\">",
"      Vade A, Sukhani R, Dolenga M, Habisohn-Schuck C. Chloral hydrate sedation of children undergoing CT and MR imaging: safety as judged by American Academy of Pediatrics guidelines. AJR Am J Roentgenol 1995; 165:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/29\">",
"      Mason KP, Zurakowski D, Zgleszewski S, et al. Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI. Paediatr Anaesth 2010; 20:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/30\">",
"      Mason KP, Zurakowski D, Zgleszewski SE, et al. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth 2008; 18:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/31\">",
"      Heard C, Burrows F, Johnson K, et al. A comparison of dexmedetomidine-midazolam with propofol for maintenance of anesthesia in children undergoing magnetic resonance imaging. Anesth Analg 2008; 107:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/32\">",
"      Lubisch N, Roskos R, Berkenbosch JW. Dexmedetomidine for procedural sedation in children with autism and other behavior disorders. Pediatr Neurol 2009; 41:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/33\">",
"      Dave J, Vaghela S. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Saudi J Anaesth 2011; 5:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/34\">",
"      Mallory MD, Baxter AL, Kost SI, Pediatric Sedation Research Consortium. Propofol vs pentobarbital for sedation of children undergoing magnetic resonance imaging: results from the Pediatric Sedation Research Consortium. Paediatr Anaesth 2009; 19:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/35\">",
"      Cravero JP, Beach ML, Blike GT, et al. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. Anesth Analg 2009; 108:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/36\">",
"      Layangool T, Sangtawesin C, Kirawittaya T, et al. A comparison of oral chloral hydrate and sublingual midazolam sedation for echocardiogram in children. J Med Assoc Thai 2008; 91 Suppl 3:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/37\">",
"      Chiaretti A, Barone G, Rigante D, et al. Intranasal lidocaine and midazolam for procedural sedation in children. Arch Dis Child 2011; 96:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/38\">",
"      McMorrow SP, Abramo TJ. Dexmedetomidine sedation: uses in pediatric procedural sedation outside the operating room. Pediatr Emerg Care 2012; 28:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/39\">",
"      Zub D, Berkenbosch JW, Tobias JD. Preliminary experience with oral dexmedetomidine for procedural and anesthetic premedication. Paediatr Anaesth 2005; 15:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/40\">",
"      Sakurai Y, Obata T, Odaka A, et al. Buccal administration of dexmedetomidine as a preanesthetic in children. J Anesth 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/41\">",
"      Annequin D, Carbajal R, Chauvin P, et al. Fixed 50% nitrous oxide oxygen mixture for painful procedures: A French survey. Pediatrics 2000; 105:E47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/42\">",
"      Luhmann JD, Kennedy RM, Porter FL, et al. A randomized clinical trial of continuous-flow nitrous oxide and midazolam for sedation of young children during laceration repair. Ann Emerg Med 2001; 37:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/43\">",
"      Ekbom K, Kalman S, Jakobsson J, Marcus C. Efficient intravenous access without distress: a double-blind randomized study of midazolam and nitrous oxide in children and adolescents. Arch Pediatr Adolesc Med 2011; 165:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/44\">",
"      Zier JL, Liu M. Safety of high-concentration nitrous oxide by nasal mask for pediatric procedural sedation: experience with 7802 cases. Pediatr Emerg Care 2011; 27:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/45\">",
"      Babl FE, Oakley E, Seaman C, et al. High-concentration nitrous oxide for procedural sedation in children: adverse events and depth of sedation. Pediatrics 2008; 121:e528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/46\">",
"      Migita RT, Klein EJ, Garrison MM. Sedation and analgesia for pediatric fracture reduction in the emergency department: a systematic review. Arch Pediatr Adolesc Med 2006; 160:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/47\">",
"      Kennedy RM, Porter FL, Miller JP, Jaffe DM. Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies. Pediatrics 1998; 102:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/48\">",
"      Godambe SA, Elliot V, Matheny D, Pershad J. Comparison of propofol/fentanyl versus ketamine/midazolam for brief orthopedic procedural sedation in a pediatric emergency department. Pediatrics 2003; 112:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/49\">",
"      Roback MG, Wathen JE, Bajaj L, Bothner JP. Adverse events associated with procedural sedation and analgesia in a pediatric emergency department: a comparison of common parenteral drugs. Acad Emerg Med 2005; 12:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/50\">",
"      Di Liddo L, D'Angelo A, Nguyen B, et al. Etomidate versus midazolam for procedural sedation in pediatric outpatients: a randomized controlled trial. Ann Emerg Med 2006; 48:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/51\">",
"      Langston WT, Wathen JE, Roback MG, Bajaj L. Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial. Ann Emerg Med 2008; 52:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/52\">",
"      Shah A, Mosdossy G, McLeod S, et al. A blinded, randomized controlled trial to evaluate ketamine/propofol versus ketamine alone for procedural sedation in children. Ann Emerg Med 2011; 57:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/53\">",
"      Andolfatto G, Willman E. A prospective case series of pediatric procedural sedation and analgesia in the emergency department using single-syringe ketamine-propofol combination (ketofol). Acad Emerg Med 2010; 17:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/3/25658/abstract/54\">",
"      Melendez E, Bachur R. Serious adverse events during procedural sedation with ketamine. Pediatr Emerg Care 2009; 25:325.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85542 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C0D21FD3A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25658=[""].join("\n");
var outline_f25_3_25658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2255305\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2258654\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6054074\">",
"      NONPHARMACOLOGIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2253043\">",
"      CHOICE OF SEDATIVE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2253050\">",
"      SEDATION FOR IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2253057\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2253064\">",
"      - Intravenous medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2253072\">",
"      - Oral, rectal, or intranasal medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2253079\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2253087\">",
"      SEDATION FOR OTHER NONPAINFUL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2253094\">",
"      SEDATION FOR PAINFUL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2253101\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2253108\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2253115\">",
"      - Minimally painful",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2253122\">",
"      - Moderately or severely painful",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2255305\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/85542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/85542|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/0/32782\" title=\"table 1\">",
"      Intravenous agents for pediatric procedural sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/28/31181\" title=\"table 2\">",
"      Agents other than intravenous for pediatric sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/5/9307\" title=\"table 3\">",
"      ASA physical status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=related_link\">",
"      Etiology and pathogenesis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=related_link\">",
"      Pharmacologic agents for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=related_link\">",
"      Preparation for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_3_25659="Factors water maintenance needs";
var content_f25_3_25659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors affecting water maintenance needs in children and infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Source",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\">",
"        Increased water needs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Decreased water needs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Skin",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Burns",
"        <br/>",
"        Fever",
"        <br/>",
"        Phototherapy",
"        <br/>",
"        Prematurity",
"        <br/>",
"        Radiant heater",
"        <br/>",
"        Sweat",
"       </td>",
"       <td>",
"        Enclosed incubator",
"        <br/>",
"        Mist tent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Lungs",
"       </td>",
"       <td>",
"        Tachypnea",
"        <br/>",
"        Tracheostomy",
"       </td>",
"       <td>",
"        Humidified air",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Gastrointestinal tract",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Diarrhea",
"        <br/>",
"        Emesis",
"        <br/>",
"        Ileostomy",
"        <br/>",
"        Nasogastric suction",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal",
"       </td>",
"       <td>",
"        Polyuria",
"       </td>",
"       <td>",
"        Oliguria/anuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Miscellaneous",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Surgical drain",
"        <br/>",
"        Increased activity",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Sedation",
"        <br/>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25659=[""].join("\n");
var outline_f25_3_25659=null;
var title_f25_3_25660="Subdural hematoma children rapid overview";
var content_f25_3_25660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Subdural hematoma (SDH) in children - rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Clinical features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate for SDH in victims of major head trauma with impaired consciousness or abnormal neurologic examination at any time after injury",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Suspect inflicted head injury (Shaken baby syndrome) in infants &le;2 years of age with SDH and no plausible mechanism for head injury",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Physical findings of SDH: irritability, vomiting, bulging anterior fontanelle, increased head circumference, pallor, lethargy, coma, or seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Findings of child abuse: retinal hemorrhages, skeletal or skull fractures with SDH (see section on \"Inflicted head injury (Shaken baby syndrome)\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Findings of cerebral herniation: lateralizing signs such as a fixed, dilated pupil and contralateral hemiparesis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Diagnostic evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Determine GCS, identify pupillary abnormalities and lateralizing motor findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Initial laboratory evaluation: complete blood count with platelets, PT, PTT, INR, bleeding time (if available), and type and cross",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obtain emergent unenhanced head CT",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lumbar puncture is contraindicated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obtain neurosurgical consultation for all patients with GCS &le;12 or in patients with identified SDH",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Make report of suspected child abuse, as indicated by physical findings,to the appropriate government agency according to local requirements and consult a child abuse team, if available",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ensure funduscopic examination by an ophthalmologist and perform skeletal survey in all children with suspected child abuse once clinically stabile",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Manage patient according to principles of advanced trauma life support*:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Immobilize cervical spine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Treat hypoxemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Assess airway, breathing, circulation, and disability and initiate supportive care",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Endotracheally intubate children with GCS &le;8 or rapidly worsening mental status",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ensure definitive management by a neurosurgeon with pediatric expertise",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SDH: subdural hematoma; PT: prothrombin time; PTT: partial thromboplastin time; INR: international normalized ratio; CT: computed tomography; GCS: Glasgow Coma Score.",
"     <br>",
"      * See \"Trauma management: Approach to the unstable child\".",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25660=[""].join("\n");
var outline_f25_3_25660=null;
var title_f25_3_25661="IV iron preparations";
var content_f25_3_25661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F88303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F88303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous iron preparations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum approved dose",
"        <br/>",
"        (mg elemental iron)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total-dose infusion possible",
"       </td>",
"       <td class=\"subtitle1\">",
"        Premedication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Test dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elemental iron concentration",
"        <br/>",
"        (mg/mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preservative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron dextran (high molecular weight)*",
"       </td>",
"       <td>",
"        Dexferrum",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        TDI only",
"       </td>",
"       <td>",
"        Required",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron dextran (low molecular weight)",
"       </td>",
"       <td>",
"        INFeD",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        TDI only",
"       </td>",
"       <td>",
"        Required",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ferric gluconate",
"       </td>",
"       <td>",
"        Ferrlecit",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Recommended if drug allergies present",
"       </td>",
"       <td>",
"        12.5",
"       </td>",
"       <td>",
"        Benzyl alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron sucrose",
"       </td>",
"       <td>",
"        Venofer",
"       </td>",
"       <td>",
"        200 to 300",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Recommended if drug allergies present",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ferumoxytol",
"       </td>",
"       <td>",
"        Feraheme",
"       </td>",
"       <td>",
"        510",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron isomaltoside",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Monofer",
"        <br/>",
"        (not available in US)",
"       </td>",
"       <td>",
"        20 mg/kg",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ferric carboxymaltose",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Ferinject",
"        <br/>",
"        (not available in US)",
"       </td>",
"       <td>",
"        20 mg/kg (maximum 1000 mg)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The use of high molecular weight iron dextran preparations, rather than low molecular weight iron dextran preparations, is not recommended, due to a higher incidence of adverse reactions.",
"     <br>",
"      &bull;&nbsp;Available in certain European countries. Common European trade name shown.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <ol>",
"      <li>",
"       Dexferrum (iron dextran) US prescribing information (revision August 2008).&nbsp; Available&nbsp;at:&nbsp;",
"       <a href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=77f5ae2a-8cd3-4f01-bddd-8158f932c8db\">",
"        file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=77f5ae2a-8cd3-4f01-bddd-8158f932c8db",
"       </a>",
"      </li>",
"      <li>",
"       INFeD (iron dextran) US prescribing information (revision September 2009). Available at:",
"       <a href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abacb7fa-2fc2-471e-9200-944eeac8ca2a\">",
"        file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abacb7fa-2fc2-471e-9200-944eeac8ca2a",
"       </a>",
"      </li>",
"      <li>",
"       Ferrlecit (sodium ferric gluconate complex in sucrose) US prescribing information (revision August 2011). Available at:",
"       <a href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1fe028ff-42ac-4329-b1a5-a9dadfcb79f6\">",
"        file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1fe028ff-42ac-4329-b1a5-a9dadfcb79f6",
"       </a>",
"      </li>",
"      <li>",
"       Venofer (iron sucrose) US&nbsp;prescribing information (revision September 2012). Available at:",
"       <a href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040\">",
"        file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040",
"       </a>",
"      </li>",
"      <li>",
"       Feraheme (ferumoxytol)&nbsp;US prescribing information (revision June 2011).&nbsp; Available at:",
"       <a href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b\">",
"        file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b",
"       </a>",
"      </li>",
"      <li>",
"       Monofer (iron&nbsp;[III]&nbsp;isomaltoside 1000) United Kingdom summary of product characteristics (revision June 1, 2012). Available at:",
"       <a href=\"file://www.medicines.org.uk/EMC/default.aspx\">",
"        file://www.medicines.org.uk/EMC/default.aspx",
"       </a>",
"      </li>",
"      <li>",
"       Ferinject (ferric carboxymaltose) United Kingdom summary of product characteristics (revision October 2011).&nbsp; Available at:",
"       <a href=\"file://www.medicines.org.uk/EMC/default.aspx\">",
"        file://www.medicines.org.uk/EMC/default.aspx",
"       </a>",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25661=[""].join("\n");
var outline_f25_3_25661=null;
var title_f25_3_25662="Ulceration in Barretts";
var content_f25_3_25662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal ulceration in Barrett's metaplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 226px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium swallow in a patient with gastroesophageal reflux and Barrett's metaplasia shows a granular appearance of the mucosa and a large proximal esophageal ulceration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anita E Spiess, MD and Peter J Kahrilas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25662=[""].join("\n");
var outline_f25_3_25662=null;
var title_f25_3_25663="Cat scratch disease";
var content_f25_3_25663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cat scratch disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with cat scratch disease has a primary inoculation lesion and prominent cervical lymphadenopathy (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joy D Jester. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_3_25663=[""].join("\n");
var outline_f25_3_25663=null;
